Upper GI Tract

Basal Crypt Dysplasia in Barrett's Esophagus: GUT | July 2026

Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may represent one of the earliest stages of dysplasia in BE. Why was this review needed? Barrett's esophagus and esophageal adenocarcinoma continue to increase worldwide. Conventional dysplasia assessment may miss early neoplastic changes confined to the crypt base. Diagnostic criteria for crypt dysplasia remain inconsistent. Better pathological recognition may improve early cancer detection. The biological significance of crypt dysplasia requires clarification. Key Takeaways: Crypt dysplasia is characterized by dysplastic changes confined to the basal crypts, with little or no involvement of the surface epithelium. Molecular studies demonstrate that crypt dysplasia shares key genetic alterations, including TP53 mutations and chromosomal instability, with conventional low-grade and high-grade dysplasia. High-grade crypt atypia should be recognized as true crypt dysplasia, whereas low-grade crypt atypia requires careful distinction from reactive inflammatory changes. Inflammation, ulceration, and erosion should be excluded before diagnosing crypt dysplasia to avoid overdiagnosis. Standardized grading into low-grade and high-grade crypt dysplasia offers a practical framework but still requires prospective validation. Further studies are needed to determine the natural history, cancer progression risk, and interobserver reproducibility of crypt dysplasia. Clinical Impact: Recognition of crypt dysplasia may enable earlier identification of neoplastic transformation in Barrett's esophagus before conventional surface dysplasia becomes evident. As diagnostic criteria become standardized, crypt dysplasia may become an important addition to Barrett's pathology reporting and risk stratification. Bottom Line: Basal crypt dysplasia is an emerging early marker of neoplasia in Barrett's esophagus. Although not yet ready for universal adoption, growing molecular and pathological evidence suggests it may become an important component of future Barrett's surveillance and management.

High-Resolution Impedance Manometry after POEM: AJG | May 2026

Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological alternative. Why was this study needed? Although TBE is widely used after POEM, it requires repeated radiographic imaging and does not assess esophageal function in real time. This study evaluated whether HRiM could accurately assess esophageal clearance and predict long-term clinical outcomes. What did the study show? Both HRiM and TBE demonstrated significant improvement in esophageal clearance after POEM. HRiM showed excellent reproducibility and strong correlation with clinical symptom improvement. Residual bolus detected by HRiM at 3 months identified patients at increased risk of treatment failure at 12 months. HRiM demonstrated higher specificity than TBE for predicting long-term POEM failure, while both tests showed excellent negative predictive value. Findings were confirmed in an independent external validation cohort. Clinical Impact: HRiM provides a reliable physiological assessment of esophageal clearance after POEM and may reduce dependence on repeated radiographic studies. It can help identify patients who require closer follow-up or additional intervention. Take-Home Message: High-resolution impedance manometry is a reproducible and effective tool for evaluating esophageal clearance after POEM. Its excellent ability to exclude future treatment failure makes it a valuable addition to the long-term follow-up of patients with achalasia.

Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026

Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving physiologic swallowing and venting mechanisms, MSA offers a less disruptive alternative to traditional antireflux surgery. Although short- and intermediate-term outcomes have been favorable, robust long-term data have been limited. Problem Statement: For any implantable antireflux device, long-term durability, symptom control, dependence on acid-suppressive medications, and device-related complications are critical considerations. Questions remain regarding the sustainability of reflux control beyond five years and the frequency of device removal or adverse events over time. Summary: This FDA post-approval study provides important long-term evidence on the effectiveness and safety of magnetic sphincter augmentation in patients with GERD. At more than five years of follow-up, most patients experienced sustained and clinically meaningful improvement in reflux-related quality of life, with the vast majority remaining free from daily proton pump inhibitor use. Objective testing confirmed durable reflux control, demonstrating persistent normalization of esophageal acid exposure in a substantial proportion of patients. A notable advantage of MSA was preservation of physiologic functions such as belching and vomiting, which are often impaired after conventional fundoplication. Dysphagia remained uncommon and generally manageable. Device-related complications were infrequent, with erosion occurring rarely. However, approximately one in eight patients required device explantation during long-term follow-up. Reassuringly, most patients who underwent device removal achieved symptom resolution through explantation alone, conversion to fundoplication, or device replacement. These findings demonstrate that MSA provides durable long-term control of GERD symptoms and reduces dependence on acid-suppressive medication while maintaining favorable functional outcomes. Although a minority of patients may ultimately require device removal, the overall long-term safety and efficacy profile supports MSA as an established surgical option for appropriately selected patients with chronic GERD.

New Strategies Needed for Resistant H. pylori : Indian J Gastroenterol | Jun 2026

Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice, yet treatment effectiveness has progressively declined worldwide because of increasing antibiotic resistance and challenges related to treatment adherence. These concerns have transformed H. pylori management into an evolving global public health issue. Problem Statement: The effectiveness of conventional eradication regimens is increasingly compromised by rising resistance to commonly used antibiotics, including macrolides, nitroimidazoles, and other key agents. In addition, poor antibiotic penetration into the gastric mucosa, bacterial biofilm formation, efflux pump activity, and the complexity of multidrug treatment regimens contribute to eradication failure. Marked geographic variation in resistance patterns further complicates the selection of optimal therapy. Summary: This review examines the growing challenge of antimicrobial resistance in H. pylori management and highlights the importance of region-specific treatment strategies. The authors emphasize that resistance patterns vary considerably across different parts of the world, making empirical treatment approaches increasingly unreliable. Consequently, local resistance epidemiology should play a greater role in guiding eradication regimens. Beyond traditional antibiotic combinations, the review explores several emerging approaches designed to overcome current limitations. Novel drug-delivery systems, including gastro-retentive formulations and nanotechnology-based therapies, aim to improve antibiotic concentration and retention at the gastric mucosa, potentially enhancing eradication success. The review also discusses non-antibiotic strategies that may reduce reliance on conventional antimicrobials and help mitigate further resistance development. These innovative approaches seek not only to improve eradication rates but also to address the biological mechanisms that allow H. pylori to persist despite therapy. Overall, the review underscores that future management of H. pylori infection will likely require a combination of antimicrobial stewardship, personalized regional treatment algorithms, and innovative therapeutic technologies. As resistance continues to rise globally, integrating these emerging strategies into clinical practice may become essential for maintaining effective eradication and reducing the long-term burden of H. pylori-related disease.

Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and efficacy are therefore urgently needed. Problem Statement: Traditional Bismuth Quadruple Therapy is effective but frequently associated with complex dosing schedules, high adverse event burden and poor patient compliance. Whether a simplified vonoprazan-based dual regimen can achieve comparable rescue eradication rates with better tolerability remained uncertain. Summary: This prospective randomized controlled trial evaluated a simplified dual regimen combining Vonoprazan and tetracycline as rescue therapy for H. pylori infection in patients with at least one prior eradication failure. The study compared 14-day vonoprazan–tetracycline dual therapy against standard bismuth quadruple therapy in 350 patients. The dual regimen achieved eradication rates that were noninferior to bismuth quadruple therapy across both modified intention-to-treat and per-protocol analyses, with eradication rates exceeding 90%. Importantly, the simplified dual regimen demonstrated a major tolerability advantage. Treatment-emergent adverse events occurred far less frequently compared with quadruple therapy, and no patients discontinued treatment because of side effects. Adherence was also significantly higher with dual therapy, likely reflecting reduced pill burden, simplified scheduling and improved gastrointestinal tolerability. These findings are clinically important because rescue H. pylori therapy frequently fails not only because of antimicrobial resistance but also because patients struggle to complete complex multidrug regimens. The study further reinforces the growing role of vonoprazan-based therapy in modern H. pylori management. Unlike traditional proton pump inhibitors, vonoprazan provides rapid, potent and sustained acid suppression, potentially improving antibiotic stability and bacterial eradication efficacy. The results are especially relevant in regions with high clarithromycin and metronidazole resistance, where conventional salvage regimens often become increasingly difficult to optimize. The use of tetracycline is also noteworthy because resistance rates remain relatively low globally compared with other commonly used antibiotics. Clinically, the regimen offers an attractive rescue strategy that balances efficacy, simplicity and tolerability, which are critical determinants of real-world eradication success. The findings additionally support an evolving treatment paradigm in H. pylori management favoring streamlined, high-potency acid suppression combined with fewer antibiotics rather than increasingly complex multidrug combinations. Importantly, the open-label design represents a limitation, and the study population was derived from China, which may affect global generalizability because regional antimicrobial resistance patterns differ substantially. Further studies comparing this regimen against rifabutin-based and susceptibility-guided rescue therapies will be important to define its position within future treatment algorithms. Longer-term surveillance will also be needed to monitor emerging tetracycline resistance if widespread adoption occurs. Overall, this trial demonstrates that vonoprazan–tetracycline dual therapy is an effective, simplified and better-tolerated rescue regimen for H. pylori infection, offering eradication efficacy comparable to bismuth quadruple therapy while substantially improving safety and adherence.

H. pylori Eradication Reduces Cancer but Mortality Benefit Remains Fragile : Gastroenterology | June 2026

Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment initiatives. Problem Statement Although eradication therapy appears to reduce gastric cancer mortality statistically, the robustness of this mortality benefit has remained uncertain. Conventional meta-analytic significance testing may overestimate certainty when outcomes are rare and vulnerable to small data perturbations. Summary This commentary applied a fragility index analysis to previously published randomized trial meta-analysis data evaluating the impact of H. pylori eradication on gastric cancer incidence and mortality. The fragility index provides a practical measure of statistical robustness by estimating how many event reclassifications would be required to convert a statistically significant result into a nonsignificant one. The analysis demonstrated a striking contrast between cancer incidence reduction and mortality benefit. The fragility index for gastric cancer incidence was robust at 53, whereas the fragility index for gastric cancer-associated mortality was only 4. In practical terms, the observed mortality benefit could lose statistical significance if only four deaths across nearly 60,000 participants were reclassified. This finding raises important methodological and clinical considerations. Rare-event outcomes such as gastric cancer mortality are particularly susceptible to sparse data bias, stochastic variation and minor classification errors. The authors emphasize that even very small inaccuracies in death attribution within registry-based or hospital-derived datasets could plausibly alter the mortality signal. Importantly, the analysis does not challenge the role of H. pylori eradication as a cancer-preventive strategy. Rather, it questions whether current evidence definitively proves a meaningful extension in overall survival. The distinction between preventing cancer occurrence and prolonging life is clinically important. Eradication may successfully delay or reduce gastric carcinogenesis while patients ultimately succumb to competing comorbidities, particularly in older or metabolically vulnerable populations. The commentary therefore reframes H. pylori eradication primarily as a disease-burden reduction strategy rather than a definitively life-prolonging intervention. From a public health perspective, this remains highly meaningful. Reducing gastric cancer incidence can decrease endoscopic workload, surgical intervention, healthcare costs and long-term morbidity even if mortality curves remain relatively unchanged. The discussion is particularly relevant for health systems considering population-based eradication programs, especially in resource-constrained settings where prioritization decisions require careful assessment of absolute benefit. The authors also highlight the importance of transparent communication in preventive medicine. Programs should emphasize reductions in cancer burden and healthcare utilization rather than overstating unproven survival advantages. Methodologically, the work illustrates the value of fragility analysis as a complementary tool alongside p-values, confidence intervals and effect estimates when interpreting large preventive trials. Clinically, the findings still support current guideline recommendations advocating H. pylori eradication to reduce gastric cancer incidence, particularly in high-prevalence regions. However, the commentary appropriately cautions against overinterpreting mortality reductions from statistically fragile data. Limitations include reliance on aggregated meta-analytic data and dependence on the quality of the underlying trials, several of which carried unclear or high risk of bias. Future studies evaluating all-cause mortality rather than gastric cancer-specific mortality may better clarify the broader survival impact of eradication therapy. Overall, this fragility analysis reinforces that H. pylori eradication is a statistically robust cancer-prevention strategy, while the currently observed mortality benefit remains quantitatively fragile and should be interpreted cautiously.

Vonoprazan Triple and Reverse Hybrid Regimens Outperform High-Dose Dual Therapy for H. pylori : AJG | May 2026

Introduction Helicobacter pylori Infection remains a major global cause of peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Rising antimicrobial resistance, particularly to clarithromycin, has progressively reduced eradication success with conventional triple therapy. The introduction of Vonoprazan has renewed interest in simplified high-acid suppression regimens capable of improving eradication rates. Problem Statement The optimal first-line vonoprazan-based eradication strategy remains uncertain, particularly regarding whether simplified high-dose dual therapy can achieve efficacy comparable to more complex triple or hybrid regimens in regions with substantial antibiotic resistance. Summary This multicenter Taiwanese randomized trial compared three contemporary first-line eradication strategies for H. pylori infection: vonoprazan high-dose dual therapy, vonoprazan triple therapy and rabeprazole-based reverse hybrid therapy over 14 days. The study demonstrated that both vonoprazan triple therapy and rabeprazole reverse hybrid therapy achieved significantly superior eradication rates compared with vonoprazan high-dose dual therapy. Intention-to-treat eradication exceeded 89% with the triple and reverse hybrid regimens, whereas vonoprazan dual therapy achieved lower efficacy at approximately 84%. These findings are clinically important because simplified dual therapies have been increasingly promoted as antibiotic-sparing approaches intended to reduce antimicrobial exposure and resistance selection. However, the results suggest that dual therapy may be insufficient in regions with significant clarithromycin resistance or heavier bacterial burden. Notably, adverse event rates were relatively low and comparable across all treatment groups, indicating that the improved efficacy of the more intensive regimens was not offset by substantially worse tolerability. This supports the clinical practicality of triple and reverse hybrid approaches in routine first-line management. The study also identified several important predictors of eradication failure. Clarithromycin resistance emerged as a major determinant of treatment failure, reinforcing the continuing global challenge posed by antimicrobial resistance in H. pylori management. Poor medication adherence demonstrated the strongest association with eradication failure, highlighting the critical importance of patient education and regimen completion. Higher body weight additionally predicted treatment failure across regimens, an observation that may reflect altered pharmacokinetics, insufficient antibiotic exposure or larger intragastric bacterial burden. This raises important questions regarding whether weight-adjusted treatment strategies may eventually be necessary in selected populations. Mechanistically, vonoprazan’s potent and sustained acid suppression likely enhances antibiotic stability and bacterial susceptibility by maintaining higher intragastric pH compared with traditional proton pump inhibitors. Nevertheless, this pharmacologic advantage alone was insufficient to fully overcome antimicrobial resistance when dual therapy was used. The strong performance of the rabeprazole reverse hybrid regimen is also noteworthy. Hybrid therapies sequentially combine dual and quadruple-type approaches to maximize bacterial eradication while balancing antibiotic exposure, and this strategy continues to demonstrate robust efficacy in Asian populations. Clinically, the findings suggest that empiric vonoprazan dual therapy should be used cautiously in areas with moderate-to-high clarithromycin resistance. Vonoprazan triple therapy or reverse hybrid regimens currently appear more reliable for achieving acceptable first-line eradication thresholds. The study further reinforces the broader principle that modern H. pylori treatment strategies must increasingly integrate regional resistance epidemiology, adherence optimization and individualized regimen selection rather than relying on universally applied empiric protocols. Overall, this randomized multicenter trial demonstrates that vonoprazan triple therapy and rabeprazole reverse hybrid therapy provide superior first-line H. pylori eradication compared with vonoprazan high-dose dual therapy. The results emphasize the persistent impact of clarithromycin resistance and support continued preference for combination regimens capable of consistently achieving high eradication success.

BRTO and TIPS Outperform Cyanoacrylate for Secondary GV Bleeding Prevention : Meta-analysis | May 2026

Introduction Gastric Varices are associated with severe hemorrhage, high transfusion requirements and substantial mortality in patients with Cirrhosis. Compared with esophageal varices, gastric varices bleed less frequently but often more catastrophically. Secondary prophylaxis after an index bleed remains challenging, and optimal management strategies continue to evolve. Current therapeutic options include endoscopic cyanoacrylate injection (ECI), Balloon-Occluded Retrograde Transvenous Obliteration and Transjugular Intrahepatic Portosystemic Shunt, each with distinct physiologic consequences and complication profiles. Problem Statement There remains no universal consensus regarding the optimal secondary prophylactic modality for gastric variceal bleeding. Comparative data among ECI, BRTO and TIPS have been limited by heterogeneity, small trial sizes and inconsistent outcome reporting. Summary This comprehensive aggregate and individual patient data meta-analysis evaluated outcomes of BRTO and TIPS compared with endoscopic cyanoacrylate injection for prevention of recurrent gastric variceal bleeding in cirrhosis. The study incorporated data from both observational studies and randomized controlled trials, strengthening comparative assessment across multiple therapeutic approaches. The primary finding was that both BRTO and TIPS significantly reduced all-cause rebleeding compared with cyanoacrylate injection alone. BRTO demonstrated the greatest reduction in recurrent bleeding risk, while TIPS also provided substantial protection against rebleeding events. These findings reinforce the superior durability of portal hemodynamic interventions compared with local endoscopic obliteration alone. Importantly, however, improved bleeding control did not translate into a demonstrable overall survival advantage. This likely reflects the multifactorial nature of mortality in advanced cirrhosis, where outcomes are influenced not only by recurrent hemorrhage but also by liver failure, infection, renal dysfunction and other portal hypertensive complications. Distinct complication profiles emerged between the endovascular strategies. BRTO was associated with increased risk of new or worsening ascites. Mechanistically, this is biologically plausible because BRTO obliterates spontaneous portosystemic shunts, thereby increasing portal venous pressure and potentially exacerbating portal hypertensive fluid accumulation. Conversely, TIPS substantially increased the risk of Hepatic Encephalopathy. By diverting portal blood away from hepatic detoxification pathways, TIPS predisposes susceptible patients to ammonia accumulation and neurocognitive dysfunction, a well-recognized tradeoff of portal decompression. One particularly important observation was that benefits in bleeding reduction were most pronounced among patients with Child-Pugh class B cirrhosis. This suggests that patients with intermediate hepatic reserve may derive the greatest net benefit from aggressive endovascular secondary prophylaxis strategies, whereas more advanced disease may attenuate therapeutic gains. Clinically, the findings support a more individualized approach to gastric variceal secondary prophylaxis. BRTO may be particularly attractive in patients with prior encephalopathy or preserved ascites control, whereas TIPS may remain preferable in patients with severe portal hypertension-related complications requiring decompression beyond gastric variceal management alone. The study additionally highlights persistent limitations in the evidence base. Long-term outcomes remain incompletely characterized, definitions of rebleeding vary across studies and heterogeneity remains especially substantial for TIPS-related outcomes because of differences in stent type, portal pressure targets and patient selection. Importantly, the analysis reinforces the concept that gastric varices differ fundamentally from esophageal varices in anatomy, hemodynamics and therapeutic response. Management algorithms designed for esophageal varices cannot simply be extrapolated to gastric variceal disease. Overall, this meta-analysis demonstrates that BRTO and TIPS are superior to endoscopic cyanoacrylate injection for reducing recurrent gastric variceal bleeding in cirrhotic patients. However, treatment selection must balance bleeding prevention against portal hypertensive complications such as ascites and hepatic encephalopathy, emphasizing the need for individualized multidisciplinary decision-making and further long-term comparative studies.

Guideline Gaps in Paediatric H. pylori Care : Frontline Gastroenterol | May 2026

Introduction Helicobacter pylori infection remains an important paediatric gastrointestinal infection worldwide, yet its diagnosis and treatment in children differ substantially from adult practice. The joint ESPGHAN–NASPGHAN guidelines advocate a restrictive, endoscopy-based diagnostic strategy with culture-guided therapy and structured eradication confirmation to minimise inappropriate antibiotic exposure and resistance development. This multicentre UK audit evaluated real-world paediatric practice against current international recommendations. Problem Statement Despite established paediatric-specific guidance, diagnostic and therapeutic approaches to H. pylori infection in children frequently remain extrapolated from adult pathways. The extent of deviation from guideline-recommended testing, treatment duration and post-treatment follow-up in UK clinical practice has remained poorly characterised. Summary This retrospective multicentre audit analysed paediatric H. pylori testing practices across nine NHS trusts between April 2023 and June 2024. More than 1900 stool antigen tests performed in children aged ≤16 years were reviewed, of which 249 (13%) were positive. The mean age of tested children was 9.6 years. Most positive tests represented initial diagnosis (84%), while only 15% were performed for eradication confirmation. The study demonstrated widespread divergence from ESPGHAN–NASPGHAN recommendations across nearly all stages of care. Stool antigen testing was frequently used as a primary diagnostic tool in symptomatic children, particularly for abdominal pain, despite guidelines discouraging non-invasive “test-and-treat” strategies in paediatric populations. Abdominal pain was the most common indication for testing across both primary and secondary care settings, reflecting persistent misconceptions regarding the causal relationship between H. pylori and functional abdominal symptoms in children. Treatment practices also showed substantial inconsistency. Empirical eradication therapy was commonly prescribed without endoscopic confirmation or antimicrobial susceptibility testing. Importantly, 88% of first-line treatment regimens and 60% of re-treatment courses deviated from ESPGHAN–NASPGHAN recommendations, most commonly because of inappropriate antibiotic combinations or shortened treatment duration. These findings raise important antimicrobial stewardship concerns, particularly in the context of rising global clarithromycin and metronidazole resistance. Post-treatment follow-up was similarly suboptimal. Only 53% of children undergoing initial treatment and 64% receiving eradication therapy underwent follow-up stool antigen testing, and testing was frequently performed outside recommended timing windows. This inconsistency limits accurate eradication assessment and may contribute to persistent infection, recurrent symptoms and unnecessary repeated antibiotic exposure. The audit additionally highlighted variability between primary and tertiary care referral patterns, with symptom profiles and testing indications differing substantially across healthcare settings. Limited awareness of paediatric-specific guidelines, alongside continued reliance on adult management paradigms, likely contributed to these discrepancies. Overall, this important UK multicentre audit demonstrates major gaps between current paediatric H. pylori practice and international guideline standards. The findings underscore the need for harmonisation of UK national recommendations with ESPGHAN–NASPGHAN guidance, improved clinician education and stronger antimicrobial stewardship frameworks to promote evidence-based, standardised paediatric H. pylori management.

BSG/ACPGBI Advise Against Routine Tranexamic Acid in GI Bleeding : Frontline Gastroenterol | May 2026

Introduction Tranexamic acid has been widely used across trauma, surgical and hemorrhagic settings because of its antifibrinolytic effects and ability to stabilize clot formation. Earlier small studies suggested potential benefit in gastrointestinal bleeding, leading to interest in its use for acute upper and lower GI hemorrhage. Problem Statement Despite historical enthusiasm, uncertainty remained regarding the efficacy and safety of tranexamic acid in gastrointestinal bleeding, particularly in the era of modern endoscopic hemostasis, proton-pump inhibitors and contemporary supportive care. Clarification from major societies was required following publication of high-quality randomized evidence. Summary This position statement from the British Society of Gastroenterology and Association of Coloproctology of Great Britain and Ireland strongly advises against the routine use of tranexamic acid in acute upper or lower gastrointestinal bleeding. The recommendation is primarily based on the landmark HALT-IT trial, a large international randomized placebo-controlled study involving more than 12,000 patients with significant GI bleeding. HALT-IT demonstrated no reduction in bleeding-related mortality with tranexamic acid administration despite earlier smaller studies suggesting possible benefit. Importantly, the trial identified increased risks of venous thromboembolism and seizures among patients receiving tranexamic acid, raising significant safety concerns. The societies emphasize that earlier positive studies were methodologically weak and conducted before widespread use of modern endoscopic therapy and optimized acid suppression. Consequently, the position statement concludes that the overall risk–benefit profile does not support routine TXA use in GI bleeding. The document further states that any exceptionally rare off-guideline use should occur only after exhaustion of standard therapies, require senior consultant-level decision-making and be clearly documented within institutional governance systems. This statement is clinically important because tranexamic acid continues to be intermittently used in GI bleeding despite robust negative evidence. The guidance reinforces evidence-based deimplementation of ineffective interventions and highlights the importance of avoiding therapies associated with potential thrombotic harm in already vulnerable bleeding populations.

Distinct Atopic Endotypes Identified in Paediatric and Adult EoE : Frontline Gastroenterol | 2026

Introduction Eosinophilic oesophagitis is an increasingly recognized type 2 inflammatory disorder characterized by oesophageal eosinophilia, dysphagia and food-related symptoms. Although EoE occurs across all age groups, differences in immunologic drivers and clinical phenotype between paediatric-onset and adult-onset disease remain incompletely understood. Problem Statement Current management strategies for EoE are largely uniform across age groups despite growing evidence suggesting biologic heterogeneity. Clarifying whether paediatric-onset and adult-onset EoE represent distinct atopic endotypes could improve diagnostic evaluation, allergen assessment and personalized therapeutic approaches. Summary This large population-based cohort study demonstrates that paediatric-onset and adult-onset EoE possess clearly distinct atopic and clinical profiles, supporting the concept of divergent disease endotypes. Paediatric-onset EoE was strongly associated with systemic allergic disease, particularly asthma, atopic dermatitis and food allergy, alongside higher peripheral eosinophil counts. These findings support a predominantly food antigen–driven inflammatory phenotype with broader systemic type 2 immune activation in younger patients. In contrast, adult-onset EoE showed stronger associations with allergic rhinitis and nasal polyposis, suggesting greater involvement of aeroallergen sensitization and upper airway allergic inflammation. The persistence of these findings after matched analysis reinforces that these differences are unlikely to be explained solely by demographic variation. The study highlights that EoE may evolve through distinct immunologic pathways depending on age at onset, potentially explaining differences in symptom presentation, trigger profiles and treatment responsiveness observed in clinical practice. Recognition of these divergent endotypes may have important implications for allergy testing, dietary therapy selection and biologic treatment strategies. The findings also support closer integration between gastroenterology, allergy and airway disease management, particularly in patients with overlapping atopic disorders. Overall, the study advances understanding of EoE heterogeneity and strengthens the rationale for precision medicine approaches tailored to age-specific inflammatory mechanisms.

FOXM1 Blockade Restores Epithelial Homeostasis in EoE : Gut | 2026

Introduction Eosinophilic oesophagitis (EoE) is a chronic Th2-mediated inflammatory disease characterized by epithelial barrier dysfunction, basal cell hyperplasia and persistent mucosal remodeling. Even after inflammatory control, epithelial transcriptomic and histologic abnormalities often persist, contributing to ongoing symptoms and disease relapse. Identifying molecular regulators of epithelial dysfunction remains a major therapeutic priority. Problem Statement Current EoE therapies primarily target inflammation but incompletely restore epithelial homeostasis. The mechanisms linking IL-13-driven inflammation to impaired epithelial differentiation and excessive proliferation are incompletely understood, limiting development of therapies that promote durable mucosal healing. Summary This translational study identifies forkhead box M1 (FOXM1) as a central transcriptional regulator of epithelial remodeling in EoE. FOXM1 expression was markedly increased in active EoE and localized predominantly to the basal epithelial layer. IL-13 stimulation upregulated FOXM1 in oesophageal epithelial cells, organoids and murine EoE models, linking Th2 inflammation directly to epithelial proliferative signaling. Functional inhibition of FOXM1 using the small-molecule inhibitor RCM-1 or siRNA restored epithelial differentiation markers including involucrin and filaggrin, reduced basal cell hyperplasia, suppressed proliferation and improved epithelial barrier integrity. In murine EoE models, FOXM1 inhibition reduced eosinophilic inflammation and reversed histologic remodeling. Mechanistically, FOXM1 directly regulated the cell-cycle gene cyclin B1 (CCNB1), driving epithelial proliferation through altered G2/M transition. The study further demonstrated that IL-13 activates a non-canonical PI3K/AKT–FOXM1 signaling axis, while FOXM1 inhibition reduced STAT6 phosphorylation and suppressed eotaxin-3 (CCL26) expression, indicating simultaneous modulation of epithelial and inflammatory pathways. Importantly, FOXM1 overexpression independently induced epithelial hyperplasia and proliferation even without IL-13 stimulation, reinforcing its pathogenic role. These findings position FOXM1 as a novel therapeutic target capable of simultaneously restoring epithelial differentiation, improving barrier function and attenuating allergic inflammation in EoE. The work also highlights a paradigm shift toward epithelial-directed therapeutic strategies in EoE beyond eosinophil suppression alone.

Exclusive Enteral Nutrition Shows Modest but Meaningful Benefit in Adult Crohn’s Disease | Indian Journal of Gastroenterology

Introduction Exclusive enteral nutrition (EEN) is a well-established induction therapy in pediatric Crohn’s disease, where it offers anti-inflammatory efficacy while avoiding corticosteroid-related toxicity. In adults, however, EEN has been less widely adopted because of concerns regarding adherence, palatability and uncertain comparative effectiveness relative to standard medical therapy. Problem Statement The role of EEN in adult Crohn’s disease remains poorly defined due to heterogeneous study designs, variable nutritional formulations and inconsistent remission outcomes across clinical trials. Whether EEN can serve as a practical steroid-sparing strategy in adults—and in which clinical settings it may be most useful—has remained an important unresolved question in inflammatory bowel disease management. Summary This systematic review and meta-analysis demonstrates that EEN can induce clinical remission in adults with active Crohn’s disease, although its efficacy appears inferior to corticosteroids for remission induction. Across real-world studies, approximately two-thirds of patients achieved remission with EEN, supporting its meaningful anti-inflammatory potential in selected adult populations. Importantly, the analysis found no significant difference in efficacy between elemental and non-elemental formulations, suggesting that therapeutic benefit is independent of formula composition and allowing greater flexibility in nutritional strategy. The review also highlights emerging evidence supporting combination therapy, where EEN used alongside biologics may improve remission outcomes compared with biologic therapy alone. Adverse events were generally mild, with poor palatability remaining the principal limitation affecting tolerability and adherence. These findings reinforce that while EEN is unlikely to replace corticosteroids as first-line induction therapy in most adults, it remains an important steroid-sparing and nutritionally supportive option, particularly in patients where corticosteroid avoidance is desirable or adjunctive nutritional therapy is clinically beneficial. The study supports a more individualized role for EEN within modern adult Crohn’s disease management.

Rome V Gastroduodenal Disorders: Gastroenterology | May 2026

The Rome V Gastroduodenal Disorders chapter introduces several important conceptual, diagnostic, and therapeutic refinements across functional dyspepsia (FD), nausea/vomiting disorders, belching disorders, inability to belch syndrome, and rumination syndrome. The most clinically important changes are the stronger emphasis on symptom-pattern phenotyping, pragmatic clinical diagnosis, and more mechanistically aligned treatment algorithms. 1. Gastroduodenal Disorders Are Now Structured Into 5 Major Rome V Categories Rome V classifies gastroduodenal disorders into 5 major categories: Functional dyspepsia (FD) Nausea and vomiting disorders Excessive belching disorders Inability to belch syndrome (new category) *Rumination syndrome This structure is more clinically intuitive and improves practical differentiation of meal-related symptoms, vomiting syndromes, and behavioral esophagogastric syndromes. 2. Functional Dyspepsia (FD): Rome V Prioritizes Symptom Phenotype Over Umbrella Label A major conceptual change in Rome V is that although functional dyspepsia (FD) remains the umbrella diagnosis, the committee explicitly recommends that clinicians preferentially classify patients using the symptom phenotype: Postprandial Distress Syndrome (PDS) Epigastric Pain Syndrome (EPS) or PDS–EPS overlap This is one of the most important practical refinements in Rome V because it shifts emphasis away from “FD” as a broad label and toward phenotype-driven diagnosis and treatment. Why this matters clinically This improves: pathophysiologic alignment, treatment selection, and clinical trial stratification. 3. Postprandial Epigastric Pain Is No Longer Automatically EPS One of the most important Rome V refinements in dyspepsia is the clarification that: Postprandial epigastric pain in the presence of PDS symptoms should be classified as PDS, not EPS. This resolves one of the major ambiguities in Rome IV, where meal-related epigastric pain often created diagnostic overlap and therapeutic confusion. Clinical significance This is a major advance because patients with: postprandial fullness, early satiety, and meal-triggered epigastric pain are now recognized as belonging to the PDS spectrum, which better aligns with impaired accommodation / delayed gastric emptying physiology and favors prokinetic-directed management. 4. Rome V Defines “Postprandial” More Precisely: Within 2 Hours of Meals Rome V now explicitly defines postprandial symptoms as those that: begin or worsen within 2 hours of meal intake This is a major methodological improvement because it gives a more physiologically meaningful and reproducible definition of meal-related symptom generation. Symptoms occurring later than 2 hours are considered less likely to reflect classical postprandial dyspeptic physiology and may represent other mechanisms. 5. PDS and EPS Thresholds Are Now More Pragmatic and Clinically Usable Rome V refines symptom thresholds to better reflect real-world disease burden: PDS Requires ≥2 days/week of: bothersome postprandial fullness and/or bothersome early satiation. EPS Requires ≥1 day/week of: bothersome epigastric pain and/or bothersome epigastric burning. These thresholds are more clinically usable and better aligned with symptom burden than prior stricter formulations. 6. Rome V Introduces a Provisional Subdivision of EPS Rome V newly acknowledges that EPS without PDS is not uniform and introduces a provisional subclassification: Postprandial EPS = pain/burning starts or worsens after meals in ≥50% of episodes Meal-unrelated EPS = pain/burning starts or worsens after meals in <50% of episodes This is an important conceptual advance because it recognizes probable biological heterogeneity within EPS and sets up future mechanistic stratification. 7. Upper Endoscopy Is No Longer Mandatory in Routine FD Diagnosis One of the most clinically relevant Rome V shifts is its more pragmatic diagnostic approach: In routine clinical practice, patients with typical dyspeptic symptoms and no alarm features can be managed without mandatory upper endoscopy. Instead, Rome V recommends: clinical assessment, medication review, H. pylori testing, selective investigations, and endoscopy only when alarm/risk features are present. For research, however, normal upper endoscopy remains mandatory. This is a major clinical modernization of Rome criteria. 8. Helicobacter pylori Testing Is Mandatory in Dyspepsia Evaluation Rome V makes one recommendation especially explicit: H. pylori status should be determined in every patient with dyspeptic symptoms. This is one of the strongest operational recommendations in the chapter. Further: if eradication leads to sustained symptom remission, the condition should be classified as H. pylori–associated dyspepsia, not FD. This is a clinically important distinction and avoids overdiagnosing DGBI in biologically attributable disease. 9. FD Pathophysiology Is Reframed as a Duodenal–Neuroimmune Disorder One of the most important scientific advances in Rome V is the much stronger mechanistic emphasis on duodenal pathobiology in FD. Rome V moves beyond older motility-centric models and reframes FD as a disorder involving: impaired gastric accommodation, delayed gastric emptying, visceral hypersensitivity, duodenal barrier dysfunction, mucosal eosinophilia / mast cell activation, neuroimmune signaling, microbiome alteration, bile acid signaling, food-triggered immune activation, and altered central processing. The pathophysiology diagram on page 4 (Figure 1) is especially important because it visually presents FD as a multifactorial gut–brain disorder centered on duodenal barrier dysfunction, immune activation, neuroimmune dysregulation, and altered brain–gut signaling, rather than simply a gastric motor disorder. This is one of the biggest conceptual scientific upgrades in Rome V gastroduodenal disease. 10. Rome V Introduces Clear Stepwise Treatment Algorithms for PDS and EPS A major practical strength of Rome V is the introduction of structured treatment algorithms: Figure 3 (page 7): PDS treatment algorithm Figure 4 (page 8): EPS treatment algorithm These are among the most clinically useful additions in the chapter. PDS algorithm Progresses through: diet/lifestyle PPI / first-line prokinetic / herbal therapy endoscopy if needed neuromodulator / brain–gut behavioral therapy gastric emptying testing in refractory disease second-line prokinetics if delayed emptying present EPS algorithm Progresses through: diet/lifestyle PPI / herbal therapy endoscopy if needed neuromodulator (especially TCA) / brain–gut behavioral therapy nutritional support / alternate diagnoses in refractory disease This is one of the most practice-changing parts of Rome V. 11. Rome V More Clearly Aligns Therapy With Phenotype Rome V makes treatment more phenotype-specific: PDS → prokinetics, accommodation-targeted therapy, gastric emptying stratification EPS → acid suppression + neuromodulation (especially TCA) This is one of the most clinically meaningful therapeutic refinements in Rome V. Examples: Acotiamide is emphasized for PDS 5-HT1A agonists (e.g., tandospirone/buspirone) for early satiety Mirtazapine for weight loss / early satiety TCA especially for EPS and pain-predominant phenotypes 12. Inability to Belch Syndrome Is a New Rome V Diagnosis One of the most notable additions in Rome V is the formal inclusion of Inability to Belch Syndrome (retrograde cricopharyngeal dysfunction) as a new diagnostic entity. This is a major addition because Rome formally recognizes a previously underdiagnosed but clinically distinctive syndrome characterized by: inability to belch, chest/neck gurgling, bloating, flatulence, chest/epigastric discomfort. This is one of the most clinically novel additions in the chapter. 13. Cannabinoid Hyperemesis Syndrome (CHS) Criteria Are More Stringent Rome V substantially strengthens CHS criteria by requiring: prolonged cannabis exposure (≥1 year), excessive use (≥4 days/week or ≥15 doses/week), and symptom resolution after sustained abstinence (≥6 months or 3 typical cycles). This is a major improvement over Rome IV and greatly improves diagnostic specificity. Clinical Bottom Line The Rome V Gastroduodenal Disorders chapter is one of the most clinically actionable Rome V updates. Its major advances are: phenotype-first FD classification (PDS/EPS over generic FD), reclassification of meal-related epigastric pain, explicit 2-hour postprandial definition, pragmatic non-endoscopic clinical diagnosis, mandatory H. pylori testing, stronger duodenal–neuroimmune FD model, structured phenotype-based treatment algorithms, formal recognition of inability to belch syndrome, and stricter CHS criteria. The single most important Rome V advance in gastroduodenal disease is this: symptom-pattern phenotyping now drives both diagnosis and treatment more explicitly than ever before.

Rome V Pediatric Upper Gastrointestinal Disorders: Gastroenterology | May 2026

Rome V substantially expands pediatric upper gastrointestinal disorders of gut–brain interaction (DGBI), moving beyond the narrower Rome IV framework to include pediatric esophageal pain disorders, esophageal air-transit disorders, functional pediatric feeding disorders (FPFD), rumination syndrome, cyclic vomiting syndrome (CVS), chronic nausea syndrome (CNS), and functional dyspepsia (FD). The most important conceptual advance is that Rome V aligns pediatric DGBI with contemporary physiology—especially pH-impedance testing, high-resolution impedance manometry (HRIM), and structured multidisciplinary phenotyping—making diagnosis more mechanistically grounded and therapeutically actionable. The overarching clinical shift is similar to adult Rome V: pediatric upper GI DGBI are no longer framed as vague symptom syndromes diagnosed only after exclusion, but as positive, physiology-supported disorders of gut–brain interaction. This is especially important in pediatrics, where symptom reporting is developmentally constrained and behavioral, sensory, autonomic, and feeding-related phenotypes often overlap. Rome V therefore formalizes a much more multidisciplinary model involving gastroenterology, psychology, nutrition, speech/swallow therapy, and behavioral medicine. 1. Pediatric Esophageal DGBI: A Major Reclassification Beyond “GERD” One of the most practice-changing updates in Rome V is the formal separation of pediatric esophageal symptoms previously grouped under presumed GERD into three distinct physiologic phenotypes: Reflux hypersensitivity (RH) Reflux-negative esophageal pain disorder (RNEPD) (pediatric analog of adult functional heartburn) Disorders of esophageal air-transit (aerophagia syndrome and supragastric belching) This is a major clinical advance because many children previously labeled as refractory GERD are now more accurately classified into esophageal DGBI phenotypes using endoscopy plus pH-impedance testing, allowing more rational treatment and avoiding unnecessary prolonged acid suppression. Reflux Hypersensitivity (RH) Rome V defines pediatric RH as reflux-related pain symptoms with: normal endoscopy, no eosinophilic esophagitis (EoE), normal acid exposure, but positive symptom association with acid or nonacid reflux on pH-impedance testing. This is one of the most important pediatric esophageal additions because it formally acknowledges that symptoms may be reflux-triggered despite normal acid burden, shifting the focus from acid quantity to sensory hypersensitivity and reflux perception. Clinical implications: PPI response is not diagnostically reliable for RH. Empiric PPI trials may still be used, but should be time-limited (≤8 weeks). Failure to improve should prompt endoscopy + pH-impedance, not indefinite acid escalation. Treatment emphasis shifts toward neuromodulation and CBT, rather than acid suppression alone. This is a major practical change in pediatrics, where prolonged empiric PPI use has historically been common. Reflux-Negative Esophageal Pain Disorder (RNEPD) RNEPD is the pediatric equivalent of adult functional heartburn and refers to reflux-like pain symptoms with: normal endoscopy, no EoE, normal acid exposure, and no temporal symptom–reflux correlation on pH-impedance testing. This is highly clinically relevant because it identifies children with esophageal pain not driven by reflux at all, despite symptom similarity to GERD. The most important therapeutic implication is explicit: Antireflux surgery is not indicated in RNEPD. Repeated escalation of acid suppression is generally inappropriate. Management should prioritize neuromodulators + CBT, not procedural reflux therapy. This is one of the most practice-protective statements in Rome V pediatric esophageal care. 2. Disorders of Esophageal Air-Transit: A New Pediatric Category Rome V newly formalizes disorders of esophageal air-transit, enabled by advances in impedance and HRIM, which can distinguish directionality of air movement. This is an important pediatric innovation because belching and bloating syndromes have historically been poorly classified and often misdiagnosed as reflux or dyspepsia. The new subtypes are: Aerophagia syndrome Supragastric belching (SGB) syndrome Aerophagia Syndrome Rome V redefines aerophagia as a syndrome only when excessive air swallowing causes clinically significant symptoms such as: progressive daytime abdominal distention, excessive belching, flatulence, bloating, and quality-of-life impairment. This is important because Rome V avoids overdiagnosing normal air swallowing as pathology. Testing is often unnecessary unless uncertainty exists; diagnosis is primarily clinical, with abdominal x-ray or impedance used selectively. Treatment is conservative and behavioral (speech therapy/CBT), with decompression reserved for severe cases. Supragastric Belching (SGB) SGB is now recognized as a distinct behavioral disorder characterized by repetitive esophageal air intake followed by immediate expulsion. This is a major conceptual advance because many children with repetitive “hiccups,” “belching,” or presumed reflux actually have behavioral air-transit disorders, not acid disease. Rome V emphasizes: SGB is usually diagnosable clinically, often does not occur during sleep, and is best treated behaviorally (breathing retraining, speech therapy, CBT), not pharmacologically. 3. Functional Pediatric Feeding Disorders (FPFD): One of the Most Important Rome V Additions The most novel and clinically transformative pediatric addition in Rome V is the formal introduction of Functional Pediatric Feeding Disorders (FPFD). This is arguably the most important pediatric innovation in the entire Rome V upper GI framework. Rome V introduces FPFD as a structured, physiology- and behavior-based alternative to the overly broad DSM-5 construct of ARFID, which the committee explicitly argues lacks sufficient granularity for GI practice. Rome V recommends replacing ARFID-like heterogeneity with more precise feeding phenotypes. This is a major conceptual and practical advance because pediatric feeding problems are common, clinically heterogeneous, and often misclassified. Rome V introduces four functional feeding phenotypes: Hypersensitive dysphagia (HD) Anticipatory restrictive feeding (ARF) Hunger dysregulation feeding disorder Medically triggered functional feeding disorder Hypersensitive Dysphagia (HD) HD is the pediatric analogue of adult functional dysphagia, but adapted for developmental limitations. Children perceive liquids/solids as passing abnormally despite: normal mucosa, normal structure, no major motor disorder, and normal bolus transit. This is a clinically valuable distinction because it separates sensory dysphagia from structural and motor disease while accounting for the fact that children often cannot localize symptoms well. Anticipatory Restrictive Feeding (ARF) ARF describes children who restrict intake because they anticipate aversive eating-related symptoms such as: pain, nausea, gagging, choking, bloating, vomiting. This is one of the most clinically useful new Rome V diagnoses because it identifies fear-based restrictive eating driven by symptom anticipation rather than structural dysfunction. Hunger Dysregulation Feeding Disorder Rome V introduces a novel hunger-axis disorder with: reduced hunger drive, or excessive hunger drive. This is a uniquely pediatric and clinically important construct, especially for children with severe dysregulated intake patterns not explained by anatomy or classic eating disorders. Medically Triggered Functional Feeding Disorder This category recognizes children whose feeding dysfunction began during a medical illness (e.g., GERD, EoE) but persists after the medical condition has resolved, due to retained maladaptive feeding behaviors or sensory conditioning. This is an especially important practical diagnosis in pediatric GI because it explains why children may remain functionally dysphagic or feeding-avoidant despite complete mucosal healing. Why FPFD Matters Clinically This entire section is one of the most practice-changing contributions of Rome V. It provides a far more clinically useful framework for children previously grouped vaguely under ARFID or “feeding difficulty,” and it strongly emphasizes: structured multidisciplinary assessment, routine screening for EoE and nutritional deficiencies, behavioral and sensory phenotyping, and targeted psychogastroenterology-based treatment. 4. Rumination Syndrome: Stronger Behavioral Framing Rome V reframes pediatric rumination syndrome as a behavioral gut–brain disorder, not a reflux disorder. This is highly important clinically because rumination remains commonly mistaken for refractory GERD, gastroparesis, or vomiting disorders. Rome V reinforces that: diagnosis is usually clinical, HRIM can confirm in atypical cases, and diaphragmatic breathing is first-line therapy. This stronger behavioral framing should substantially reduce unnecessary testing and procedural escalation. 5. CVS and Cannabinoid Hyperemesis: Better Modernization Rome V updates pediatric CVS and formally incorporates cannabinoid hyperemesis syndrome (CHS) as a pediatric-relevant subgroup, reflecting increasing adolescent cannabis exposure. This is clinically important because Rome V now explicitly requires: chronic cannabis exposure, stereotypical CVS-like vomiting, and symptom resolution with sustained cannabis cessation to diagnose CHS. This improves diagnostic precision and helps avoid mislabeling adolescents with occasional cannabis exposure as CHS. 6. Chronic Nausea Syndrome (CNS): Formal Recognition of a Real Pediatric Syndrome Rome V renames and formalizes chronic nausea syndrome, recognizing chronic nausea as a legitimate pediatric DGBI often linked to: autonomic dysfunction, POTS, anxiety, and functional comorbidity. This is an important conceptual advance because chronic nausea has historically been under-recognized and often dismissed as nonspecific. 7. Functional Dyspepsia: Better Pediatric Alignment With Adult Rome V Rome V updates pediatric FD to align more closely with adult criteria, particularly by: formalizing PDS and EPS subtypes, increasing required symptom frequency for PDS, and refining postprandial symptom timing. This improves diagnostic consistency across age groups and should improve trial design and phenotype-specific management. Clinical Bottom Line Rome V Pediatric Upper GI DGBI is a major advance because it moves pediatric neurogastroenterology from symptom-based empiricism to structured physiologic and behavioral phenotyping. The most important practice-changing advances are: formal physiologic separation of pediatric esophageal pain syndromes from GERD, introduction of air-transit disorders (aerophagia, SGB), creation of functional pediatric feeding disorders (FPFD) as a major new diagnostic framework, stronger behavioral reframing of rumination syndrome, formal pediatric incorporation of CHS, recognition of chronic nausea syndrome as a distinct disorder, and better harmonization of pediatric FD with adult Rome criteria. Among these, the single most important innovation is the introduction of FPFD, while the most immediately practice-changing esophageal update is the shift from empiric “refractory GERD” labeling to pH-impedance-based esophageal phenotyping. Collectively, Rome V makes pediatric upper GI DGBI substantially more precise, multidisciplinary, and clinically actionable.

Rome V Functional Esophageal Disorders: Gastroenterology | May 2026

Rome V reframes functional esophageal disorders as esophageal disorders of gut–brain interaction (E-DGBI), emphasizing that these syndromes arise from altered esophageal sensory signaling and central perceptual processing rather than occult structural disease. The defining clinical principle is that patients present with heartburn, chest pain, globus, or dysphagia, but without explanatory structural pathology, major esophageal motor disorders, or pathologic reflux. Rome V’s most important conceptual advance is the formal integration of Lyon Consensus 2.0 for reflux assessment and Chicago Classification v4.0 (CCv4.0) for motility, making the diagnosis of E-DGBI more physiologically rigorous and less exclusionary by approximation. This update substantially improves clinical precision. Rather than labeling persistent esophageal symptoms as “functional” after a normal endoscopy alone, Rome V now requires systematic exclusion of mucosal disease, GERD, eosinophilic esophagitis (EoE), and major motor disorders using contemporary physiologic testing. This is a major practical shift because it reduces both underdiagnosis of subtle esophageal disease and overdiagnosis of functional syndromes. The central pathophysiologic model is now explicit: symptom generation reflects esophageal hypersensitivity, hypervigilance, altered autonomic regulation, and maladaptive brain–gut processing, often amplified by psychosocial stressors and symptom-specific anxiety. Functional Chest Pain: A More Rigorous Diagnosis of Exclusion Rome V defines functional chest pain as recurrent retrosternal chest pain of presumed esophageal origin, distinct from heartburn and unexplained by GERD, mucosal disease, or major motility disorders. The major practical refinement is that this diagnosis now requires exclusion using Lyon 2.0 reflux thresholds, CCv4.0 motility criteria, and selective mucosal biopsy rather than broad empiricism. Importantly, cardiac disease must still be excluded first, because symptom pattern alone cannot reliably distinguish esophageal from cardiac pain. A key Rome V change is that esophageal biopsies are no longer required for all patients with chest pain, unlike Rome IV. Biopsies are now recommended only when chest pain is meal-related, where occult EoE may mimic pain-predominant disease. This reduces unnecessary biopsy burden while preserving diagnostic sensitivity in clinically relevant cases. Rome V also clarifies that ineffective esophageal motility (IEM) is not exclusionary, while conclusive EGJOO, achalasia, DES, and hypercontractile esophagus remain exclusionary. Mechanistically, Rome V strongly anchors functional chest pain in esophageal hypersensitivity and altered central pain processing. Up to 75% of patients demonstrate heightened sensitivity to esophageal distension, and psychiatric comorbidity—particularly anxiety, depression, and somatization—is highly prevalent and clinically relevant. Treatment therefore shifts away from acid suppression and toward neuromodulation and behavioral therapy. TCAs, SNRIs, trazodone, and selected SSRIs remain the pharmacologic backbone, while GI-CBT, gut-directed hypnotherapy, and biofeedback are now explicitly recognized as evidence-based therapeutic options rather than adjunctive alternatives. Functional Heartburn: More Stringent Separation From GERD Rome V retains functional heartburn as a distinct diagnosis but makes its boundaries with GERD more rigorous. Functional heartburn is now defined as retrosternal burning that persists despite optimized antisecretory therapy, with no evidence of GERD, EoE, EGJ dysfunction, or major motility disorder. The most important clinical advance is a sharper physiologic distinction between functional heartburn and GERD using Lyon 2.0 criteria, especially prolonged reflux monitoring and adjunctive impedance metrics. Rome V reinforces that a normal endoscopy is insufficient to exclude GERD. Diagnosis now requires objective reflux exclusion, ideally with 96-hour wireless pH monitoring off therapy. Functional heartburn is favored when acid exposure remains physiologic and symptom association is negative. Mean nocturnal baseline impedance (MNBI) is now clinically useful: MNBI >2500 Ω supports functional heartburn, whereas low impedance favors GERD. This is a major practical step toward physiologic phenotyping of refractory heartburn. Therapeutically, Rome V strongly discourages repeated invasive testing and explicitly states that antireflux surgery should be avoided in functional heartburn. This is one of the most practice-changing statements in the document. Management should instead focus on reassurance, reduction of hypervigilance, and neuromodulation. GI-CBT, diaphragmatic breathing, hypnotherapy, and low-dose neuromodulators are emphasized as mechanistically aligned and clinically safer than procedural escalation. Reflux Hypersensitivity: Preserved but Better Defined Rome V preserves reflux hypersensitivity but refines its boundaries. This disorder now requires heartburn and/or chest pain with physiologic acid exposure but positive reflux–symptom association, distinguishing it from both GERD and functional heartburn. The critical clinical distinction is that symptoms remain temporally linked to reflux events despite physiologic reflux burden. Rome V now explicitly excludes regurgitation and belching as qualifying symptoms in isolation, which is clinically important because these symptoms often reflect mechanical or behavioral disorders such as rumination or supragastric belching rather than reflux hypersensitivity. This reduces diagnostic contamination and improves phenotypic precision. Management remains similar to functional heartburn, but Rome V acknowledges that some patients—particularly those with acid-sensitive esophagus or hiatal hernia—may respond to acid suppression or, selectively, antireflux surgery. However, the dominant therapeutic model remains neuromodulation plus psychogastroenterology rather than acid suppression alone. Globus: Less Procedural, More Conservative Rome V retains globus largely unchanged but makes one clinically important correction: the role of gastric inlet patch is substantially de-emphasized. Rome IV was more permissive toward inlet patch ablation; Rome V is more conservative and states that while inlet patch may be relevant in selected patients, evidence supporting ablation remains low quality and should not drive routine intervention. This change matters clinically because globus is common, benign, and often chronic, yet historically over-investigated and overtreated. Rome V favors a structured but conservative approach: exclude local structural disease and laryngeal pathology, consider a short PPI trial, then proceed toward reassurance and behavioral management if unrevealing. Once GERD and structural disease are excluded, CBT-based psychoeducation, speech therapy, pharyngolaryngeal relaxation, and hypnosis are favored over repeated endoscopy, ablation, or procedural escalation. Functional Dysphagia: The Most Important Diagnostic Upgrade Functional dysphagia undergoes the most meaningful diagnostic modernization in Rome V. While Rome IV relied largely on normal endoscopy and HRM, Rome V now recognizes that subtle EGJ dysfunction and impaired distensibility may be missed by conventional testing. Accordingly, functional lumen imaging probe (FLIP) and supportive timed barium esophagram are now explicitly incorporated into the diagnostic framework. This is arguably the most important technical advance in Rome V functional esophageal disorders. This change has major practical implications. Rome V acknowledges that many patients previously labeled with functional dysphagia under Rome IV likely had subtle EGJ outflow resistance, impaired distensibility, or borderline achalasia physiology that standard manometry failed to detect. FLIP can identify these hidden physiologic abnormalities and therefore reduce false-positive diagnosis of functional dysphagia. As a result, true functional dysphagia becomes a more specific—and likely less common—diagnosis. Rome V also clarifies that esophageal biopsies are essential in dysphagia, even when mucosa appears normal, because EoE and other inflammatory disorders may be histologically occult. It further reinforces that IEM does not exclude functional dysphagia, whereas achalasia, conclusive EGJOO, DES, and hypercontractile esophagus do. This improves diagnostic discipline and reduces overcalling minor motility findings as causative. Management remains conservative and phenotype-directed. Reassurance, swallowing modification, and selective neuromodulation remain foundational. However, Rome V also recognizes that selected patients with unexplained solid-food dysphagia may benefit from empiric bougie dilation, especially where subtle proximal mechanical dysfunction is suspected despite negative routine testing. With FLIP integration, this can now be better targeted and more physiologically justified. Clinical Bottom Line Rome V significantly modernizes functional esophageal disorders by replacing broad symptom-based exclusion with physiology-driven phenotyping. The most important practical changes are: formal integration of Lyon 2.0 and Chicago Classification v4.0, selective rather than routine biopsy in functional chest pain, stronger physiologic separation of functional heartburn vs reflux hypersensitivity vs GERD, de-escalation of procedural management in globus, and incorporation of FLIP as a major diagnostic advance in functional dysphagia. Collectively, these changes move practice away from empiricism, repeated acid suppression, and procedural overuse, and toward mechanism-based diagnosis, neuromodulation, psychogastroenterology, and precision esophageal physiology. For clinical practice, Rome V is less about renaming functional esophageal disorders and more about redefining them with substantially greater physiologic rigor.

Achalasia and Oesophagal Cancer: Gastroenterology | May 2026

Introduction Achalasia is a chronic oesophagal motility disorder characterised by impaired lower oesophagal sphincter relaxation and food stasis. Long-standing stasis, bacterial overgrowth, and chronic inflammation have raised concerns about an increased risk of oesophagal cancer, particularly squamous cell carcinoma. However, previous studies were small and lacked adjustment for key confounders such as smoking and alcohol. The association with adenocarcinoma has remained even more uncertain. Problem Statement Clinicians often struggle with two key questions: 👉 Does achalasia independently increase the risk of oesophagal cancer? 👉 Should these patients undergo structured cancer surveillance? Existing data have been limited by small sample sizes and inadequate adjustment for major risk factors. In particular, whether achalasia contributes to adenocarcinoma risk beyond associated gastroesophageal reflux remains unclear. Summary This large multinational population-based study from Nordic countries provides robust evidence addressing these gaps. Achalasia was found to be strongly associated with oesophagal squamous cell carcinoma, with nearly a 9-fold increased risk, even after adjusting for smoking and alcohol. This confirms that achalasia itself is an independent risk factor for squamous malignancy. In contrast, achalasia showed only a modest association with oesophagal adenocarcinoma, which became non-significant after adjusting for GERD. This suggests that the observed risk of adenocarcinoma is largely driven by reflux rather than achalasia per se. Interestingly, patients who had undergone treatment such as myotomy or dilation had an even higher risk of squamous cell carcinoma, likely reflecting longer disease duration and persistent mucosal exposure to stasis-related injury. Overall, the study clearly differentiates cancer risk patterns in achalasia: high and independent risk for squamous cell carcinoma Limited and GERD-mediated risk for adenocarcinoma These findings reinforce the need for heightened awareness of squamous cancer risk in long-standing achalasia while suggesting a more nuanced approach toward adenocarcinoma surveillance.

Gastric Polyps: AGA Clinical Practice Update | April 2026

Introduction Gastric polyps are frequently encountered during upper gastrointestinal endoscopy and represent a heterogeneous group of lesions ranging from benign fundic gland polyps to premalignant adenomas and neuroendocrine tumours. Their clinical significance lies not only in the histologic subtype of the polyp itself but also in the underlying gastric mucosal environment, which may reflect conditions such as Helicobacter pylori infection, autoimmune gastritis, or intestinal metaplasia. The latest update from the American Gastroenterological Association provides a structured, evidence-based approach to the detection, classification, and management of gastric polyps in routine practice. Problem Statement Despite their common occurrence, gastric polyps are often managed empirically without a standardised, pathology-driven approach. This can lead to missed underlying mucosal disease, inappropriate surveillance, or unnecessary interventions. There is a need for a clear, lesion-specific and mucosa-oriented strategy to optimise patient outcomes. Summary The guideline emphasises that careful endoscopic evaluation should not be limited to the polyp alone but must include systematic assessment of the surrounding gastric mucosa, as this determines both aetiology and management. Biopsy of both the polyp and adjacent mucosa is essential, and resection should be considered based on histologic subtype and risk profile. A key recommendation is universal testing for H. pylori in patients with adenomatous or hyperplastic polyps, as eradication may reduce recurrence and malignancy risk. Importantly, fundic gland polyps associated with proton pump inhibitor use do not require discontinuation of therapy if clinically indicated. Overall, this update reinforces a mucosa-driven, individualised approach, shifting practice from simple polyp removal to comprehensive gastric disease management.

Pediatric Eosinophilic Esophagitis- ASGE Consensus: GIE | March 2026

Introduction Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by progressive esophageal inflammation that can evolve into fibrostenotic complications such as strictures and food impaction. Endoscopy plays a central role not only in diagnosis but also in long-term disease monitoring and therapeutic decision-making. This American Society for Gastrointestinal Endoscopy consensus document expands prior guidance by focusing on disease assessment, monitoring strategies, and pediatric-specific considerations, reflecting the evolving understanding of EoE as a lifelong condition requiring structured and multidisciplinary care. Summary This consensus emphasizes that eosinophilic esophagitis should be approached as a disease requiring integrated assessment across symptoms, endoscopic findings, and histology, as no single domain reliably reflects disease activity. Initial diagnostic endoscopy should be performed off treatment to avoid false-negative results and must include adequate biopsies, with at least six samples from multiple esophageal levels. The guideline highlights that symptoms alone are unreliable due to adaptive eating behaviors and poor correlation with inflammation, reinforcing the need for objective monitoring. A key advancement is the growing role of less invasive monitoring tools such as transnasal endoscopy and esophageal string testing, which can reduce procedural burden but are not suitable for initial diagnosis or for patients with suspected strictures. Structured monitoring intervals are recommended based on treatment type, with earlier reassessment for dietary and pharmacologic therapies and longer intervals for biologics. The document also underscores that endoscopic detection of strictures is often insensitive, requiring adjunctive methods such as esophagography or functional lumen assessment. In pediatric populations, early recognition based on feeding difficulties and growth concerns is critical, and transition planning to adult care is essential to prevent loss of follow-up. The guideline strongly emphasizes that gaps in monitoring are associated with progression to fibrostenosis, making continuous follow-up a cornerstone of care. Conclusion This ASGE consensus provides a comprehensive, practice-oriented framework for the endoscopic management of eosinophilic esophagitis beyond diagnosis. The key message is that effective care requires structured, longitudinal monitoring using a combination of clinical, endoscopic, and histologic parameters, with selective integration of less invasive tools. By standardizing assessment and minimizing gaps in care, these recommendations aim to prevent disease progression and improve long-term outcomes in both adult and pediatric patients.

Dupilumab for Pediatric EoE: AJG, March 2026

Introduction Eosinophilic esophagitis (EoE) is a chronic immune-mediated oesophagal disease in children that causes feeding difficulty, vomiting, abdominal pain, dysphagia, and poor quality of life. Standard therapy often includes proton-pump inhibitors and swallowed topical corticosteroids (STCs). However, many children either do not respond adequately, cannot tolerate STCs, or have contraindications to their use. This creates an important therapeutic gap, especially in younger children with persistent inflammation and risk of long-term oesophagal remodelling. Problem statement The key clinical question is whether dupilumab remains effective in children with EoE who have already used STCs, particularly those with inadequate response, intolerance, or contraindication (IRIC) to steroid therapy. Summary This subgroup analysis from the phase 3 EoE KIDS study evaluated children aged 1–11 years with EoE not responsive to proton-pump inhibitors. Among 102 patients, 80% had prior STC use and 58% had prior IRIC to STCs. At week 16, higher-exposure dupilumab achieved histologic remission in about 61% of children with prior STC exposure and in a similar proportion of those with prior IRIC, compared with 0% on placebo. Improvements in endoscopic and histologic secondary outcomes paralleled these findings. Benefits were maintained through week 52, and children switched from placebo to dupilumab also improved. Lower-exposure dupilumab showed similar but generally smaller responses. Safety was consistent with the known dupilumab profile. Overall, this study supports dupilumab as an effective steroid-sparing option for children with difficult-to-treat EoE.

MEK Inhibitors and Gastric Precancerous Lesions: Gastroenterology | March 2026

What Are MEK Inhibitors? MEK inhibitors are targeted drugs that block the MAPK/ERK signalling pathway, specifically the MEK (mitogen-activated protein kinase kinase) enzyme. This pathway regulates cell proliferation, survival, and differentiation, and its abnormal activation contributes to several cancers. Drugs such as trametinib are already used in oncology (e.g., melanoma and BRAF-mutant cancers) and are now being explored for reversing early precancerous changes in tissues before cancer develops. What Are Gastric Precancerous Lesions? Gastric precancerous lesions are pathological changes in the stomach lining that increase the risk of gastric cancer. The most important include: 1. Chronic atrophic gastritis 2. Intestinal metaplasia (IM) 3. Dysplasia These lesions often arise after long-term Helicobacter pylori infection and may progress to gastric cancer over many years. Summary In a phase 1 clinical trial evaluating trametinib, a MEK inhibitor, for reversing gastric precancerous lesions such as intestinal metaplasia and parietal cell atrophy. The trial suggested that short-term, low-dose MEK inhibition may improve gastric mucosal histology, indicating a potential preventive strategy against gastric cancer. However, the authors highlight important limitations. The study included only 15 patients, lacked a randomised placebo-controlled group, and focused exclusively on patients with previously resected stage I gastric cancer and prior H. pylori eradication, limiting generalizability. Additionally, histologic improvements are intermediate markers and do not prove reduced cancer risk, particularly with only 1 year of follow-up. Statistical concerns, such as a lack of adjustment for multiple comparisons, were also noted. Despite these limitations, the study represents the first human investigation of MEK inhibitors for gastric cancer prevention, providing early proof-of-concept and laying the groundwork for larger, long-term trials assessing cancer incidence as the ultimate outcome.

Eosinophilic Gastrointestinal Diseases in 2026: Gastroenterology | March 26

Introduction Eosinophilic gastrointestinal diseases (EGIDs) are chronic, immune-mediated disorders defined by eosinophil-predominant inflammation in the GI tract. Over the past 30 years, EGIDs—especially eosinophilic esophagitis (EoE)—have risen sharply without a clear plateau. This review summarises what has changed most in epidemiology, natural history, diagnosis, and treatment, and where the biggest gaps remain. 20 Key Takeaways (Clinician-focused) Two big buckets: EGIDs are now classified as EoE (oesophagus only) and non-EoE EGIDs (stomach, small bowel, colon ± overlap). New nomenclature matters: “Eosinophilic gastroenteritis” is being de-emphasised in favour of site-specific labels (EoG, EoN, EoC), improving clarity for care and research. EoE is no longer rare: Incidence and prevalence have continued to climb globally, often faster than endoscopy/biopsy rates. “Tip of the iceberg” problem: Many patients likely remain undiagnosed due to under-biopsying, missed follow-up after food bolus impaction, and diagnostic delay (often years). High-yield clinical settings for EoE: EoE is common in dysphagia, extremely common in food impaction, and should be excluded before antireflux surgery or when strictures are present. Atopy linkage is strong: Food allergy, asthma, eczema, and allergic rhinitis markedly increase EoE probability; risk rises with more atopic comorbidities. Diagnosis of EoE is straightforward: Symptoms of oesophageal dysfunction + ≥15 eos/hpf on oesophageal biopsy + exclusion of competing causes. Severity tracking is evolving: Tools like I-SEE help frame symptoms/complications, inflammatory activity, and fibrostenotic features over time. Non-EoE EGIDs remain uncommon—but likely underrecognized: Prevalence is low in many datasets, but symptom nonspecificity and biopsy/reading variability may miss cases. Non-EoE diagnosis is harder because eosinophils are “normal” distally: Unlike the oesophagus, eosinophils are normal residents in stomach/small bowel/colon—so thresholds and context matter. Proposed histologic thresholds vary by segment: Practical cutoffs (approximate) increase from stomach/duodenum toward ileum/right colon and then decline leftward. Non-EoE EGIDs can be mucosal, muscular, or serosal: Symptoms and complications reflect depth—muscular disease can obstruct; serosal disease can present with eosinophilic ascites. Natural history of EoE is chronic and often progressive: Untreated inflammation can move toward fibrosis/stricture (fibrostenosis); risk increases with time and gaps in care. EoE relapse is the rule when therapy stops: Multiple RCTs show high recurrence rates after withdrawing effective treatment. EoE treatment pillars are now established: PPI, swallowed topical corticosteroids (STCs), food elimination diets (FEDs), and dupilumab are central options. PPI is a legitimate anti-inflammatory strategy in EoE: About half achieve histologic remission; twice-daily dosing tends to perform better than once daily; maintenance can work for many responders. STCs are highly effective and now disease-specific: Budesonide formulations (e.g., oral suspension/orodispersible tablet) have strong induction and maintenance data; candidiasis is the most common AE. Dupilumab is the first approved biologic for EoE: It targets IL-4/IL-13 signaling and achieves meaningful histologic and symptom benefits, with a generally favourable safety profile. Diet therapy is effective but should start simply: Empiric elimination is recommended, often beginning with the least restrictive (commonly milk elimination) and escalating stepwise if needed; allergy tests do not reliably identify triggers. Non-EoE EGIDs: steroids still dominate; biologics are emerging: Evidence is mostly observational; systemic/topical steroids and elemental/elimination diets are used, while newer agents (e.g., IL-13 pathway drugs, dupilumab in EoG/EoN trials) are promising, but the field still lacks approved therapies and robust endpoints.

Falling Prevalence of GI Malignancy in Adults With Iron Deficiency Anaemia – IDIOM V: Endoscopy | 2026

Introduction Iron deficiency anaemia (IDA) has long been considered an important red flag for underlying gastrointestinal (GI) malignancy. However, with evolving referral patterns, widespread endoscopic access, and prior imaging, the true contemporary cancer yield in IDA requires reassessment. Summary In this audit of 1253 consecutive adults referred to a hospital IDA service (2022–2023), 934 underwent full GI investigation. The prevalence of GI cancer was 5.6%, confirming a continued decline compared with historical figures. Two variables showed strong negative associations with malignancy: prior colonic imaging within 5 years and long-term proton pump inhibitor (PPI) exposure. Incorporating PPI status into the existing IDIOM risk score improved predictive discrimination (c-statistic 0.84 vs 0.77). These findings support a shift toward refined risk stratification rather than universal invasive investigation, with prospective validation needed before practice change.

Wedge Pillow vs Evening PPI for Nocturnal Reflux: Neurogastro & Motility | Feb. 2026

Many patients continue to experience nocturnal heartburn or regurgitation despite taking a standard morning proton pump inhibitor (PPI). Current practice often escalates to a second (evening) PPI dose, while wedge pillows are recommended as a non-pharmacologic option—yet direct comparative evidence has been limited. This randomized noninferiority trial enrolled patients with frequent nocturnal reflux symptoms despite at least four weeks of morning PPI therapy. Participants were randomized for four weeks to either (1) add a wedge pillow while continuing morning PPI, or (2) intensify to twice-daily PPI. Outcomes included nocturnal symptom burden (NGSSIQ), quality of life, sleep quality, daytime sleepiness, and objective reflux metrics using 24-hour pH-impedance monitoring. Pillow adherence was objectively tracked using a pressure-sensing timekeeper. At four weeks, the wedge pillow strategy was non-inferior to twice-daily PPI for improving nocturnal reflux symptoms. Notably, sleep quality improved more with the wedge pillow. Objective reflux testing showed only limited differences between groups, suggesting that the symptomatic benefit may not be solely explained by measurable reductions in reflux episodes, and may involve improved sleep mechanics or arousal thresholds. Compliance and satisfaction with the pillow were high. Clinical takeaway: For patients with persistent nocturnal reflux symptoms on morning PPI, adding a wedge pillow is a credible, low-risk alternative to escalating acid suppression—particularly when sleep disruption is a dominant complaint.

Capsule Sponge Triage for Reflux

This large, single-center, prospective cohort study evaluated a non-endoscopic capsule sponge (CS) triage pathway for patients routinely referred with reflux symptoms over 4 years. The goal was to assess its impact on endoscopy utilisation, diagnostic yield, and long-term safety. Among 871 patients who underwent capsule sponge testing, nearly 88% provided adequate samples. Importantly, 62% avoided endoscopy, and most of these low-risk patients were safely discharged. Abnormal CS results were seen in approximately 10% of patients and were strongly associated with significant pathology. One case of esophageal cancer, two cases of Barrett’s dysplasia, and 34 cases of Barrett’s esophagus were detected. The positive predictive value for Barrett’s esophagus in patients with abnormal CS was 43.5%, while the negative predictive value was high at 98.2%. Long-term follow-up (over 2,000 patient-years) confirmed safety. Only a small proportion of patients with a negative CS who later underwent endoscopy for persistent symptoms were found to have Barrett’s or atrophic gastritis. Patient acceptability was excellent, with over 97% finding the test acceptable. Overall, the capsule sponge pathway safely stratifies reflux patients, increases the yield of significant endoscopic diagnoses, reduces unnecessary procedures, and supports more efficient endoscopy resource utilization.

Metopimazine in Gastroparesis: Safe, Mixed Efficacy Signals- AJG Feb.2026

Gastroparesis is a chronic, debilitating disorder characterised by nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Current pharmacologic options are limited by modest efficacy and safety concerns, particularly central nervous system and cardiac adverse effects. There is therefore a strong need for new, well-tolerated therapies that effectively target core symptoms—especially nausea. Metopimazine is a dopamine D2 receptor antagonist that is peripherally restricted, reducing the risk of central neurologic side effects. It has been used in Europe for decades to treat nausea and vomiting. This phase 2 study evaluated NG101, an oral mesylate formulation of metopimazine, for the treatment of gastroparesis. In this multicenter, double-blind trial, patients with diabetic or idiopathic gastroparesis received NG101 at varying doses or placebo for 12 weeks. Symptom severity was tracked using daily patient-reported outcome diaries, with a primary focus on nausea severity and multiple secondary assessments of global symptom improvement. Although NG101 did not significantly reduce nausea severity compared with placebo on the primary symptom score, patients receiving NG101 consistently reported greater overall improvement in nausea when asked to rate their global change in symptoms. This suggests that patients perceived meaningful benefit, even if the magnitude of symptom change on numeric scales was modest. Importantly, NG101 was well tolerated, with a favorable safety profile across all doses. Notably, treatment effects appeared more favorable in idiopathic gastroparesis than in diabetic gastroparesis, raising the possibility of phenotype-specific benefit. This finding aligns with emerging evidence that gastroparesis subtypes respond differently to pharmacologic therapies. In summary, while NG101 did not meet its primary efficacy endpoint, it demonstrated good tolerability and encouraging patient-reported improvements, particularly in idiopathic gastroparesis. These results support further targeted studies to clarify its role in symptom-directed management of gastroparesis.

LPS vs LPRD: The San Diego Consensus Redefines LPR- AJG Feb.26

Introduction “Laryngopharyngeal reflux (LPR)” has become a catch-all label for chronic throat and upper airway complaints—cough, throat clearing, hoarseness, phlegm, throat pain—often without objective evidence of reflux. This has led to overdiagnosis, prolonged proton-pump inhibitor (PPI) trials, unnecessary testing, and frequent frustration for both patients and clinicians. The San Diego Consensus is a multidisciplinary effort (GI + ENT + speech-language pathology + psychology) that proposes a modern, objective, and practical care pathway. The central paradigm shift 1) Rename the symptom state Laryngopharyngeal Symptoms (LPS) = the symptom cluster (throat/upper airway symptoms) that may be reflux-related. Laryngopharyngeal Reflux Disease (LPRD) = LPS plus objective evidence of reflux. ✅ Key message: LPS ≠ LPRD. Most patients with LPS do not have proven reflux-driven disease. What changes in daily practice? 2) Laryngoscopy is necessary, but it cannot diagnose LPRD Laryngoscopy is valuable to: evaluate nonreflux laryngeal pathology (including malignancy), identify benign lesions and alternative ENT diagnoses. But laryngoscopic signs are nonspecific and should not be used alone to diagnose “LPR.” 3) Split patients early: LPS with GERD symptoms vs isolated LPS This is a major practical step because the algorithm diverges: A) LPS + typical oesophageal reflux symptoms (heartburn/regurgitation) Reasonable to start lifestyle measures + empiric acid suppression (often PPI twice daily for ~3 months) ± alginate. If symptoms persist or management will escalate (long-term therapy or invasive reflux procedures): objective testing is required. B) Isolated LPS (no typical GERD symptoms) Do not default to empiric PPI-first management. Prioritize: ENT evaluation (laryngoscopy), early consideration of behavioural/laryngeal hypersensitivity mechanisms, and objective reflux testing if reflux is being considered as the driver. 4) Reflux monitoring is the reference standard for LPRD For diagnosing reflux-driven disease, the consensus emphasises: 24-hour pH-impedance (best to characterise reflux episodes, nonacid/proximal events; helpful in isolated LPS when mechanism matters) 96-hour wireless pH (best for day-to-day variability and confirming/ excluding abnormal acid burden; particularly useful when considering escalation of reflux management) These modalities are not mutually exclusive; they answer different questions. Also: Testing in “unproven GERD” should typically be done off acid suppression. Oropharyngeal pH monitoring alone is not supported as a stand-alone diagnostic test due to poor specificity. The “forgotten driver”: laryngeal hyperresponsiveness and hypervigilance The consensus brings a clinician-friendly framing: many patients have symptoms driven or amplified by: laryngeal hypersensitivity, hyperresponsive behaviors (cough/throat clearing cycles), symptom-specific anxiety and hypervigilance. These respond to: laryngeal recalibration therapy (voice-specialized SLP approaches), neuromodulators (selected cases), targeted behavioral therapies (e.g., CBT aimed at symptom-specific processes). ✅ Key message: Even when reflux exists, brain–larynx behavioral drivers can coexist and perpetuate symptoms. Bottom-line takeaway: The San Diego Consensus replaces “LPR as a diagnosis” with a more accurate framework: define LPS, confirm LPRD only with objective reflux evidence, avoid reflexive long-term PPI use in isolated throat symptoms, and explicitly treat laryngeal hyperresponsiveness/hypervigilance when present. One-line GastroAGI takeaway Most “LPR” isn’t reflux disease—diagnose LPRD with objective testing and treat the brain–larynx axis when needed.

Psychological Factors Shape Outcomes After Achalasia Treatment- Gastroenterology Feb.26

Introduction Achalasia is traditionally managed as a pure motility disorder, and treatment success is usually judged by technical outcomes—lower oesophageal sphincter (LES) disruption, improved emptying on timed barium esophagram (TBE), and manometric changes. Yet, many clinicians recognise a frustrating reality: Some patients continue to report dysphagia, chest pain, and poor quality of life despite objectively successful treatment. This study addresses an often-overlooked question: Do psychological factors—specifically oesophageal hypervigilance and anxiety—predict how patients feel after achalasia treatment? The clinical problem Persistent symptoms after pneumatic dilation, POEM, or Heller myotomy are commonly attributed to: incomplete myotomy, reflux, or residual obstruction. However, these explanations do not fully account for patients who have: good oesophageal emptying, acceptable manometry, and no major structural issues—yet remain highly symptomatic. This raises the possibility that central symptom processing, not oesophageal mechanics alone, influences outcomes. What the authors studied: The investigators evaluated achalasia patients after definitive therapy and assessed: Oesophageal Hypervigilance and Anxiety using the EHAS (a validated scale), Oesophageal-specific quality of life (E-QOL / NEQOL), Objective measures such as TBE. They then examined whether psychological measures predicted post-treatment symptoms and quality of life independent of objective oesophageal findings. Key findings clinicians should understand 1) Hypervigilance and anxiety strongly predict patient-reported outcomes Higher scores on oesophageal hypervigilance and anxiety were associated with: worse post-treatment symptoms, and poorer oesophageal-specific quality of life. This relationship persisted even when objective measures were acceptable. 2) Objective success does not guarantee symptomatic success Patients with good TBE results and technically successful interventions still reported poor outcomes if hypervigilance and anxiety were high. 3) Achalasia outcomes are not purely mechanical These findings support a brain–esophagus interaction, where heightened symptom monitoring, fear of symptoms, and anxiety amplify symptom perception after treatment. Why this matters in clinical practice Explains “unexplained failure” This study helps explain why some patients remain dissatisfied after technically successful achalasia therapy. Pre-treatment counseling Identifying high hypervigilance/anxiety before intervention may: set realistic expectations, reduce post-treatment dissatisfaction. Post-treatment management Persistent symptoms should not automatically trigger: repeat dilation, redo POEM, or escalation to surgery. In selected patients, psychological or behavioural interventions may be more appropriate. Practical take-home messages If post-treatment symptoms do not match objective findings, consider hypervigilance and anxiety. Use validated tools (like EHAS) to identify at-risk patients. A multidisciplinary approach—including behavioural therapy, reassurance, and symptom education—may improve outcomes more than additional procedures. Bottom-line takeaway: In achalasia, patient outcomes are driven not only by oesophagal emptying, but also by how symptoms are perceived and processed. Addressing oesophagal hypervigilance and anxiety is essential to improving real-world treatment success. One-line GastroAGI takeaway Successful achalasia treatment requires treating both the esophagus and the brain.

Beyond Gastric Cancer: The True Burden of H. pylori- Gastroenterology Feb.26

Introduction Helicobacter pylori is universally recognised as a major cause of gastric cancer, and screen-and-treat strategies are often evaluated almost exclusively through this lens. However, H. pylori also drives a broad spectrum of other gastrointestinal diseases—many far more common than cancer—that substantially affect patients, healthcare systems, and quality of life. This study asks an important but often ignored question: How much disease burden attributable to H. pylori are we overlooking when we focus only on gastric cancer? The problem with current policy thinking Most cost-effectiveness models and guideline discussions around H. pylori eradication prioritise: gastric cancer incidence and mortality. What they frequently exclude or underweight: peptic ulcer disease (PUD), functional dyspepsia, and gastric lymphomas (eg, MALT lymphoma). As a result, the true public-health benefit of eradication is likely underestimated, especially in countries with moderate H. pylori prevalence. What the authors did: Performed a systematic review of studies linking H. pylori to PUD, dyspepsia, and gastric lymphoma. Calculated population attributable fractions (PAF)—the proportion of disease directly caused by H. pylori. Estimated how many cases of each condition could be prevented through eradication, both globally and in individual countries with different H. pylori prevalence. Key findings clinicians and policymakers should grasp 1) H. pylori drives a large share of ulcer disease worldwide More than half of peptic ulcer disease globally is attributable to H. pylori. This translates into millions of preventable ulcer cases—far exceeding the absolute number of gastric cancers prevented. 2) Dyspepsia matters—even with lower attributable fractions Although only a smaller proportion of dyspepsia is attributable to H. pylori, the sheer prevalence of dyspepsia means that tens of millions of cases worldwide could potentially be prevented or improved with eradication. 3) Gastric lymphoma prevention is real, though less frequent A meaningful fraction of gastric lymphomas—rare but serious—are also attributable to H. pylori, reinforcing eradication as a cancer-prevention strategy beyond adenocarcinoma. 4) Benefits persist even in low-prevalence countries Even in countries like the United States, where H. pylori prevalence is relatively low, preventable numbers of ulcers and dyspepsia cases remain substantial. This challenges the notion that eradication only “makes sense” in high-prevalence Asian settings. This paper reframes H. pylori eradication as: not just a cancer-prevention tool, but a multidisease prevention strategy with broad population-level benefits. When PUD and dyspepsia are included: The health gains increase dramatically, Cost-effectiveness improves, and screen-and-treat strategies may be justified in a wider range of healthcare systems. Key nuance: timing matters The authors rightly caution that the true benefit depends on biology: If H. pylori triggers irreversible disease pathways early in life, later eradication may not fully prevent disease. This highlights the importance of early-life or young-adult eradication strategies in future models. Bottom-line takeaway: By focusing only on gastric cancer, we are substantially underestimating the public-health value of H. pylori eradication. Including peptic ulcer disease and dyspepsia fundamentally changes the balance in favour of broader screen-and-treat strategies. One-line GastroAGI takeaway H. pylori eradication prevents far more disease than gastric cancer alone—and policy models should reflect that reality.

Vonoprazan based dual therapy of H.Pylori infection - Front. Med.,2026

The study titled "Vonoprazan-based dual therapy for H. pylori eradication" published in *Frontiers in Medicine* in 2026 systematically evaluates the efficacy and safety of Vonoprazan-based high-dose dual therapy (VPZ-HDDT) compared to proton pump inhibitor-based high-dose dual therapy (PPI-HDDT) for Helicobacter pylori (H. pylori) eradication as a first-line treatment. Below is a detailed summary of the study findings, including an explanation of Vonoprazan and the ideal dual therapy for H. pylori eradication. --- ### **What is Vonoprazan?** Vonoprazan (VPZ) is a novel potassium-competitive acid blocker (P-CAB) that has emerged as a highly effective acid-suppressing agent. Unlike traditional proton pump inhibitors (PPIs), Vonoprazan exhibits: - **Rapid onset of action**: It begins suppressing gastric acid secretion quickly. - **Potent acid inhibition**: It provides stronger acid suppression compared to PPIs. - **Long-lasting effect**: It maintains a stable, high pH environment in the stomach for an extended period. These properties make Vonoprazan particularly suitable for enhancing the effectiveness of H. pylori eradication therapies, as adequate acid suppression is critical for the success of such treatments. --- ### **What is the Ideal Dual Therapy for H. pylori Eradication?** The ideal dual therapy for H. pylori eradication involves: 1. **High-dose acid suppression**: To maintain a consistently high gastric pH, which enhances the efficacy of antibiotics. 2. **Amoxicillin**: A broad-spectrum antibiotic with low resistance rates that targets H. pylori. 3. **Simplified regimen**: A two-drug regimen (high-dose dual therapy) is preferred over triple or quadruple therapies due to reduced complexity, fewer side effects, and better patient compliance. Vonoprazan-based high-dose dual therapy (VPZ-HDDT) includes: - Vonoprazan: Provides potent and stable acid suppression. - Amoxicillin: Administered at a high dose (3,000 mg/day) to maximize its antibacterial activity. This dual therapy regimen is designed to improve eradication rates while minimizing adverse effects and ensuring high patient compliance. ### **Study Summary** - **Efficacy**: VPZ-HDDT demonstrated superior H. pylori eradication rates compared to PPI-HDDT, making it a more effective first-line treatment option. - **Safety**: Both regimens had comparable safety profiles, with no significant differences in adverse event rates. - **Compliance**: High compliance was observed in both groups, indicating that patients tolerated both regimens well. ### **Key Takeaway** Vonoprazan-based high-dose dual therapy (VPZ-HDDT) is a highly effective and safe first-line treatment for H. pylori eradication, outperforming traditional PPI-based dual therapy in terms of eradication rates while maintaining comparable safety and compliance. This novel approach has the potential to become the new standard for H. pylori management.

Barrett’s esophagus with indefinite dysplasia(GIE, Jan-2026)

Barrett’s esophagus with indefinite dysplasia (IND) represents a challenging diagnostic category, characterized by histologic uncertainty between nondysplastic Barrett’s esophagus and low-grade dysplasia. This ambiguity often arises due to overlapping features and confounding factors such as inflammation or technical issues during biopsy interpretation. IND is considered a "gray zone" diagnosis with significant variability in pathologic interpretation among different pathologists, leading to inconsistent clinical management. Patients with IND are at risk of harboring undetected dysplasia, underscoring the importance of early re-evaluation through repeat endoscopy after optimizing acid suppression. Persistent IND over time signals a meaningful risk of progression to higher-grade dysplasia or esophageal adenocarcinoma, necessitating careful surveillance and potentially more aggressive management strategies. High-quality endoscopic techniques, systematic biopsy protocols, and improved training for endoscopists are critical to reducing missed dysplasia and ensuring accurate diagnosis. Emerging technologies, such as artificial intelligence-based computer-aided detection systems, show promise in enhancing the recognition of Barrett’s-related neoplasia. Additionally, risk stratification beyond histology, incorporating clinical factors and biomarkers, may help identify IND patients at highest risk for progression. Given the progression risk comparable to low-grade dysplasia, closer surveillance and selective therapeutic interventions are increasingly justified for patients with IND to mitigate the risk of advanced disease.

EREFS as a Clinical Trial Endpoint in Eosinophilic Oesophagitis

**Introduction:** Eosinophilic oesophagitis (EoE) is a chronic immune-mediated condition that significantly contributes to upper gastrointestinal morbidity. Historically, clinical trials evaluating treatments for EoE have relied on two co-primary endpoints: symptom improvement and histologic assessment, primarily measured by peak eosinophil count (PEC). While PEC has been widely used as an objective biomarker of disease activity, it has limitations in fully capturing the global severity and activity of EoE. Endoscopic evaluation, particularly through the Hirano EoE Endoscopic Reference Score (EREFS), has emerged as a promising outcome metric that offers a more comprehensive assessment of disease activity. This review explores the potential of EREFS as a "trial-ready" endpoint, alongside or in place of PEC, in clinical trials for EoE. --- **Problem Statement:** The current reliance on PEC as a primary histologic endpoint in EoE clinical trials may not fully encapsulate the complexity of disease activity or its impact on the oesophagus. PEC provides a snapshot of eosinophilic infiltration but does not reflect structural changes, complications, or the broader severity of the disease. On the other hand, endoscopic findings, as classified by the EREFS system, provide a standardized and validated method to assess key oesophageal features such as rings, furrows, exudates, edema, and strictures. EREFS has demonstrated accuracy, responsiveness, and clinical relevance, making it a strong candidate for inclusion as a co-primary or standalone endpoint in EoE trials. However, its integration into clinical trials requires further exploration and consensus on defined thresholds for response and its association with clinically meaningful outcomes. --- **Conclusion:** The Hirano EoE Endoscopic Reference Score (EREFS) offers a validated and standardized approach to assessing oesophageal disease activity and severity in eosinophilic oesophagitis. Evidence supports its accuracy, responsiveness to therapy, and clinical relevance, making it a viable and "trial-ready" endpoint for clinical trials. While PEC remains an important measure of histologic response, EREFS provides a complementary perspective that encompasses structural and functional changes in the oesophagus. Incorporating EREFS as a co-primary biologic endpoint in EoE trials could enhance the evaluation of therapeutic efficacy and provide a more comprehensive understanding of disease activity. This approach has the potential to improve clinical care and advance the development of effective treatments for EoE.

First genome-wide association study and idiopathic achalasia

**Introduction:** Idiopathic achalasia (IA) is a rare disorder where the neurons in the myenteric plexus degenerate, causing irreversible esophageal dysfunction. While immune-mediated mechanisms have been suggested as a cause, the exact reasons for IA remain unclear. To address this, researchers conducted the first genome-wide association study (GWAS) to explore the genetic factors contributing to IA. This study analyzed genetic data from 4,602 European patients with IA and compared it to 10,766 ethnically-matched controls. **Problem Statement:** The study aimed to uncover the genetic risk architecture of IA by identifying specific genetic variants (SNPs) and mechanisms linked to the disease. The researchers focused on the role of the HLA (human leukocyte antigen) region, as well as other genetic variants outside the HLA locus, to better understand IA's underlying biology. **Conclusion:** The study revealed that variations in the HLA-DQB1 gene, specifically an 8-amino acid insertion, are strongly associated with IA risk. Additional genetic associations were found in HLA-DQα1, HLA-DQβ1, and HLA-DRβ1 positions, highlighting the importance of HLA class II genes in IA. Outside the HLA region, three genetic variants were linked to IA, including one affecting immune-related genes like PTPN22 and TNFSF8. The findings also showed shared genetic risk between IA and Crohn’s disease, and identified memory T-cells (FOS+Tc4+CD8+) as central to IA development. This groundbreaking study provides new insights into IA’s genetic and immune-related mechanisms, paving the way for better understanding and potential therapeutic strategies.

Magnetically controlled capsule endoscopy and Gastric conditions

Magnetically Controlled Capsule Endoscopy (MCE) is an innovative, noninvasive diagnostic technology designed to evaluate gastric conditions as an alternative to the traditional esophagogastroduodenoscopy (EGD). EGD, although highly accurate, is an invasive procedure requiring sedation and the insertion of an endoscope, which can cause discomfort and potential risks for patients. MCE, on the other hand, involves swallowing a small capsule equipped with a camera that captures high-resolution images of the gastrointestinal tract. The capsule's movement is controlled externally using magnetic fields, allowing for thorough visualization of gastric anatomy without the need for invasive intervention. A recent review aimed to assess the diagnostic accuracy of MCE compared to EGD, which is considered the gold standard for detecting gastric conditions. The analysis included ten studies with a total of 1,667 diagnostic units, and the findings demonstrated that MCE has a high diagnostic accuracy. The pooled sensitivity and specificity of MCE were both 0.92, indicating its ability to correctly identify both the presence and absence of gastric abnormalities. The area under the receiver operating characteristic curve (AUC) was 0.96, reflecting excellent diagnostic performance. Furthermore, the diagnostic odds ratio (DOR) of 129 suggests that MCE is highly effective at distinguishing between diseased and non-diseased states. Despite its promising results, substantial heterogeneity (I² = 97%) was observed across studies, particularly in specificity, highlighting the need for further standardization and research. MCE offers significant potential as a noninvasive alternative to EGD, especially for patients who cannot tolerate traditional endoscopy. Future studies should focus on optimizing its clinical application, addressing interstudy variability, and evaluating its cost-effectiveness to establish its role in routine clinical practice.

Endoscopy and Celiac Disease

Endoscopy plays a crucial role in diagnosing celiac disease, a condition characterized by damage to the small intestinal lining, specifically villous atrophy (VA). Villous atrophy refers to the flattening or loss of the tiny finger-like projections (villi) in the small intestine, which are essential for nutrient absorption. Identifying VA is a key diagnostic step for celiac disease, and this is typically confirmed through duodenal biopsies taken during endoscopy. Endoscopic techniques have evolved to help in detecting VA more effectively. While standard white-light endoscopy is commonly used, it has limitations in sensitivity, meaning it may miss subtle or patchy lesions. Advanced endoscopic techniques, however, have shown improved accuracy in identifying these changes. Key advanced techniques include: 1. **Water Immersion Technique**: This method involves immersing the area with water during the procedure, enhancing visibility. It has demonstrated excellent sensitivity and specificity, making it highly effective in detecting VA. 2. **Narrow Band Imaging (NBI)**: This technique uses specific wavelengths of light to enhance the visualization of mucosal and vascular patterns. It has shown high accuracy in identifying villous atrophy. 3. **Dye-Based Chromoendoscopy**: By applying dyes to the intestinal lining during endoscopy, this method highlights abnormalities and improves the detection of subtle lesions. 4. **White Light Magnification Endoscopy**: This technique magnifies the intestinal surface for better visualization. While it has good sensitivity, its specificity is relatively lower compared to other advanced techniques. 5. **Confocal Endomicroscopy**: This is a highly advanced imaging method that provides microscopic views of the intestinal lining in real-time. It has shown good sensitivity and specificity for detecting VA. 6. **i-Scan**: A digital enhancement technology that improves mucosal visualization. Its performance is similar to standard white-light endoscopy but with slightly lower specificity. Overall, advanced endoscopic techniques like water immersion, narrow band imaging, and dye-based chromoendoscopy are particularly effective in detecting subtle or patchy lesions that might be missed by standard white-light endoscopy. These methods offer improved sensitivity and specificity, aiding in more accurate and reliable diagnosis of celiac disease. Endoscopy, combined with targeted biopsies, remains a cornerstone of diagnosing celiac disease, especially in cases where symptoms or blood tests suggest the condition.

Low FODMAP and Functional Dyspepsia

The low FODMAP diet (LFD) has emerged as a promising dietary intervention for individuals suffering from functional dyspepsia (FD), a common gastrointestinal disorder characterized by symptoms such as postprandial distress, bloating, and epigastric pain. Recent research has shed light on the potential role of increased duodenal mucosal permeability in the pathophysiology of FD, with adverse reactions to certain nutrients being a key underlying mechanism. One such group of nutrients implicated in symptom exacerbation is fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs). ### Key Findings on Low FODMAP Diet and FD: 1. **Symptom Improvement:** - A 6-week adherence to a low FODMAP diet resulted in significant improvement in symptom severity for 73% of FD patients, as measured by the Leuven Postprandial Distress Syndrome (LPDS) daily diary. - Additional validated tools, such as the Short Form-Nepean Dyspepsia Index (SF-NDI), the Patient Assessment of Upper Gastrointestinal Symptoms (PAGI-SYM), and the Patient Health Questionnaire (PHQ), also showed significant improvement in symptom scores during the LFD. 2. **Duodenal Mucosal Permeability:** - While the LFD improved symptoms, it was not associated with significant changes in mucosal integrity, as measured by transepithelial electrical resistance (TEER) and dextran flux in duodenal biopsies. - Interestingly, there was a positive correlation between changes in TEER and symptom improvement (delta TEER correlated positively with delta LPDS), suggesting that mucosal integrity may still play a role in symptom modulation for some patients. 3. **FODMAP Reintroduction and Individual Triggers:** - Following the LFD, patients underwent a blinded reintroduction phase where they were challenged with various FODMAP powders, including fructans, fructose, galacto-oligosaccharides (GOS), lactose, mannitol, sorbitol, and glucose. - A wide variety of FODMAPs were found to trigger symptoms, with mannitol being the most common trigger (23% of cases). - Interestingly, 27% of patients experienced symptom exacerbation even with glucose, which is not classified as a FODMAP, pointing to individual variations in nutrient sensitivity. ### Implications: - The study highlights that a low FODMAP diet can be an effective strategy for managing symptoms in FD patients. However, the response to individual FODMAPs varies significantly, underscoring the need for personalized dietary approaches. - The findings also suggest that while mucosal integrity is not universally altered in FD, it may still play a role in symptom generation for a subset of patients. - The unexpected symptom provocation by glucose in some individuals raises questions about other potential mechanisms, such as visceral hypersensitivity or altered gut-brain signaling, which warrant further investigation. ### Conclusion: A low FODMAP diet offers significant symptom relief for many FD patients, though the underlying mechanisms may not be solely related to mucosal permeability. Individualized reintroduction of FODMAPs is crucial to identify specific triggers and optimize dietary management. Further research is needed to explore the complex interplay of dietary factors, mucosal integrity, and symptom generation in functional dyspepsia.

Proton Pump Inhibitors and Gastric Cancer Risk: A Systematic Review

The systematic review and evidence synthesis you referred to evaluates the long-debated association between proton pump inhibitor (PPI) use and gastric cancer risk. It aims to assess potential causality through a life course epidemiology framework. Here's a detailed summary of the findings: ### **Overview of the Evidence** The review includes a comprehensive analysis of studies up to October 2024, examining the relationship between PPI use and gastric cancer risk in humans. The evidence base consists of: - **33 original studies** - **21 meta-analyses** - **Three umbrella meta-analyses** - **One individual patient data meta-analysis** - **One Markov model** ### **Key Findings** 1. **Association Between PPI Use and Gastric Cancer Risk**: - Across the studies, PPIs were consistently associated with an increased risk of gastric cancer. - Out of 21 meta-analyses, 20 reported pooled relative risks (RRs) ranging from approximately **1.3 to 2.9**, indicating a significant association. 2. **Challenges in Interpretation**: - **Confounding by indication**: Patients prescribed PPIs often have underlying conditions that may themselves increase gastric cancer risk. - **Reverse causation**: Gastric cancer symptoms may lead to PPI prescriptions, rather than PPIs causing cancer. - **Insufficient lag time**: Many studies did not account for the time required for cancer to develop. - **Helicobacter pylori infection and eradication therapy**: It was difficult to separate the effects of PPIs from those of H. pylori eradication therapies, which are also linked to gastric cancer risk. 3. **Consistency Across Study Designs**: - Despite methodological challenges, the association between PPI use and gastric cancer risk remained consistent across different study designs, populations, and analytical approaches. ### **Life Course Epidemiology Framework** The authors propose a "sensitive period" model, suggesting that exposure to PPIs during early life, childhood, or young adulthood may pose greater long-term gastric cancer risk compared to exposure later in life. Supporting evidence includes: - Exploratory analyses of Swedish cancer incidence data showing: - Declining overall gastric cancer rates since 1970. - Increasing incidence among younger men (<40 years) starting in the early 2000s, which aligns with widespread PPI use and Helicobacter pylori eradication strategies. ### **Implications for Prescribing Practices** - **Older Adults**: In older adults with clear indications for PPI use (e.g., gastroesophageal reflux disease or peptic ulcers), the gastric cancer risk may be limited. - **Younger Populations**: The widespread and often unwarranted long-term use of PPIs in younger populations raises concern, given the potential long-term risk of gastric cancer. - **Caution in Prescribing**: - The study underscores the need for a more cautious, evidence-based approach to prescribing PPIs. - Avoiding unnecessary long-term PPI use, especially in younger individuals, is recommended. ### **Conclusion** This systematic review highlights a consistent association between PPI use and increased gastric cancer risk, particularly when exposure occurs during sensitive periods of life. While the risk may be limited in older adults with clear indications for PPI use, the findings suggest that unwarranted long-term use—especially in younger populations—should be minimized. Healthcare providers are encouraged to adopt a more cautious and evidence-based prescribing approach to mitigate potential risks. Let me know if you'd like further clarification or additional details!

Impact of pH Impedance Monitoring on Management of Proven vs Unproven GERD

The study highlights the differing impacts of pH-impedance monitoring on the management of patients with *proven* versus *unproven* gastroesophageal reflux disease (GERD). Below is a detailed breakdown of the findings: ### 1. **Proven GERD (Diagnosed Off-PPI Testing)** - **Off-PPI Testing as the Gold Standard**: The study found that off-PPI wireless pH monitoring remains the foundational diagnostic tool for identifying GERD. Patients with proven GERD off PPI had clear evidence of abnormal acid exposure that confirmed the diagnosis. - **On-PPI pH-Impedance Monitoring in Proven GERD**: - For patients with proven GERD, on-PPI pH-impedance monitoring could help identify those with *refractory GERD*—persistent reflux symptoms despite optimized PPI therapy. - However, it was noted that even in these patients, on-PPI testing often failed to show conclusive evidence of GERD, as more than half of patients with proven GERD off PPI showed no conclusive GERD evidence during on-PPI testing. - **Management Implications**: - On-PPI pH-impedance testing may have limited utility in guiding PPI management decisions for patients with previously proven GERD. - Off-PPI acid exposure time modestly predicted refractory GERD on PPI, reinforcing the importance of off-PPI testing in guiding treatment strategies. ### 2. **Unproven GERD (No Clear Diagnosis Off-PPI Testing)** - **On-PPI Testing in Unproven GERD**: - The study demonstrated that on-PPI pH-impedance monitoring does not add significant diagnostic or management value in patients with unproven GERD. - None of the on-PPI pH-impedance metrics (e.g., acid exposure time, reflux episodes, symptom association) were predictive of PPI management decisions. - Relying solely on on-PPI pH-impedance testing would miss a substantial proportion of true GERD cases because these patients may not show conclusive evidence of GERD while on PPI therapy. - **Management Implications**: - On-PPI pH-impedance testing should not be used as a primary diagnostic tool in patients with unproven GERD. - These patients should undergo off-PPI testing first to establish a definitive GERD diagnosis before considering PPI therapy or further evaluation of refractory symptoms. ### 3. **Key Takeaways on Management Decisions** - **Proven GERD**: On-PPI pH-impedance testing may be helpful in identifying refractory GERD, but its utility is limited, and off-PPI testing remains more predictive of GERD status and treatment response. - **Unproven GERD**: On-PPI pH-impedance monitoring is not useful as a primary diagnostic tool. Diagnosis and management decisions should rely on off-PPI testing to confirm GERD. ### 4. **Overall Conclusion** On-PPI pH-impedance monitoring has limited utility in managing GERD patients, particularly those with unproven GERD. It should not replace off-PPI testing as the primary diagnostic strategy. Instead, it should be reserved for select cases of refractory GERD in patients with previously documented GERD who continue to experience symptoms despite optimized PPI therapy.

Long-term treatment of EoE: BOS, BOT, and PPIs

Long-term treatment of Eosinophilic Esophagitis (EoE) focuses on preventing relapse and complications like fibrostenosis by maintaining remission through sustained therapy. Recent studies have evaluated three main therapeutic options: **Budesonide Oral Suspension (BOS)**, **Budesonide Orodispersible Tablets (BOT)**, and **Proton Pump Inhibitors (PPIs)**. Here’s a detailed breakdown of their efficacy and safety: --- ### **1. Budesonide Oral Suspension (BOS):** - **Efficacy**: A four-year U.S. multicenter open-label continuation study demonstrated that BOS maintained remission in over 50% of treated patients with EoE. - **Safety**: - Some evidence of adrenal suppression was observed, which is a potential side effect of corticosteroids. - Bone mineral density remained stable in adolescents, suggesting that BOS did not significantly affect bone health over the study period. - Mild esophageal candidiasis was reported as a side effect in some patients. --- ### **2. Budesonide Orodispersible Tablets (BOT):** - **Efficacy**: A three-year European study found BOT to be highly effective, maintaining remission in a greater proportion of patients compared to BOS. - **Safety**: - Minimal cortisol suppression was observed, indicating a lower risk of systemic corticosteroid side effects compared to BOS. - Similar to BOS, mild esophageal candidiasis was reported in some cases. --- ### **3. Proton Pump Inhibitors (PPIs):** - **Efficacy**: An updated systematic review showed that PPIs achieved remission in a substantial number of patients with EoE. PPIs are thought to work by reducing esophageal acid exposure and possibly through anti-inflammatory mechanisms. - **Maintenance**: Dose tapering was found to successfully maintain remission in most responders, making PPIs a viable long-term strategy for many patients. - **Safety**: PPIs are generally well-tolerated, with fewer systemic side effects compared to corticosteroids. --- ### **Key Insights from the Studies:** - **Effectiveness**: Both BOS and BOT are effective in maintaining long-term remission in EoE, with BOT showing slightly better outcomes in terms of remission rates and lower cortisol suppression. - **Side Effects**: Mild esophageal candidiasis is a common side effect of both BOS and BOT, while PPIs are associated with fewer side effects overall. - **Patient Monitoring**: Long-term therapy requires ongoing monitoring, especially in younger populations, to assess for potential side effects like adrenal suppression or bone health concerns. - **Non-Responders**: For patients who do not respond to these therapies, alternative strategies remain a clinical priority. --- ### **Clinical Implications:** - **Treatment Personalization**: The choice between BOS, BOT, and PPIs should be individualized based on patient response, safety profiles, and preferences. - **Safety Monitoring**: Regular monitoring for potential adverse effects, such as adrenal suppression, bone density changes, and esophageal candidiasis, is crucial, particularly in younger patients. - **Research Priorities**: Further studies are needed to explore alternative treatments for non-responders and to optimize long-term management strategies. --- In summary, BOS, BOT, and PPIs are all effective options for the long-term management of EoE, with each therapy offering distinct benefits and risks. BOT appears to have a slight advantage in terms of efficacy and safety over BOS, while PPIs provide a non-corticosteroid alternative with good remission rates and minimal side effects.

GLP-1 agonist, DM and GI safety - Real World Data

GLP-1 receptor agonists are a class of medications commonly used for the treatment of type 2 diabetes mellitus (DM) and, more recently, for obesity management. These drugs work by mimicking the action of the hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. ### Gastrointestinal (GI) Safety of GLP-1 Agonists in Type 2 Diabetes A recent large real-world study published in *Annals of Internal Medicine* focused on the gastrointestinal (GI) safety of three GLP-1 receptor agonists—**dulaglutide**, **semaglutide**, and **tirzepatide**—in adults with type 2 diabetes. The study analyzed data from over 130,000 matched patient pairs using Optum’s Clinformatics database, comparing these drugs head-to-head and against a different class of diabetes medications, **SGLT2 inhibitors**. #### Key Findings: 1. **Similar GI Safety Profiles Among GLP-1 Agonists**: - When dulaglutide, semaglutide, and tirzepatide were compared directly, they showed **no significant differences** in the risk of serious GI events. - Hazard ratios (HR) for severe GI events were: - **Tirzepatide vs. Dulaglutide**: HR 0.96 - **Semaglutide vs. Dulaglutide**: HR 0.96 - **Tirzepatide vs. Semaglutide**: HR 1.07 - These findings suggest that all three drugs carry **comparable levels of GI risk** when used in routine clinical practice. 2. **Higher GI Risk Compared to SGLT2 Inhibitors**: - When each GLP-1 agonist was compared to SGLT2 inhibitors, all three showed a **higher risk of GI adverse events**: - **Tirzepatide**: HR 1.53 - **Dulaglutide**: HR 1.36 - **Semaglutide**: HR 1.22 - The increased risk was primarily attributed to **GI motility-related issues**, such as delayed gastric emptying. This effect is a known physiological consequence of GLP-1 and GIP hormone stimulation. 3. **Types of Serious GI Events Studied**: - The study assessed a composite of serious GI events, including: - Bowel obstruction - Gastroparesis (delayed stomach emptying) - Pancreatitis - Biliary disease - Severe constipation - Despite these risks, the differences within the GLP-1 class were minimal, reassuring clinicians about the safety of these treatments. #### Clinical Implications: - **GLP-1 Agonists in Routine Practice**: - Clinicians can feel confident that dulaglutide, semaglutide, and tirzepatide have **similar GI safety profiles** and can be used interchangeably based on patient-specific factors such as efficacy, weight loss benefits, and tolerability. - **Comparison to SGLT2 Inhibitors**: - While GLP-1 agonists are associated with higher GI risks than SGLT2 inhibitors, these risks are generally manageable and expected due to the mechanism of action of GLP-1 receptor agonists. - **Monitoring and Counseling**: - Patients on GLP-1 agonists should be counseled about potential GI side effects, including nausea, vomiting, and constipation, which are common but often transient. - Clinicians should monitor for more serious GI events, especially in patients with pre-existing GI conditions like gastroparesis. #### Limitations of the Study: - The study relied on diagnostic codes from electronic health records, which may lead to **underreporting or misclassification** of GI events. - Uncontrolled confounding factors could influence the results, and the data may not fully capture all real-world adverse events. - The findings primarily apply to patients with type 2 diabetes and may not fully extend to individuals using these drugs for obesity treatment without diabetes. ### Conclusion: GLP-1 receptor agonists (dulaglutide, semaglutide, tirzepatide) are effective treatments for type 2 diabetes and obesity, with **similar GI safety profiles** within the class. However, they carry a **higher risk of GI adverse events** compared to SGLT2 inhibitors, driven mainly by delayed gastric emptying. Clinicians should consider these risks when prescribing GLP-1 agonists and provide appropriate monitoring and patient education. Ongoing studies and post-marketing surveillance are essential as these drugs are increasingly used in broader populations, including non-diabetic individuals for obesity management.

Endoscopic biopsy techniques in Barrett esophagus

**Ideal Recommendation for Endoscopic Biopsy in Barrett's Esophagus:** Based on the study findings, the ideal technique for endoscopic biopsy in Barrett's esophagus (BE) surveillance is the **single-biopsy method** combined with the **turn-and-suction technique**. This combination consistently produces the largest and highest-quality biopsy specimens, which are essential for accurate histological diagnosis, including detecting dysplasia or early cancer. **Key Findings:** 1. **Single vs Double Biopsy:** - Single-biopsy samples were about **25% larger** than double-biopsy samples, providing more tissue for analysis. - Larger biopsy samples improve diagnostic accuracy for identifying dysplasia or early cancer. 2. **Biopsy Techniques:** - The **turn-and-suction technique** produced slightly larger biopsy samples compared to the advance-and-close technique. - While the difference was modest, the turn-and-suction method was still superior. 3. **Optimal Combination:** - The combination of **single-biopsy + turn-and-suction** yielded the largest biopsy samples overall, with a mean size of **3.54 mm²**, outperforming all other methods. 4. **Real-World Validation:** - In Part II of the study, this optimal approach was implemented in clinical practice with another 90 patients. Biopsy sizes increased by **18%**, confirming the method's effectiveness in real-world settings. **Summary of the Text:** This study investigated the best endoscopic biopsy techniques for Barrett's esophagus surveillance, focusing on biopsy size as a critical factor for diagnostic accuracy. A randomized multicenter trial involving 107 patients showed that single-biopsy samples were significantly larger than double-biopsy samples, and the turn-and-suction technique produced slightly larger biopsies than the advance-and-close technique. The combination of single-biopsy with turn-and-suction yielded the largest biopsy specimens. In subsequent real-world practice involving 90 patients, biopsy sizes increased by 18%, validating the approach. The study strongly recommends using the single-biopsy method with the turn-and-suction technique for BE surveillance, as this combination produces the largest, highest-quality specimens needed for accurate histological diagnosis.

Barrett’s esophagus afte RF ablation vs. cryoballoon ablation - Rate of Recurrence

The study compared the long-term recurrence rates of Barrett's esophagus (BE) in patients who achieved complete remission of intestinal metaplasia (CRIM) after undergoing treatment with either radiofrequency ablation (RFA) or cryoballoon ablation (CBA). Below is a detailed breakdown of the recurrence rates and key findings: ### **Overall Recurrence of Barrett's Esophagus** - **Initial Analysis**: RFA appeared to have a higher risk of "any BE recurrence" compared to CBA. However, this difference disappeared when minimal recurrence at the gastroesophageal junction was excluded and when patient characteristics were balanced using propensity-score matching. - **Final Conclusion**: After accounting for these factors, the recurrence rates of Barrett’s esophagus were found to be comparable between RFA and CBA. Both treatments demonstrated similar long-term durability in preventing recurrence. ### **Dysplastic Recurrence Rates** - Dysplastic recurrence refers to the return of abnormal or precancerous changes in the esophageal tissue, which is a more concerning outcome than non-dysplastic recurrence. - The rates of dysplastic recurrence were **similar** between the two groups in all analyses: - **Cryoballoon ablation (CBA)**: 3.7 per 100 patient-years - **Radiofrequency ablation (RFA)**: 2.8 per 100 patient-years - The recurrence curves for dysplasia were nearly overlapping between the two groups, indicating no significant difference in the risk of dysplastic recurrence. ### **Key Predictor of Recurrence** - The **baseline length of the Barrett’s segment** was identified as a significant predictor of recurrence. Patients with longer BE segments at the start of treatment were more likely to experience both: - Any recurrence of BE - Dysplastic recurrence - This finding was consistent regardless of whether the patient received RFA or CBA. ### **Conclusion** Both RFA and CBA are effective and durable options for treating Barrett's esophagus and preventing its recurrence after achieving CRIM. The long-term rates of both any recurrence and dysplastic recurrence are comparable between the two modalities. The choice of treatment may depend on other factors, such as patient-specific characteristics, physician expertise, and resource availability, rather than significant differences in recurrence rates.

AGA Guideline on Surveillance of Barrett’s Esophagus

The American Gastroenterological Association (AGA) guideline on the surveillance of Barrett's Esophagus (BE) provides evidence-based recommendations aimed at improving early detection of dysplasia and reducing the risk of esophageal adenocarcinoma (EAC). Below is a detailed overview of the guideline's key aspects: ### **1. Purpose of the Guideline** The primary goal of the AGA guideline is to provide clinicians and patients with clear, evidence-based recommendations for endoscopic surveillance in Barrett’s Esophagus. This surveillance is intended to detect early neoplasia and reduce mortality associated with EAC. ### **2. Main Objective** The guideline seeks to answer critical questions about when and how surveillance should be performed, ensuring optimal outcomes for patients with BE. It emphasizes early detection of dysplasia or carcinoma while balancing risks, benefits, and feasibility. ### **3. Evidence Framework** The recommendations are developed using the GRADE methodology, which evaluates the quality of evidence, balances benefits against harms, incorporates patient values, and considers feasibility in clinical practice. --- ### **4. Key Recommendations** The guideline addresses various aspects of BE surveillance, including frequency, imaging techniques, sampling protocols, biomarkers, and chemoprevention. Below are the major recommendations: #### **Surveillance Frequency** - **Nondysplastic Barrett's Esophagus (NDBE):** AGA conditionally recommends surveillance endoscopy every **3 years** for most patients with NDBE to detect early dysplasia or carcinoma. - **Low-Risk Patients:** For patients with **short-segment BE (<3 cm)** and low risk of progression, surveillance intervals can be extended up to **5 years**. - **Discontinuation of Surveillance:** Surveillance should be stopped in patients with advanced age, significant comorbidities, or limited life expectancy. This is typically discussed around age **75**. #### **Columnar-Lined Esophagus <1 cm** - Surveillance is **not recommended** for BE segments under **1 cm** with intestinal metaplasia due to the extremely low risk of progression to cancer. --- ### **5. Imaging Strategy** - **High-Definition White-Light Endoscopy (WLE) + Chromoendoscopy (CE):** AGA strongly recommends combining high-definition WLE with CE for better dysplasia detection compared to WLE alone. - **Choice of Chromoendoscopy:** Either **dye-based CE** or **virtual CE** can be used, depending on the endoscopist's expertise and the available technology. --- ### **6. Sampling Technique** - A structured biopsy protocol is advised: - **Targeted biopsies** from visible lesions. - **Four-quadrant random biopsies** every **2 cm** (or every **1 cm** if there is a history of dysplasia). #### **Use of WATS-3D** - The guideline does not make a recommendation for or against **WATS-3D adjunctive sampling** due to insufficient evidence, highlighting this as a research gap. --- ### **7. Role of Biomarkers** - Routine biomarker testing (such as **p53** or **TissueCypher**) is **not recommended**. Current evidence is limited and inconsistent, making their role in clinical practice unclear. --- ### **8. Chemopreventive Therapy** - **Proton Pump Inhibitors (PPIs):** Daily PPI therapy is conditionally recommended for BE patients to reduce the risk of neoplastic progression. - **PPIs vs. Antireflux Surgery:** PPIs are preferred over antireflux surgery for preventing high-grade dysplasia or EAC due to better safety and comparable efficacy. --- ### **9. Quality Standards for Endoscopy** - Surveillance endoscopy should be performed using **high-quality examinations** by trained specialists to ensure accurate detection of dysplasia or early neoplasia. --- ### **10. Expert Pathology Confirmation** - Diagnoses of dysplasia or early EAC must be confirmed by an **expert gastrointestinal pathologist** to avoid misclassification, which can lead to inappropriate management. --- ### **11. Patient-Centered Approach** - Shared decision-making between clinicians and patients is emphasized. Surveillance intensity should align with individual risks, preferences, and values. --- ### **12. Safety of Endoscopy** - Surveillance endoscopy is considered safe, with **very low complication rates**. Serious adverse events such as bleeding or perforation occur in fewer than **1 in 10,000 cases**. --- ### **13. Research Gaps and Future Focus** The guideline identifies several areas requiring further study to optimize BE management: - **Biomarkers:** Research is needed to validate biomarkers for risk stratification. - **Nonendoscopic Screening Tools:** Developing tools like capsule-sponge tests for easier and less invasive screening. - **Surveillance Intervals:** Better-defined intervals for endoscopic surveillance based on individual risk factors. --- ### **Conclusion** The AGA guideline provides a comprehensive framework for the surveillance of Barrett's Esophagus, emphasizing evidence-based practices to improve early detection and outcomes while minimizing unnecessary interventions. It highlights the importance of personalized care, expert pathology review, and high-quality endoscopic techniques. Further research is required to address gaps in knowledge, particularly regarding biomarkers and nonendoscopic screening methods.

BOSS trial

The BOSS trial (Barrett’s Oesophagus Surveillance Study) was a landmark randomized controlled trial designed to evaluate whether scheduled endoscopic surveillance improves survival outcomes in patients with Barrett's esophagus compared to symptom-driven or "at-need" endoscopy. Below is a detailed summary of the trial: ### **Purpose and Background** The primary aim of the BOSS trial was to determine if routine, scheduled surveillance endoscopy leads to better survival outcomes for patients with Barrett's esophagus, a condition that can increase the risk of developing esophageal adenocarcinoma (EAC). Historically, guidelines recommended regular surveillance for Barrett’s esophagus, based on an assumed annual progression rate to EAC of 1%. However, this trial sought to challenge that assumption and provide evidence-based guidance on the necessity of routine surveillance. ### **Study Design** - **Participants:** 3453 patients diagnosed with Barrett’s esophagus. - **Randomization:** Patients were randomized into two groups: 1. **Surveillance group:** Underwent scheduled endoscopy every 2 years. 2. **At-need group:** Underwent endoscopy only when clinically indicated by symptoms (e.g., dysphagia, bleeding, or other signs of disease progression). - **Follow-up:** Median follow-up duration was 12.8 years, making it one of the longest trials for Barrett’s esophagus. - **Centers:** Conducted across 109 centers in the UK. ### **Key Findings** 1. **Overall Survival:** - No significant difference in overall survival between the two groups. - Surveillance group: 19.2% deaths. - At-need group: 20.7% deaths. - Hazard ratio (HR): 0.95 (95% CI 0.82–1.10; P = .503). 2. **Cancer-Specific Survival:** - No significant difference in cancer-related mortality. - Surveillance group: 108 deaths. - At-need group: 106 deaths. - HR: 1.01 (95% CI 0.77–1.33). 3. **Esophageal Adenocarcinoma (EAC) Incidence:** - EAC was diagnosed in 71 patients (2.1% of the cohort). - Surveillance group: 40 cases. - At-need group: 31 cases. - Routine surveillance did not significantly reduce EAC incidence. 4. **Cancer Stage at Diagnosis:** - The stage distribution of EAC was similar between groups. - A slightly higher proportion of T1a cancers (early-stage) was detected in the surveillance arm, but this difference was not statistically significant. 5. **Adverse Events:** - Serious endoscopy-related adverse events were rare and comparable between groups: - Surveillance group: 0.46%. - At-need group: 0.41%. 6. **Endoscopy Burden:** - Surveillance patients underwent significantly more endoscopies: - Surveillance group: 6124 procedures. - At-need group: 2424 procedures. - This translated to a 1.62-fold higher rate of procedures in the surveillance arm, with no corresponding survival benefit. 7. **Risk of EAC Progression:** - The annual risk of developing EAC in the cohort was only 0.23% per year, far lower than the previously assumed rate of 1%. 8. **Impact by Age:** - Subgroup analysis suggested a possible survival benefit for patients aged >65 years (HR 0.74, 95% CI 0.60–0.91), but no benefit was observed for younger patients. This finding requires cautious interpretation. 9. **Quality of Detection:** - Surveillance increased detection of dysplasia (low-grade dysplasia [LGD] and high-grade dysplasia [HGD]), but this did not translate into reduced EAC incidence or mortality. 10. **Exit Endoscopy Findings:** - At the end of the trial, additional endoscopies in the at-need group identified 8 cases of EAC and 9 cases of HGD, highlighting that delayed detection did not impact overall survival. ### **Conclusions** - **Limited Benefit of Routine Surveillance:** Scheduled surveillance for nondysplastic Barrett’s esophagus did not improve overall survival or cancer-specific survival compared to symptom-triggered endoscopy. - **Low Risk of Malignant Progression:** The annual progression rate to EAC was much lower than previously thought (0.23% vs the assumed 1%). - **Guideline Implications:** The findings challenge current global guidelines recommending routine surveillance for nondysplastic Barrett’s esophagus, particularly for low-risk patients or those with short-segment Barrett’s esophagus. - **Resource Utilization:** Routine surveillance programs may overuse healthcare resources without providing clear survival benefits. - **Tailored Approach:** The study supports tailoring surveillance intervals or adopting “at-need” endoscopy for low-risk patients with Barrett’s esophagus. ### **Historical Context** When the trial began in 2009, the prevailing belief was that Barrett’s esophagus carried a substantial risk of progression to EAC, warranting frequent surveillance. The BOSS trial has since reshaped this understanding, demonstrating that malignant progression is much rarer than previously estimated. ### **Real-World Representation** The study's participants closely mirrored real-world Barrett’s populations: - Mean age: 63 years. - Gender: 71% male. - Approximately 94% of participants were on proton pump inhibitors (PPIs), reflecting typical clinical management of Barrett’s esophagus. ### **Clinical Implications** The BOSS trial provides robust evidence against routine surveillance for nondysplastic Barrett’s esophagus, particularly in low-risk patients. It reinforces the need for a more individualized approach to management, balancing the procedural burden against the actual risk of progression to EAC. For patients over 65 years, further research may be needed to explore potential age-related benefits. ### **Guideline Recommendations** The trial’s findings suggest reconsideration of current guidelines advocating routine surveillance for nondysplastic Barrett’s esophagus, with a focus on risk stratification and resource optimization. In summary, the BOSS trial represents a pivotal moment in the management of Barrett’s esophagus, offering long-term data to guide evidence-based clinical practice.

Blood-Based T-Cell Diagnosis of Celiac Disease

The blood-based T-cell diagnosis of celiac disease (CeD) represents a groundbreaking advancement in the diagnostic landscape, particularly for individuals adhering to a gluten-free diet (GFD). The study introduces and validates the whole-blood interleukin-2 (IL-2) release assay (WBAIL-2) as a novel diagnostic tool, addressing the limitations of traditional serology and intestinal biopsy methods. ### Key Highlights of Blood-Based T-Cell Diagnosis for CeD: #### 1. **Study Objective**: - The WBAIL-2 assay was developed to detect gluten-specific CD4⁺ T cells by measuring IL-2 release after gluten peptide stimulation in blood samples. - This approach is particularly useful for diagnosing CeD in patients already on a GFD, where conventional diagnostics often fail due to normalized serology or lack of active symptoms. #### 2. **Clinical Challenge**: - Traditional diagnostic methods for CeD, such as serological tests and intestinal biopsy, require active gluten consumption, posing challenges for patients who have adopted a GFD to manage symptoms. - These methods are invasive, time-consuming, and may not yield reliable results for GFD patients. #### 3. **Novel Diagnostic Approach**: - WBAIL-2 provides a non-invasive, blood-based alternative that bypasses the need for gluten consumption. - The assay measures IL-2 secretion from gluten-specific CD4⁺ T cells, offering a practical and simpler workflow compared to complex T-cell assays or biopsy procedures. #### 4. **Study Design**: - The validation study involved 181 adults, including: - 88 patients with CeD (75 on GFD and 13 with active disease), - 32 individuals with nonceliac gluten sensitivity (NCGS), - 61 healthy controls. - This diverse cohort allowed robust assessment of the assay’s diagnostic performance. #### 5. **High Diagnostic Accuracy**: - In HLA-DQ2.5⁺ patients, WBAIL-2 demonstrated: - **90% sensitivity** and **95% specificity** for CeD. - The assay performed comparably to HLA-tetramer-based methods but with a simpler and more accessible workflow. #### 6. **Correlation With T-Cell Activity**: - WBAIL-2 results strongly correlated with tetramer-positive gluten-specific T-cell frequency and serum IL-2 levels after gluten challenge, confirming its biological relevance. - Higher WBAIL-2 and serum IL-2 levels also predicted more severe gluten-induced symptoms, such as vomiting, making it a potential biomarker for clinical response. #### 7. **Performance in GFD Patients**: - A significant advantage of WBAIL-2 is its ability to accurately identify CeD even in patients strictly adhering to a GFD, unlike serology tests that often normalize with gluten withdrawal. #### 8. **Mechanistic Validation**: - Cytokine capture assays confirmed that IL-2 secretion originates directly from gluten-specific CD4⁺ T cells, validating the assay’s mechanistic basis as a disease marker. #### 9. **In Vivo–In Vitro Correlation**: - A strong correlation was observed between serum IL-2 levels after gluten ingestion (GCIL-2) and WBAIL-2 values, indicating complementary diagnostic potential. #### 10. **Dynamic Response to Gluten Exposure**: - After a gluten challenge, WBAIL-2 values increased up to 30-fold, mirroring the expansion of circulating gluten-reactive T-effector memory cells. #### 11. **HLA Genotype Influence**: - The assay’s sensitivity was genotype-specific, with lower sensitivity (56%) observed in HLA-DQ8⁺ patients compared to HLA-DQ2.5⁺ individuals. #### 12. **First-Degree Relatives**: - Some first-degree relatives of CeD patients showed positive WBAIL-2 results despite negative serology, suggesting subclinical immune activation or genetic predisposition toward CeD. #### 13. **Comparison With Cytokine Markers**: - IL-2 emerged as the strongest diagnostic biomarker among cytokines tested, outperforming IFN-γ and IL-17A in specificity. #### 14. **Variability and Precision**: - The WBAIL-2 assay demonstrated acceptable variability (18–46% coefficient of variation), comparable to other widely used immune assays like QuantiFERON-Gold for tuberculosis. #### 15. **No Effect of Autoimmunity**: - IL-2 responses were unaffected by the presence of other autoimmune diseases in CeD patients, confirming the assay’s specificity to gluten-reactive T-cell activation. #### 16. **Clinical Applicability**: - WBAIL-2 requires only 4 mL of blood and simple laboratory equipment, making it feasible for routine use in clinical settings without specialized immunology infrastructure. #### 17. **Advantages Over Tetramer Assays**: - Unlike tetramer-based methods, WBAIL-2 does not require knowledge of patient HLA type or large blood volumes, making it more practical for widespread diagnostic use. #### 18. **Future Potential**: - The assay could serve as a biopsy-free diagnostic tool for CeD and may also be used to monitor disease activity or assess treatment response in CeD and other T-cell–mediated conditions. #### 19. **Translational Implications**: - WBAIL-2 and serum IL-2 assays represent a shift toward immune-based, non-invasive diagnosis for CeD, offering a practical, rapid, and patient-friendly alternative to traditional biopsy-dependent methods. ### Conclusion: The WBAIL-2 assay marks a significant advancement in diagnosing celiac disease, providing a sensitive, specific, and non-invasive alternative to traditional methods. It is particularly beneficial for patients on a gluten-free diet, offering accurate results without requiring gluten consumption. With its simple workflow and minimal blood volume requirements, WBAIL-2 has the potential to become a routine diagnostic tool, paving the way for more accessible and patient-centered care in celiac disease management.

Standardizing FLIP Interpretation

Standardizing FLIP (Functional Lumen Imaging Probe) interpretation is crucial for ensuring its reliability and utility in clinical practice, especially for diagnosing and managing esophageal motility disorders. FLIP is a diagnostic tool that uses impedance planimetry to measure the geometry and distensibility of the esophagogastric junction (EGJ) and other parts of the esophagus. It provides valuable insights into esophageal function by assessing parameters like the EGJ distensibility index (EGJ-DI), which can help identify motility disorders such as achalasia. However, the paper highlights several challenges in standardizing FLIP interpretation. One major issue is the lack of calibration standards across different FLIP systems, which results in inconsistencies due to variations in catheter size, balloon compliance, and software versions. Without harmonized calibration protocols, data reproducibility is compromised, particularly in multicenter studies and artificial intelligence modeling efforts. Furthermore, FLIP is underutilized for longitudinal monitoring, limiting its potential as a tool to track treatment outcomes over time. The absence of clinical correlation between FLIP measurements and validated symptom scores, such as the Eckardt score or EAT-10, further complicates its interpretation. The authors call for future consensus updates to focus on calibration protocols, predictive modeling, and longitudinal quantification to transform FLIP into a standardized biomarker for esophageal motility assessment. This would enhance its diagnostic accuracy and utility in clinical practice.

Infantile Hypertrophic Pyloric Stenosis (IHPS)

**Infantile Hypertrophic Pyloric Stenosis (IHPS): A Comprehensive Overview** Infantile Hypertrophic Pyloric Stenosis (IHPS) is a condition in infants that involves abnormal thickening (hypertrophy) of the pyloric muscle, which functions as a valve between the stomach and the duodenum (the first part of the small intestine). This thickening leads to **gastric outlet obstruction**, making it difficult for food to pass from the stomach into the intestines. As a result, affected infants experience **severe, non-bilious projectile vomiting**, which progressively worsens if left untreated. IHPS is one of the most common causes of gastrointestinal obstruction in infants and requires prompt medical attention. --- ### **Epidemiology** - **Incidence**: IHPS occurs in approximately **3 in 1,000 live births** in the United States, with variations in incidence globally (ranging from 1 to 8 in 1,000 live births). - **Gender**: Males are 4–5 times more likely to develop IHPS compared to females. - **Ethnicity**: The condition is most common in Caucasian infants, particularly those of Northern European descent, while it is less common in African American and Asian infants. - **Age of Onset**: Symptoms typically appear between **3–6 weeks of age** and rarely occur after 12 weeks. - **Familial Tendency**: IHPS often runs in families, suggesting a **polygenic inheritance pattern**. Male relatives of affected females have a particularly high risk. --- ### **Causes and Risk Factors** The exact cause of IHPS is not fully understood, but it is believed to result from a combination of **genetic** and **environmental factors**. #### **Genetic Factors**: - IHPS exhibits familial clustering, indicating a genetic predisposition. - Specific genetic loci have been identified, including **NOS1 (12q24.2)**, **IHPS2 (16p12-p13)**, and **IHPS3 (11q14-q22)**. - Genome-wide association studies have implicated genes such as **MBNL1** and **NKX2-5** in increasing the risk of IHPS. #### **Environmental Factors**: - **Male sex**: Males are significantly more likely to develop IHPS. - **Firstborn status**: Firstborn infants show a higher incidence of IHPS. - **Macrolide antibiotics**: Exposure to macrolide antibiotics (e.g., erythromycin) during infancy or indirectly through breastfeeding increases the risk. - **Formula feeding**: Formula-fed infants have a higher risk compared to breastfed infants. - **Maternal factors**: Advanced maternal age, smoking during pregnancy, and bottle feeding are associated with increased risk. --- ### **Pathophysiology** The hallmark of IHPS is **hypertrophy and hyperplasia** of the circular muscle layer of the pylorus, leading to narrowing of the pyloric canal. This narrowing causes **gastric outlet obstruction**, preventing food from moving into the small intestine. Several hypotheses have been proposed to explain the underlying mechanisms: 1. **Nitric Oxide Deficiency**: A localized deficiency in **nitric oxide synthase**, an enzyme responsible for smooth muscle relaxation, may lead to sustained contraction of the pyloric muscle. 2. **Abnormal Neural Development**: Impaired neuronal innervation and reduced **interstitial cells of Cajal** (cells responsible for gut motility) have been implicated. 3. **Hormonal Influence**: Elevated levels of hormones such as **gastrin** and **prostaglandins** may contribute to the development of pyloric muscle hypertrophy. --- ### **Clinical Features** IHPS typically presents with the following symptoms and signs: 1. **Projectile Vomiting**: - Vomiting begins as mild regurgitation and progresses to **forceful, projectile vomiting** after feedings. - Vomitus is **non-bilious**, as the obstruction occurs before the duodenum where bile enters the gastrointestinal tract. - Occasionally, the vomitus may contain traces of blood due to irritation of the stomach lining. 2. **Feeding Difficulties**: - Infants are often hungry after vomiting and may feed vigorously ("hungry vomiting"). - Prolonged vomiting can lead to **poor weight gain** or weight loss. 3. **Dehydration**: - Symptoms include dry mucous membranes, sunken fontanelle, decreased urine output, and lethargy. - Severe dehydration can lead to **failure to thrive**. 4. **Palpable "Olive" Mass**: - A firm, mobile, olive-shaped mass may be felt in the **right upper quadrant** or **epigastrium**, representing the hypertrophied pylorus. - This is best palpated during or immediately after feeding. 5. **Visible Peristalsis**: - Visible peristaltic waves may be observed moving from left to right across the abdomen as the stomach attempts to push food through the obstructed pylorus. --- ### **Diagnosis** The diagnosis of IHPS is based on **clinical findings** and **imaging studies**. #### **Laboratory Findings**: - **Electrolyte Imbalance**: - **Hypochloremic metabolic alkalosis** due to the loss of hydrochloric acid from persistent vomiting. - **Hypokalemia** due to secondary loss of potassium through the kidneys. - **Dehydration**: Elevated blood urea nitrogen (BUN) and creatinine levels. #### **Imaging Studies**: 1. **Ultrasound** (Gold Standard): - Highly sensitive and specific for diagnosing IHPS. - Key findings include: - **Pyloric muscle thickness** >3–4 mm. - **Pyloric channel length** >14–20 mm. - "Target sign" or "donut sign" on transverse view of the pylorus. 2. **Upper Gastrointestinal (GI) Contrast Study**: - Used when ultrasound results are inconclusive. - Findings include: - **String sign**: Narrowing of the pyloric canal. - **Shoulder sign**: Bulging of the hypertrophied pylorus into the antrum. --- ### **Management** The treatment of IHPS involves **preoperative stabilization** and **surgical intervention**. #### **Preoperative Management**: 1. **Fluid and Electrolyte Replacement**: - Intravenous (IV) fluids are administered to correct dehydration. - Electrolyte imbalances, such as **hypochloremic metabolic alkalosis**, are treated with normal saline and potassium supplementation. #### **Definitive Treatment**: 2. **Ramstedt Pyloromyotomy**: - This is the standard surgical procedure for IHPS. - A surgeon makes a longitudinal incision through the hypertrophied pyloric muscle down to the submucosa, allowing the pylorus to relax and restore normal gastric emptying. - The procedure can be performed laparoscopically or via an open surgical approach. #### **Postoperative Care**: 3. **Post-Surgery Feeding**: - Feeding is resumed 12–24 hours after surgery, starting with small, frequent feeds. - Most infants tolerate feeding well and recover quickly. 4. **Follow-Up**: - Regular monitoring for any signs of complications, such as infection or delayed gastric emptying. --- ### **Complications** If untreated, IHPS can lead to serious complications: 1. **Severe Dehydration**: Prolonged vomiting may result in hypovolemic shock. 2. **Electrolyte Imbalances**: - Metabolic alkalosis can impair respiratory drive and lead to apnea. 3. **Malnutrition**: Persistent vomiting can cause failure to thrive. 4. **Gastric Perforation**: Rare but life-threatening due to increased intragastric pressure. --- ### **Differential Diagnosis** Conditions that can mimic IHPS include: 1. **Gastroesophageal Reflux Disease (GERD)**: Vomiting is non-projectile and associated with heartburn. 2. **Pylorospasm**: A functional obstruction without hypertrophy, often resolves spontaneously. 3. **Duodenal Atresia/Stenosis**: Causes bilious vomiting due to obstruction beyond the pylorus. 4. **Malrotation with Midgut Volvulus**: Presents with bilious vomiting and requires emergency surgical intervention. 5. **Sepsis or Meningitis**: May present with vomiting, lethargy, and poor feeding. --- ### **Prognosis** The prognosis for IHPS is excellent when diagnosed and treated promptly. After surgical intervention, most infants recover fully, resume normal feeding, and achieve healthy growth and development. Long-term complications are rare, though some infants may experience transient delayed gastric emptying or mild gastroesophageal reflux. --- ### **Key Points to Remember** 1. IHPS is a common cause of gastrointestinal obstruction in infants, typically presenting between **3–6 weeks of age**. 2. The hallmark symptom is **non-bilious projectile vomiting** and a palpable **olive-shaped mass** in the abdomen. 3. Diagnosis is confirmed via **ultrasound**, which shows thickened and elongated pyloric muscle. 4. Treatment involves **preoperative stabilization** followed by **Ramstedt pyloromyotomy**, which is highly effective. 5. Early diagnosis and treatment are crucial to prevent complications such as dehydration, malnutrition, and shock. If you have further questions or need more details, feel free to ask!

Anorexia Nervosa and Bulimia Nervosa

Anorexia Nervosa (AN) and Bulimia Nervosa (BN) are two of the most common eating disorders, both of which involve significant disturbances in eating behavior and an intense preoccupation with body weight, shape, and appearance. While they share some similarities, they are distinct disorders with unique clinical presentations, pathophysiology, and complications. Below is a detailed overview of both conditions: --- ## **Anorexia Nervosa (AN)** ### **Definition**: Anorexia nervosa is a psychiatric disorder characterized by **self-imposed starvation**, an intense fear of gaining weight, and a distorted body image. Individuals with AN often have significantly low body weight and suffer from severe malnutrition. ### **Diagnostic Criteria (DSM-5)**: 1. **Restriction of energy intake** leading to significantly low body weight (less than minimally normal for age, sex, and health). 2. **Intense fear of gaining weight** or becoming fat, even when underweight. 3. **Disturbance in body image**, undue influence of body weight/shape on self-evaluation, or persistent lack of recognition of the seriousness of low body weight. ### **Types of Anorexia Nervosa**: 1. **Restricting Type**: Weight loss is achieved through strict dieting, fasting, or excessive exercise. 2. **Binge-Eating/Purging Type**: Regular episodes of binge eating followed by purging behaviors (e.g., self-induced vomiting or misuse of laxatives, diuretics, or enemas). ### **Pathophysiology**: - **Neuroendocrine Dysregulation**: Dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, leading to hormonal imbalances such as reduced gonadotropins, thyroid hormones, and increased cortisol levels. - **Starvation Effects**: Chronic caloric restriction causes metabolic adaptations like bradycardia, hypothermia, and reduced basal metabolic rate. - **Psychological Factors**: Perfectionism, anxiety disorders, and obsessive-compulsive traits are common comorbidities. ### **Clinical Features**: 1. **Systemic Features**: - Severe weight loss, emaciation. - Hypothermia, bradycardia, hypotension. - Amenorrhea (absence of menstruation) in females due to hormonal imbalances. - Fatigue, brittle nails, thinning hair, and lanugo (fine body hair). 2. **Gastrointestinal Symptoms**: - **Gastroparesis**: Delayed gastric emptying leading to bloating, early satiety, nausea, and constipation. - **Abdominal pain**: Often caused by slowed gut motility. - **Refeeding Syndrome**: A dangerous condition when nutrition is reintroduced, causing electrolyte imbalances (e.g., hypophosphatemia), cardiac arrhythmias, and fluid shifts. 3. **Psychological Features**: - Distorted body image and intense fear of weight gain. ### **Complications**: 1. **Cardiovascular**: Bradycardia, hypotension, arrhythmias, and heart failure. 2. **Endocrine**: Hypothyroidism, osteoporosis (due to estrogen deficiency), and growth retardation in adolescents. 3. **Hematologic**: Anemia, leukopenia, and thrombocytopenia. 4. **Gastrointestinal**: Chronic constipation, gastric atrophy, and superior mesenteric artery syndrome. 5. **Neurological**: Cognitive impairment, peripheral neuropathy, and brain atrophy. --- ## **Bulimia Nervosa (BN)** ### **Definition**: Bulimia nervosa is an eating disorder characterized by **recurrent episodes of binge eating** followed by **compensatory behaviors** such as self-induced vomiting, excessive exercise, or misuse of laxatives to prevent weight gain. Unlike anorexia nervosa, individuals with bulimia nervosa typically maintain a **normal or near-normal body weight**. ### **Diagnostic Criteria (DSM-5)**: 1. **Recurrent episodes of binge eating**, characterized by: - Eating an unusually large amount of food within a discrete period. - A sense of lack of control over eating during the episode. 2. **Recurrent compensatory behaviors** to prevent weight gain, such as vomiting, fasting, excessive exercise, or misuse of laxatives. 3. The binge eating and compensatory behaviors occur at least **once a week for three months**. 4. Self-evaluation is excessively influenced by body weight and shape. ### **Pathophysiology**: - **Neurochemical Imbalances**: Disruption in serotonin and dopamine pathways, which regulate appetite, mood, and reward systems. - **Behavioral Cycle**: Binge eating episodes are followed by feelings of guilt, shame, and compensatory behaviors, creating a vicious cycle. - **Gastrointestinal Effects**: Frequent vomiting leads to damage to the esophagus, teeth, and other parts of the GI tract. ### **Clinical Features**: 1. **Systemic Features**: - Normal or slightly overweight body weight. - Electrolyte disturbances (e.g., hypokalemia, hypochloremia, metabolic alkalosis due to vomiting). 2. **Gastrointestinal Symptoms**: - **Recurrent vomiting**: Causes dental enamel erosion, parotid gland swelling, and esophagitis. - **Constipation**: Often due to laxative abuse or dehydration. - **Abdominal pain**: Common after binge episodes. 3. **Psychological Features**: - Feelings of guilt, shame, and loss of control over eating. ### **Complications**: 1. **Gastrointestinal**: - Esophagitis, Barrett’s esophagus, and Mallory-Weiss tears. - Gastric rupture from severe binge eating. - Chronic constipation and rectal prolapse due to laxative abuse. 2. **Metabolic**: - Electrolyte imbalances (e.g., hypokalemia, hyponatremia) leading to arrhythmias. 3. **Dental**: - Enamel erosion, dental caries, and gum disease from stomach acid exposure due to repeated vomiting. 4. **Cardiovascular**: - Arrhythmias and cardiac arrest due to electrolyte imbalances. --- ## **Comparison Between Anorexia Nervosa and Bulimia Nervosa** | **Feature** | **Anorexia Nervosa (AN)** | **Bulimia Nervosa (BN)** | |-----------------------------|----------------------------------------------------------|--------------------------------------------------------| | **Body Weight** | Significantly underweight (BMI < 17.5 kg/m²). | Normal or slightly overweight. | | **Eating Behavior** | Restriction of caloric intake; may include purging. | Binge eating followed by compensatory behaviors. | | **Body Image** | Distorted body image, intense fear of weight gain. | Preoccupation with body shape, but less distorted. | | **Compensatory Behaviors** | May include purging, excessive exercise, or fasting. | Frequent purging (vomiting, laxatives, diuretics). | | **Hormonal Effects** | Common (e.g., amenorrhea, osteoporosis). | Less common. | | **Gastrointestinal Effects**| Severe (e.g., gastroparesis, superior mesenteric artery syndrome). | Vomiting-related damage (e.g., esophagitis, dental erosion). | | **Prognosis** | Higher mortality due to medical complications. | Better prognosis but higher relapse rate. | --- ## **Management of Anorexia Nervosa and Bulimia Nervosa** ### **Multidisciplinary Approach**: Effective treatment requires a team of healthcare professionals, including psychiatrists, psychologists, dietitians, and medical doctors. ### **Treatment Goals**: 1. **Nutritional Rehabilitation**: - For AN: Gradual refeeding to avoid **refeeding syndrome**. - For BN: Establishing regular and healthy eating habits. 2. **Psychotherapy**: - **Cognitive Behavioral Therapy (CBT)**: Gold standard for both disorders, addressing distorted thoughts about body image and eating behaviors. - **Family-Based Therapy (FBT)**: Particularly effective in adolescents with AN. 3. **Pharmacotherapy**: - **Anorexia Nervosa**: Medications have limited benefit, but antidepressants may help with comorbid anxiety or depression. - **Bulimia Nervosa**: **Fluoxetine (SSRI)** is FDA-approved for BN, reducing binge-purge episodes and improving mood. 4. **Monitoring for Complications**: - Electrolyte imbalances, cardiac arrhythmias, and other medical complications must be promptly addressed. - Hospitalization may be required in severe cases. --- ## **Prognosis** 1. **Anorexia Nervosa**: - Chronic and relapsing course. - Long-term mortality rate: 5–20%, primarily due to medical complications or suicide. - Early diagnosis and treatment improve outcomes. 2. **Bulimia Nervosa**: - Generally better prognosis compared to AN but has a higher relapse rate. - Long-term complications may occur if untreated. --- ## **Key Takeaways**: - **Anorexia Nervosa** involves extreme weight loss due to self-starvation and a distorted body image, often leading to life-threatening complications. - **Bulimia Nervosa** involves cycles of binge eating and compensatory behaviors (e.g., vomiting), with individuals maintaining a normal or slightly overweight body weight. - Both disorders significantly impact the gastrointestinal system and overall health, requiring a **multidisciplinary approach** for treatment. - Early diagnosis, nutritional rehabilitation, psychotherapy, and medical monitoring are essential for improving outcomes and preventing long-term complications. Let me know if you need further clarification or have specific questions!

Refractory Helicobacter pylori infection

### **Refractory Helicobacter pylori Infection: A Comprehensive Overview** #### **Definition** Refractory Helicobacter pylori (H. pylori) infection refers to persistent H. pylori infection despite undergoing two or more failed eradication attempts with appropriate antibiotic regimens. It is a growing clinical challenge, largely driven by increasing antibiotic resistance and ineffective treatment approaches. --- #### **Diagnosis of Refractory H. pylori Infection** Diagnosing refractory H. pylori infection requires confirmation of persistent infection after failed eradication attempts. The diagnostic process typically includes: 1. **Confirmation of H. pylori Infection Persistence:** - Non-invasive tests such as: - **Urea Breath Test (UBT):** Detects active infection by measuring urease activity. - **Stool Antigen Test:** Identifies H. pylori antigens in fecal samples. - Invasive tests such as: - **Endoscopy with Biopsy:** Histological examination, rapid urease testing, or culture of gastric biopsy specimens. - **Molecular Testing:** PCR-based methods to detect H. pylori DNA and assess antibiotic resistance mutations. 2. **Antibiotic Susceptibility Testing:** - Gastric biopsy samples are cultured to determine the resistance profile of H. pylori strains to commonly used antibiotics (e.g., clarithromycin, metronidazole, levofloxacin). - Molecular testing can identify genetic mutations conferring resistance. 3. **Assessment of Microbiota Dysbiosis:** - Advanced techniques such as **16S rRNA gene sequencing** are used to evaluate the composition and diversity of the gastric and gut microbiota, which may be disrupted by repeated antibiotic exposure. --- #### **Management Strategies for Refractory H. pylori Infection** Managing refractory H. pylori infection is challenging due to antibiotic resistance and the impact of repeated treatments on the gastrointestinal microbiota. The following strategies are recommended: 1. **Optimized Antibiotic Regimens:** - **Tailored Therapy:** Based on antibiotic susceptibility testing to select effective agents. - **Quadruple Therapy:** A combination of bismuth, proton pump inhibitor (PPI), tetracycline, and metronidazole is preferred for refractory cases. - **Levofloxacin-Based Therapy:** Used in cases where susceptibility is confirmed. - **Rifabutin-Based Therapy:** An alternative for multidrug-resistant strains. 2. **Avoidance of Empirical Therapy:** - Avoid repeating failed regimens without testing for resistance, as this promotes further antibiotic resistance. 3. **Adjunctive Therapies to Support Eradication:** - **Probiotics:** Helps restore microbiota balance and reduce treatment side effects. - **Prebiotics:** Promotes the growth of beneficial bacteria. - **Fecal Microbiota Transplantation (FMT):** Emerging as a potential strategy to restore gut microbiota and improve treatment outcomes. 4. **Non-Antibiotic Approaches:** - **Vaccination:** Research into H. pylori vaccines is ongoing but not yet widely available. - **Phytotherapy:** Use of natural compounds with antimicrobial properties (e.g., mastic gum, cranberry extract). 5. **Monitoring and Follow-Up:** - Confirm eradication success post-treatment using UBT or stool antigen testing. - Long-term follow-up is essential to prevent reinfection and monitor for complications such as peptic ulcers or gastric cancer. --- #### **Impact of Refractory H. pylori Infection on Gut Microbiota** Refractory H. pylori infection and repeated antibiotic exposure significantly disrupt the gastrointestinal microbiota, leading to **microbial dysbiosis**. Key findings include: 1. **Gastric Microbiota Alterations:** - **Reduced Alpha Diversity:** Loss of microbial richness and diversity. - **Pathogenic Dominance:** Increased abundance of harmful genera such as *Pseudomonas*, *Burkholderia*, *Veillonella*, and *Peptostreptococcus*. - **Depletion of Beneficial Commensals:** Reduction in beneficial bacteria like *Bifidobacterium*, *Blautia*, and *Roseburia*. 2. **Gut Microbiota Dysbiosis:** - **Elevated Pathogenic Genera:** Increased levels of *Streptococcus* and *Veillonella*. - **Reduced Beneficial Genera:** Decreased abundance of *Bacteroides* and other beneficial microbes. 3. **Systemic Effects:** - Dysbiosis can impair digestion, nutrient absorption, and immune function. - It may contribute to long-term gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and increased risk of metabolic conditions. --- #### **Clinical Implications** The findings underscore the importance of: - **Optimizing First-Line Treatment:** To minimize the risk of treatment failure and resistance development. - **Antibiotic Stewardship:** Judicious use of antibiotics to prevent resistance and microbiota disruption. - **Microbiota-Modulating Strategies:** Incorporating probiotics, prebiotics, or fecal microbiota transplantation into treatment plans to restore microbial balance and improve outcomes. --- #### **Conclusion** Refractory H. pylori infection poses significant challenges due to rising antibiotic resistance and its detrimental effects on the gastrointestinal microbiota. Effective management requires tailored antibiotic regimens, adjunctive therapies, and microbiota restoration strategies. Early diagnosis, resistance testing, and personalized treatment approaches are crucial to overcoming this complex condition and preventing long-term complications.

Etiology of upper gastrointestinal bleeding (UGIB) changed over recent decades

The etiology of upper gastrointestinal bleeding (UGIB) has undergone significant changes over the past few decades due to advancements in medical management and preventive strategies. UGIB, defined as bleeding originating from the esophagus, stomach, or duodenum, has experienced a decline in global incidence, largely driven by changes in the underlying causes and improved therapeutic interventions. Below is a detailed explanation of how the etiology has evolved: ### **Decline in Peptic Ulcer Disease (PUD) as a Major Cause** - **Helicobacter pylori Eradication**: One of the most transformative changes in UGIB etiology has been the widespread eradication of *H. pylori*. This bacterium was historically a leading cause of peptic ulcer disease, which in turn was the most common cause of UGIB. With effective diagnostic tools and eradication therapies (e.g., antibiotics and PPIs), the prevalence of *H. pylori*-related ulcers has dramatically decreased, leading to fewer cases of ulcer-related bleeding. - **Proton Pump Inhibitors (PPIs)**: PPIs have become a cornerstone in the prevention and treatment of acid-related injuries to the gastrointestinal mucosa. Their widespread use has reduced the risk of ulcers and bleeding associated with excessive stomach acid production. ### **Current Major Causes** Despite the decline in *H. pylori*-related ulcers, peptic ulcer disease remains the leading cause of UGIB, accounting for 43.6% of cases. Other notable causes include: 1. **Gastritis and Duodenitis (27.6%)**: These inflammatory conditions of the stomach and duodenum are often associated with NSAID use, alcohol consumption, or stress-related mucosal damage. 2. **Esophageal Variceal Bleeding (8%)**: This remains a significant cause of UGIB, particularly in patients with liver disease and portal hypertension. Variceal bleeding has not declined as markedly as ulcer-related bleeding. 3. **Esophagitis (5.6%)**: Linked to gastroesophageal reflux disease (GERD), esophagitis has become a more prominent cause of UGIB in some populations. 4. **Less Common Causes**: - **Malignancies**: Gastric or esophageal cancers can lead to bleeding, although these are less frequent causes. - **Dieulafoy’s Lesions**: Rare vascular abnormalities that can cause severe bleeding. - **Mallory-Weiss Tears**: Tears in the mucosa at the gastroesophageal junction due to forceful vomiting or retching. ### **Impact of Aging Populations and Medication Use** - **Increased Use of NSAIDs, Anticoagulants, and Antiplatelet Agents**: These medications are associated with a higher risk of gastrointestinal bleeding. However, their impact on UGIB rates has been counterbalanced by the protective effects of *H. pylori* eradication and PPIs. - **Aging Populations**: Older adults are more likely to use medications that predispose them to UGIB, yet the overall incidence has declined due to improved preventive strategies. ### **Improved Risk Mitigation** The epidemiological shift in UGIB causes reflects advancements in gastroenterology: - Better understanding of risk factors (e.g., *H. pylori*, NSAIDs, anticoagulants). - Effective preventive measures, including eradication therapies and acid suppression with PPIs. - Enhanced management of chronic liver disease and portal hypertension to reduce variceal bleeding. ### **Conclusion** Over recent decades, the etiology of UGIB has shifted positively due to medical advancements. While peptic ulcer disease remains the predominant cause, its incidence has significantly declined owing to *H. pylori* eradication and widespread PPI use. Other causes, such as gastritis, duodenitis, and variceal bleeding, continue to contribute to UGIB cases, but overall, improved prevention and treatment have led to better outcomes and fewer cases of UGIB globally.

Endoscopic versus surgical anti-reflux procedures for GERD

Endoscopic and surgical anti-reflux procedures are both effective treatment options for managing gastroesophageal reflux disease (GERD), but they differ significantly in terms of efficacy, safety, and patient suitability. Below is a detailed comparison based on the findings from the systematic review and network meta-analysis: ### 1. **Efficacy** - Both endoscopic and surgical interventions are more effective than continued proton pump inhibitor (PPI) therapy alone for controlling GERD symptoms and reducing the need for PPI use. - **Surgical Procedures**: - **Laparoscopic Nissen Fundoplication (LNF)**: Demonstrated the highest overall efficacy for reflux control and medication discontinuation (SUCRA = 0.84). It is considered the gold standard for GERD surgery. - **Laparoscopic Toupet Fundoplication (LTF)**: Ranked second in efficacy (SUCRA = 0.71). It is a partial fundoplication that may have fewer side effects compared to LNF. - **Anterior Partial Fundoplication (APF)**: Ranked third in efficacy (SUCRA = 0.70), offering a less invasive surgical option with good outcomes. - **Endoscopic Procedures**: - **Transoral Incisionless Fundoplication (TIF)**: While not as effective as surgical options for overall reflux control, TIF excelled in symptom relief, particularly for reducing heartburn (SUCRA = 0.87) and bloating (SUCRA = 0.86). ### 2. **Safety** - Surgical and endoscopic procedures generally have comparable safety profiles to continued PPI therapy. - **Surgical Procedures**: - LNF, while highly effective, is associated with a higher risk of postoperative complications such as dysphagia and gas-related symptoms. - **Endoscopic Procedures**: - TIF has the lowest rate of adverse effects among all evaluated procedures, making it a safer and less invasive alternative for patients who prioritize minimal side effects. ### 3. **Suitability** - **Surgical Procedures**: - Best suited for patients with severe GERD symptoms, significant anatomical abnormalities (e.g., large hiatal hernia), or those who require the strongest reflux control and long-term independence from medication. - However, patients must be aware of the potential for higher postoperative complications, particularly with LNF. - **Endoscopic Procedures**: - Ideal for patients who prefer a minimally invasive approach with fewer risks and are primarily seeking symptom relief (e.g., heartburn and bloating) rather than complete reflux control. - TIF, in particular, is a promising option for patients who are not candidates for surgery or who prioritize safety and quicker recovery. ### 4. **Patient Priorities** - Patients who prioritize long-term reflux control and independence from PPIs are better suited for surgical treatments like LNF. - Patients who prioritize safety, minimal invasiveness, and symptom relief without significant recovery time may prefer endoscopic treatments like TIF. ### Conclusion: Both endoscopic and surgical anti-reflux procedures are effective for GERD management, but the choice of treatment depends on individual patient needs, priorities, and risk tolerance. LNF provides the strongest reflux control and medication independence but carries a higher risk of complications. TIF, on the other hand, offers a safer, less invasive alternative with excellent symptom relief and minimal side effects, making it a promising option for selected patients. Consulting with a healthcare provider is essential to determine the most suitable approach based on the severity of GERD, anatomical considerations, and personal preferences.

Optimal timing for endoscopic treatment in patients with GERD

The optimal timing for endoscopic treatment in patients with gastroesophageal reflux disease (GERD) should be carefully individualized based on the patient's clinical profile, response to prior treatments, and overall health status. Endoscopic therapy is considered an intermediate option between pharmacological treatment (e.g., proton pump inhibitors, PPIs) and surgical intervention. Below are the key considerations for determining the optimal timing for endoscopic treatment: ### 1. **Failure of Proton Pump Inhibitor (PPI) Therapy** - **Primary Indication:** Endoscopic treatment is most appropriate for patients who have **refractory GERD**, meaning they experience persistent symptoms despite adequate PPI therapy. This includes incomplete relief of symptoms or continued issues such as regurgitation or atypical manifestations of GERD (e.g., chronic cough, laryngitis, or asthma). - **Relapse After PPI Discontinuation:** Patients who initially respond to PPIs but relapse after discontinuing the medication may also benefit from endoscopic therapy to reduce dependence on long-term pharmacological treatment. ### 2. **Patients Unwilling or Unable to Undergo Surgery** - **Surgical Alternatives:** While surgical options like fundoplication are effective for GERD, some patients may be unwilling to undergo invasive procedures or may have contraindications to surgery due to age, comorbidities, or other factors. Endoscopic therapy can serve as a less invasive alternative for these patients. - **Preference for Minimally Invasive Options:** Patients seeking a minimally invasive solution with shorter recovery times may opt for endoscopic treatment. ### 3. **Special Populations** - **Elderly Patients:** Older individuals, particularly those with multiple comorbidities, may not tolerate surgical intervention well. Endoscopic therapy can be considered earlier in such cases to improve quality of life while minimizing risks. - **Patients with Atypical or Extra-Esophageal GERD Symptoms:** Those with atypical symptoms (e.g., chest pain, chronic cough, or hoarseness) or extra-esophageal manifestations may benefit from endoscopic treatment if PPI therapy is insufficient. ### 4. **Symptom Burden and Quality of Life** - **Impact on Daily Life:** Patients whose GERD symptoms significantly impair their quality of life, despite medical therapy, may be candidates for endoscopic treatment. Timing should consider the severity of symptoms and their impact on daily functioning. ### 5. **Contraindications to Endoscopic Therapy** - Timing must also account for contraindications, such as anatomical abnormalities (e.g., large hiatal hernia), severe esophagitis, or esophageal motility disorders. These factors may necessitate alternative approaches like surgery. ### 6. **Individualized Decision-Making** - **Patient Selection:** Optimal timing requires a personalized approach, factoring in the patient's symptom profile, treatment history, and preferences. Shared decision-making between the patient and healthcare provider is critical. - **Biomarkers and Diagnostic Tools:** Future research may identify biomarkers or diagnostic criteria to better guide the timing of endoscopic intervention. ### 7. **Limitations and Evidence Gaps** - Current evidence lacks robust long-term outcome data and cost-effectiveness analyses for endoscopic therapies. As a result, timing decisions should be made cautiously, considering the patient's immediate needs and balancing the risks and benefits. ### Summary of Optimal Timing: Endoscopic treatment is optimally timed **after failure of PPI therapy** or in situations where patients cannot tolerate or prefer not to undergo surgery. It is particularly valuable for patients with refractory GERD, those with atypical manifestations, and special populations like the elderly or those with comorbidities. Timing decisions should be individualized and based on symptom severity, quality of life considerations, and contraindications to alternative therapies. Future research is needed to refine criteria for optimal timing and patient selection.

H. pylori infection in children and adolescents

Helicobacter pylori (H. pylori) infection in children and adolescents is a significant health concern due to its potential long-term impact on gastrointestinal health. This bacterial infection primarily affects the stomach lining and is associated with conditions such as gastritis, peptic ulcers, and, in severe cases, an increased risk of gastric cancer. Below is a detailed overview of the latest advancements in diagnosing and treating H. pylori infection in this age group: ### Diagnosis: 1. **Challenges in Pediatric Diagnosis**: - Diagnosing H. pylori in children is more complex than in adults due to differences in clinical presentation and the need for non-invasive testing methods. - Symptoms in children may include abdominal pain, nausea, vomiting, and poor appetite, but these are often non-specific. 2. **Emerging Molecular Diagnostic Methods**: - New molecular techniques are revolutionizing H. pylori detection and antimicrobial susceptibility testing. - These methods correlate strongly with traditional culture-based tests but are less reliant on factors like sample transport, timing, or laboratory expertise. - Molecular diagnostics are particularly useful for children with upper gastrointestinal bleeding and may soon expand to stool-based testing, offering a non-invasive alternative to endoscopy-based biopsy methods. - Stool antigen tests and urea breath tests are already widely used in children for non-invasive diagnosis. ### Treatment: 1. **Increasing Antimicrobial Resistance**: - Rising rates of antimicrobial resistance in pediatric H. pylori cases mirror adult trends, complicating treatment options. - Resistance to commonly used antibiotics like clarithromycin and metronidazole is a growing problem, necessitating tailored treatment strategies based on susceptibility testing. 2. **Updated Therapeutic Strategies**: - Optimized antibiotic regimens and acid suppression therapy are central to treatment. - Potassium-competitive acid blockers (PCABs), a newer class of acid-suppressive drugs, are being introduced. These drugs provide superior acid control compared to traditional proton pump inhibitors (PPIs) and may improve eradication rates. - Triple therapy (antibiotics + acid suppression) and quadruple therapy (antibiotics + bismuth + acid suppression) remain the standard approaches, but treatment regimens are increasingly individualized based on resistance profiles. 3. **Eradication Benefits**: - Successful eradication of H. pylori in children is critical for preventing complications like peptic ulcers and reducing the risk of gastric cancer later in life. - Large-scale studies in adults have shown that eradication lowers gastric cancer risk, and pediatric research is beginning to document the progression of premalignant gastric lesions. ### Innovations and Future Directions: 1. **Non-Invasive Testing**: - The development of stool-based molecular diagnostic tests could transform how H. pylori is detected in children, offering a painless and convenient alternative to invasive procedures like endoscopy. 2. **Personalized Medicine**: - Advances in molecular diagnostics are paving the way for more tailored treatment approaches. By identifying specific antibiotic resistance patterns, clinicians can select the most effective therapy for each child, minimizing the need for repeated empirical treatments. 3. **Guideline Updates**: - While official pediatric guidelines are still awaited, emerging data and innovations in diagnostics and treatment are expected to shape future recommendations for managing H. pylori infection in children. ### Conclusion: H. pylori infection in children and adolescents presents unique challenges in diagnosis and treatment, but recent advancements in molecular diagnostic techniques and acid-suppressive therapies offer promising solutions. These innovations aim to improve eradication rates, reduce antimicrobial resistance issues, and provide individualized care. As research continues, the focus remains on minimizing the long-term health risks associated with H. pylori infection in the pediatric population.

H.Pylor related chronic atrophic gastritis and Gastric Cancer

Helicobacter pylori (H. pylori)-related chronic atrophic gastritis (CAG) is a condition where long-term infection by H. pylori bacteria leads to damage in the stomach lining. This damage includes inflammation, loss of stomach gland cells (atrophy), and replacement of normal stomach tissue with intestinal-like cells, known as intestinal metaplasia (IM). CAG caused by H. pylori significantly increases the risk of developing gastric cancer. H. pylori is classified as a Class I carcinogen due to its strong link to stomach cancer. The bacteria release harmful proteins, such as CagA and VacA, which disrupt normal cell functions, trigger chronic inflammation, and cause DNA damage. This persistent inflammation accelerates the progression of Correa’s cascade, a step-by-step process from gastritis to IM, dysplasia (abnormal cell growth), and eventually gastric cancer. Additionally, H. pylori can evade the immune system, allowing the infection to persist and promote cancer development. Epigenetic changes, such as DNA methylation, play a major role in this process. H. pylori silences tumor-suppressor genes and activates cancer-promoting pathways like WNT and NF-κB. Co-infection with Epstein–Barr virus (EBV) further increases cancer risk through combined effects on cellular growth and signaling. While early eradication of H. pylori can prevent progression, advanced stages of IM or dysplasia may become irreversible. Treatment typically involves antibiotics combined with proton pump inhibitors, with newer therapies like vonoprazan showing promise. Regular monitoring after eradication is essential, as early detection and intervention can significantly reduce the risk of gastric cancer.

Gut microbiome mediates the associations between lifestyle factors and colorectal high-risk adenoma

The study you are referencing provides compelling evidence that the gut microbiome acts as a mediator in the relationship between lifestyle factors—such as obesity, smoking, and alcohol consumption—and the development of colorectal high-risk adenomas (HRAs). To address your query comprehensively, let's explore the concepts of the gut microbiome, high-risk colorectal adenomas, and how lifestyle factors and the gut microbiome influence the risk of developing HRAs. ### What is the Gut Microbiome? The gut microbiome refers to the community of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside in the gastrointestinal tract. These microbes play crucial roles in digestion, immune system modulation, nutrient absorption, and maintaining overall gut health. Importantly, the gut microbiome can influence systemic inflammation, immune responses, and even the development of diseases, including colorectal cancer (CRC). ### What are High-Risk Colorectal Adenomas (HRAs)? High-risk colorectal adenomas (HRAs) are precancerous lesions found in the colon or rectum. They are advanced adenomas with significant malignant potential, meaning they are more likely to progress into colorectal cancer (CRC) if left untreated. HRAs are characterized by features such as large size (>10 mm), villous histology, or high-grade dysplasia. Identifying and understanding the risk factors for HRAs is critical for early prevention of CRC. ### How Lifestyle Factors Influence HRA Development The study identified three key lifestyle factors—obesity, smoking, and alcohol consumption—that independently increase the risk of developing HRAs. Here's how each factor contributes: 1. **Obesity**: Elevated body mass index (BMI) was found to increase the risk of HRAs, with an odds ratio (OR) of 1.06 per kg/m². Obesity is linked to chronic low-grade inflammation, insulin resistance, and altered hormone levels, all of which can promote colorectal neoplasia. Additionally, obesity alters gut microbiota composition, potentially amplifying inflammation and carcinogenesis. 2. **Smoking**: Heavy cigarette smoking (>30 pack-years) increased HRA risk by 44%. Tobacco exposure introduces carcinogenic compounds into the body, which can directly damage DNA and promote inflammation. Smoking also reshapes the gut flora, favoring pro-inflammatory microbial taxa such as Tyzzerella 4 and Actinomyces, which are implicated in colorectal tumorigenesis. 3. **Alcohol Consumption**: High alcohol intake (>4 units per week) was associated with a 65% increase in HRA risk. Alcohol metabolism generates acetaldehyde, a known carcinogen, which can damage DNA and impair mucosal barriers in the gut. Alcohol also influences gut microbiota composition, enriching harmful taxa like Fusobacterium while depleting beneficial bacteria such as Bifidobacterium. ### How the Gut Microbiome Mediates Lifestyle-Driven HRA Risk The study revealed that lifestyle factors alter the gut microbiome, and these microbial changes mediate the carcinogenic effects of obesity, smoking, and alcohol consumption. Key findings include: 1. **Microbiome Diversity**: Gut microbiota diversity (β-diversity) varied significantly across groups based on BMI, smoking, and alcohol consumption. This indicates that lifestyle factors disrupt microbial composition, potentially creating a pro-inflammatory and tumor-promoting environment. 2. **Key Microbial Genera**: - **Fusobacterium**: Alcohol consumption was positively correlated with Fusobacterium, which was significantly enriched in HRA patients. Fusobacterium is known to promote chronic inflammation, immune suppression, and mucosal barrier dysfunction, all of which accelerate neoplastic transformation. - **Tyzzerella 4**: Smoking intensity was linked to an increase in Tyzzerella 4, another pro-inflammatory genus enriched in HRA patients. Tyzzerella 4 completely mediated 14.2% of the effect of smoking on HRA risk, highlighting its role in tumor-promoting inflammation. - Beneficial genera such as Faecalibacterium, Lachnospira, and Parasutterella were depleted in HRA patients, suggesting a loss of anti-inflammatory and gut-protective microbes. 3. **Sex-Specific Findings**: Mediation by Fusobacterium and Tyzzerella 4 was observed only in male participants, suggesting that sex-dependent differences in microbial composition and immune responses play a role in HRA development. ### Mechanistic Insights The study provided mechanistic insights into how Fusobacterium and Tyzzerella 4 contribute to HRA risk: - **Chronic Inflammation**: Both genera are implicated in promoting inflammation, which is a key driver of colorectal tumorigenesis. - **Immune Suppression**: These microbes can suppress immune surveillance, allowing precancerous lesions to progress. - **Mucosal Barrier Dysfunction**: Fusobacterium and Tyzzerella 4 can disrupt the gut's protective mucosal barrier, increasing susceptibility to carcinogens. ### Preventive Implications The findings suggest that modifying gut microbiota composition could lower HRA risk. Potential interventions include: - **Probiotics**: Introducing beneficial bacteria to counteract harmful taxa. - **Dietary Changes**: Consuming a high-fiber, low-fat diet to promote gut health and microbial diversity. - **Lifestyle Modifications**: Reducing alcohol consumption, quitting smoking, and maintaining a healthy weight to prevent microbial shifts associated with HRAs. ### Study Limitations While the study provides valuable insights, it has limitations: - **Retrospective Design**: The study relied on self-reported lifestyle data, which may be subject to recall bias. - **16S rRNA Sequencing**: This method provides genus-level resolution but cannot identify species-level microbial changes. - **Population Specificity**: The cohort was limited to East Asian populations, which may constrain generalizability to other ethnic groups. ### Conclusion The study underscores the critical role of the gut microbiome in mediating the effects of lifestyle factors on colorectal high-risk adenomas. Specifically, Fusobacterium and Tyzzerella 4 emerge as microbial links between alcohol and smoking exposure and HRA risk. These findings highlight the potential of gut microbiome-targeted interventions—such as probiotics, dietary changes, and lifestyle modifications—for early prevention of colorectal cancer.

Eosinophilic esophagitis and food allergies: A US National Analysis

Eosinophilic Esophagitis (EoE) and food allergies are closely intertwined. A recent US national analysis, leveraging data between 2016 and 2022, provides critical insights into the relationship between EoE and IgE-mediated food allergies such as milk, egg, peanut, and seafood allergies. Here is a detailed breakdown of the findings: ### **Study Objective** The study aimed to evaluate the association between EoE and specific food allergies using a large inpatient dataset. EoE is a chronic, immune-mediated esophageal disease driven by eosinophil inflammation, often triggered by food antigens. However, the exact relationship between specific food allergies and EoE had not been fully quantified prior to this study. ### **Study Design and Dataset** - **Design**: Retrospective cross-sectional analysis. - **Dataset**: National Inpatient Sample (NIS), the largest publicly available all-payer inpatient database in the US. - **Study Period**: 2016–2022. - **Population**: Included all US hospitalizations with a diagnosis of EoE (ICD-10 code K20.0) and comorbid food allergies (milk, egg, peanut, seafood). ### **Key Findings** #### **Sample Size** - Out of 46,575 EoE hospitalizations: - **Milk allergy**: 1,765 cases (3.79%) - **Egg allergy**: 1,535 cases (3.30%) - **Peanut allergy**: 1,460 cases (3.13%) - **Seafood allergy**: 1,185 cases (2.54%) #### **Demographics** - **Age**: Mean age of EoE patients was 36.4 years. However, patients with food allergies were significantly younger: - Milk, egg, and peanut allergy cases: Around 13–15 years. - Seafood allergy cases: Around 22 years. - **Sex Distribution**: Males constituted the majority of EoE cases (65–68%), confirming a strong male predominance. - **Racial Disparities**: White patients had the highest rates of EoE. Black and Hispanic patients had lower odds of EoE (adjusted odds ratio [aOR] of 0.47 and 0.45, respectively), suggesting potential disparities in diagnosis or healthcare access. #### **Socioeconomic and Insurance Trends** - **Income**: Patients from the highest household income quartile (≥$86,000) had increased odds of EoE (aOR 1.79), indicating differences in healthcare access and diagnosis. - **Insurance**: Privately insured (aOR 3.09) and Medicaid-covered (aOR 2.34) patients had higher odds of EoE compared to Medicare patients, possibly due to differences in healthcare utilization and referral pathways. #### **Geographic Trends** - The highest proportion of EoE cases with food allergies was reported in the South (35–41%), followed by the Midwest and Northeast. This may reflect regional diagnostic or environmental influences. #### **Hospital Characteristics** - Most EoE admissions occurred in large metropolitan hospitals (over 60%), suggesting better access to diagnostic procedures like endoscopy in high-volume centers. #### **Age-Related Trends** - **Pediatric patients (<18 years)**: Had the highest likelihood of EoE. - **Adults aged 45–64 and ≥65 years**: Had significantly reduced odds of EoE (aOR 0.18 and 0.06, respectively). #### **Food Allergy-Specific Associations** - Logistic regression revealed strong associations between EoE and specific food allergies: - **Milk allergy**: Strongest association (aOR 7.52, p<0.001). - **Egg allergy**: aOR 4.77. - **Peanut allergy**: aOR 3.94. - **Seafood allergy**: aOR 2.57. #### **Temporal Trends** - Between 2016 and 2022, EoE-related hospitalizations increased significantly (from 5,620 to 7,664 cases). However, the relative proportions of specific food allergies remained stable. #### **Sex-Specific Findings** - Female patients with food allergies had lower odds of EoE (aOR 0.52, p<0.001), reinforcing the male predominance in EoE prevalence. #### **Comorbidity Impact** - EoE patients with fewer comorbidities (Charlson Comorbidity Index = 1) were more likely to have food allergy-related EoE (aOR 1.58), suggesting that EoE often occurs in otherwise healthy individuals. #### **Clinical Insights** - **Milk Allergy**: Milk allergy’s strong association with EoE supports the "cow’s milk hypothesis," where milk proteins are a predominant trigger for EoE. This validates dietary elimination approaches like the one-food elimination diet (1FED). - **Screening Importance**: Early screening for EoE in children with known food allergies, particularly males and those with milk sensitivity, is crucial to prevent chronic inflammation and fibrosis. ### **Clinical Implications** 1. **Tailored Dietary Management**: The study highlights the need for personalized dietary interventions for EoE patients with food allergies, especially milk sensitivity. 2. **Early Detection**: Screening high-risk groups—children, males, and those with milk allergy—can prevent long-term complications like esophageal fibrosis. 3. **Equitable Access**: Addressing racial and socioeconomic disparities in diagnosis and management is essential for improving patient outcomes. 4. **Regional Focus**: Understanding geographic trends can help allocate resources to regions with higher EoE prevalence. ### **Conclusions** This national analysis demonstrates a strong, statistically significant link between EoE and specific food allergies—especially milk, egg, peanut, and seafood. The findings emphasize the importance of early diagnosis, tailored dietary management, and equitable healthcare access to improve outcomes for EoE patients. Milk allergy, in particular, stands out as a predominant trigger, validating dietary elimination strategies and underscoring the need for focused clinical interventions.

FLIP panometry

FLIP panometry, or Functional Lumen Imaging Probe panometry, is a diagnostic tool used during endoscopy to assess the esophagogastric junction (EGJ) opening and esophageal contractile activity. It complements traditional motility testing by providing additional information about esophageal function. Despite its growing use, variability in procedures and interpretations has caused inconsistencies in clinical practice. To address this, the Dallas Consensus was developed by 19 international experts using a structured Delphi process. Through three rounds of voting and discussions, the group created standardized guidelines for performing and interpreting FLIP panometry. They finalized 40 statements covering procedural techniques, data interpretation, and motility classification systems. These guidelines aim to ensure uniformity and reliability in clinical use worldwide. FLIP results should always be interpreted alongside clinical presentation, endoscopic findings, and complementary motility studies for accurate diagnosis. A "normal" FLIP panometry strongly indicates the absence of major motor disorders, providing reassurance in diagnosis. Additionally, diminished or absent contractile responses combined with reduced EGJ opening can identify EGJ outflow obstruction, supporting the diagnosis of related disorders. The Dallas Consensus introduced an updated motility classification system, aligning FLIP interpretations with high-resolution manometry and improving clinical outcomes. By standardizing procedures and interpretive criteria, the consensus enhances the reliability and broader application of FLIP panometry in diagnosing esophageal motility disorders. This tool is now better equipped to help clinicians evaluate and manage conditions affecting esophageal function.

Familial Eosinophilic Esophagitis

Familial Eosinophilic Esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus with a strong genetic basis. Research has shown that EoE often clusters within families, suggesting genetic predisposition plays a significant role. A recent study aimed to uncover specific genes linked to familial EoE by using two advanced techniques: whole exome sequencing (to analyze rare genetic variants) and RNA sequencing (to study gene expression). The study analyzed 50 familial EoE cases from 21 extended families using exome sequencing and 43 cases from 18 nuclear families using RNA sequencing. Exome sequencing identified 189 rare genetic variants across 181 genes shared among affected family members. RNA sequencing revealed 698 genes with altered expression in EoE cases compared to healthy controls, indicating widespread changes in gene activity linked to the disease. Three genes—MUC16, ADGRE1, and TENM3—stood out as strong candidates for EoE susceptibility. These genes not only carried rare variants shared by affected relatives but also showed abnormal expression patterns. Additionally, 36 other genes demonstrated partial variant sharing and differential expression, suggesting a complex polygenic nature of EoE. Interestingly, some EoE-related genes were abnormally expressed in unaffected family members, hinting at a latent genetic predisposition or subclinical molecular changes. Many identified genes are involved in immune regulation, epithelial barrier function, and cell adhesion, processes central to EoE development. This study supports a "multihit" model for familial EoE, where inherited genetic vulnerabilities interact with environmental or immune triggers to cause the disease. These findings offer insights into the genetic and molecular mechanisms underlying EoE and may guide future research and treatments.

AGES-D Score and GERD

The AGES-D score is a diagnostic tool developed to predict gastroesophageal reflux disease (GERD) with moderate-to-high accuracy by integrating demographic and high-resolution manometric (HRM) parameters. It was specifically designed to assist clinicians in evaluating patients with inconclusive reflux monitoring results, particularly when esophageal acid exposure time (AET) falls within the indeterminate range of 4–6%. ### Key Features of the AGES-D Score: 1. **Purpose**: - The AGES-D score aims to provide a structured, quantitative approach to diagnosing GERD in patients with ambiguous pH monitoring results. It is particularly useful in cases where traditional diagnostic methods fail to yield conclusive results. 2. **Parameters Used**: The AGES-D score is based on five independent predictors of GERD, which form the acronym "AGES-D": - **A**ge: Older age is associated with a higher likelihood of GERD. - **G**ender: Male sex is a significant risk factor for GERD. - **E**GJ (Esophagogastric Junction) Contractile Integral (EGJ-CI): Lower EGJ-CI values are indicative of a weakened anti-reflux barrier. - **S** LES–Crural Diaphragm Distance (LES-CD): A larger LES-CD distance suggests a greater separation between the lower esophageal sphincter (LES) and the diaphragmatic crura, often associated with hiatal hernia and GERD. - **D**istal Contractile Integral (DCI): Lower DCI values indicate impaired esophageal peristaltic function, which compromises acid clearance and increases the risk of reflux. 3. **Calculation**: The AGES-D score is calculated using the following logistic regression equation: ``` AGES-D score = -0.6162 + (0.0222 × age) + (0.5917 if male) + (0.02298 × LES-CD) – (0.01771 × EGJ-CI) – (0.00037183 × DCI) ``` - A cutoff score of **≥0.125** provides 73% sensitivity and 75% specificity for diagnosing GERD. 4. **Validation**: - The AGES-D score was validated using a cohort of 391 adult patients with GERD symptoms who underwent 24-hour pH or pH-impedance monitoring and HRM. - In the derivation cohort (n=261), the score achieved an area under the curve (AUC) of 0.76, and in the validation cohort (n=130), it achieved an AUC of 0.82, demonstrating strong reproducibility and diagnostic accuracy. 5. **Clinical Utility**: - The AGES-D score is particularly valuable for patients with inconclusive pH or impedance monitoring results (AET 4–6%), where traditional diagnostic methods cannot definitively confirm or rule out GERD. - It provides a practical and cost-effective tool that incorporates both demographic and manometric data to improve diagnostic certainty without requiring subjective maneuvers or additional impedance-based variables. 6. **Advantages Over Existing Scores**: - The AGES-D score is simpler than other diagnostic systems like the Milan, COuGH RefluX, and Lyon scores. - It relies solely on objective and routinely available HRM parameters, avoiding subjective measures such as symptom scoring or complex maneuvers like leg-raising. 7. **Limitations**: - The study was retrospective and conducted at a single center, which may limit the generalizability of the findings. - The tool has not yet been validated in prospective multicenter studies or across diverse ethnic populations. - The study excluded patients with indeterminate AET values (4–6%), which is the population for whom the score is ultimately intended, potentially introducing a selection bias. 8. **Future Research**: - Prospective multicenter studies are needed to externally validate the AGES-D score. - Research should also assess the score’s predictive value for treatment response and compare it directly with established reflux diagnostic models. ### Clinical Implications: The AGES-D score represents a significant advancement in the diagnostic workup of GERD, particularly for cases where traditional reflux testing is inconclusive. By combining demographic factors (age and gender) with HRM metrics (EGJ-CI, LES-CD, and DCI), the score provides a comprehensive assessment of both structural and functional aspects of the esophagus. This makes it a valuable adjunct to traditional reflux testing, helping clinicians make more informed treatment decisions. In summary, the AGES-D score is a robust, evidence-based tool that enhances GERD diagnosis by integrating easily obtainable parameters. While promising, further validation in diverse populations and clinical settings is necessary to confirm its utility and reliability in routine practice.

pH-integrated ultrathin endoscopy for ambulatory GERD monitoring

The pH-integrated ultrathin endoscopy, known as the EndoMonitor System, represents a groundbreaking innovation for ambulatory gastroesophageal reflux disease (GERD) monitoring. This newly developed device integrates real-time pH measurement with direct video imaging of reflux episodes, addressing limitations of traditional pH-impedance catheters, such as subjective interpretation, delayed analysis, and lack of visual correlation with reflux events. The EndoMonitor is a 2.8 mm ultrathin transnasal endoscope equipped with an antimony pH electrode and a miniature CMOS camera. It connects to mobile devices for live visualization, allowing simultaneous recording of pH changes and reflux events. Preclinical evaluation included in vitro (porcine esophagus-stomach models) and in vivo (miniature pig) experiments, demonstrating superior detection accuracy compared to conventional pH-impedance catheters. The EndoMonitor achieved 100% detection of distal acid, distal mixed, and horizontal acid reflux, outperforming the catheters, which showed significantly lower detection rates. Additionally, it accurately identified proximal reflux events with over 90% accuracy. The device offers real-time visualization of reflux episodes and pH drops, enabling objective identification of reflux type, height, duration, and composition (acidic vs. mixed) without the need for post-hoc analysis. It also provides insights into esophageal motility and clearance through documentation of post-reflux swallow-induced peristaltic waves (PSPW), critical for assessing reflux burden and mucosal protection. The safety profile was excellent, with no device malfunctions or adverse effects observed during prolonged monitoring. While preclinical limitations exist, such as the absence of symptomatic human subjects, planned clinical trials aim to validate the EndoMonitor in conscious humans for long-term use. This dual-mode system offers the potential to redefine GERD diagnostics by combining physiologic data and anatomical imaging, setting a new standard for real-time, visualized reflux assessment.

RefluxStop surgery in the treatment of acid reflux

RefluxStop surgery is an innovative and highly effective procedure for the treatment of chronic gastroesophageal reflux disease (GERD), addressing the root causes of acid reflux while minimizing common side effects associated with traditional surgical approaches like Nissen fundoplication. Below is a detailed explanation of the procedure, its mechanism, clinical outcomes, and advantages: ### **Mechanism of RefluxStop Surgery** RefluxStop is designed to correct all three components of the anti-reflux barrier: 1. **Crural Diaphragm:** The procedure restores the natural anatomy by maintaining the lower esophageal sphincter (LES) below the diaphragm, reducing the risk of reflux. 2. **Lower Esophageal Sphincter (LES):** It repositions the LES to improve its function without applying external pressure or encircling it, which avoids complications like dysphagia. 3. **Gastroesophageal Flap Valve:** The surgery reconstructs the flap valve to enhance reflux resistance while preserving the natural mechanics of swallowing. Unlike fundoplication, RefluxStop avoids wrapping or compressing the esophagus and stomach, which minimizes postoperative issues such as gas-bloating and difficulty swallowing. ### **Clinical Outcomes** The RefluxStop procedure has demonstrated exceptional safety and effectiveness in a prospective multicenter study conducted over a mean follow-up period of 5.7 years. Key findings include: 1. **Symptom Relief:** - GERD symptom improvement was dramatic, with a 90% reduction in GERD-HRQL (Health-Related Quality of Life) scores. Median scores decreased from 29.5 at baseline to 3.0 at 5 years (p<0.001), indicating substantial long-term relief. 2. **Objective Acid Control:** - Esophageal acid exposure time decreased by 90.4%, from 16.35% at baseline to 1.57% at 5 years (p<0.001). This confirms durable control of acid reflux, comparable to or better than traditional surgical outcomes. 3. **PPI Discontinuation:** - At 5 years, 97.9% of patients were no longer taking daily proton pump inhibitors (PPIs). Only one patient resumed PPIs, but for unrelated kidney disease rather than reflux recurrence. 4. **Regurgitation Control:** - 93.6% of patients reported no or minimal regurgitation at 5 years, demonstrating the procedure’s ability to prevent mechanical reflux through effective LES repositioning and flap valve restoration. 5. **Device Stability:** - No instances of device migration, dislocation, erosion, or explantation were observed over the entire study period, highlighting the long-term integrity of the implant. ### **Safety Profile** The procedure has shown an excellent safety record: 1. **Adverse Events:** - Across five years, no device-related adverse events (ADEs or SADEs) occurred. Two severe postoperative complications (bleeding and infection) resolved completely without long-term consequences. 2. **Postoperative Dysphagia:** - Only one patient (2%) experienced transient mild dysphagia, which resolved within the study period. Overall, 97.9% of patients reported no dysphagia, a significant advantage over fundoplication techniques. 3. **Gastritis Symptoms:** - Eight patients experienced gastritis-related symptoms, but these were isolated and not indicative of surgical failure or reflux recurrence. ### **Comparison to Nissen Fundoplication** RefluxStop surgery offers several advantages over traditional fundoplication: 1. **Preservation of Normal Function:** - Unlike fundoplication, which causes dysphagia in nearly 29% of patients and gas-bloating in over 50%, RefluxStop preserved full ability to belch and vomit (100%) and eliminated bloating in 95.7% of patients. 2. **Minimized Complications:** - By avoiding wrapping the stomach around the esophagus, RefluxStop reduces mechanical pressure on the LES, preventing long-term esophageal complications and postoperative discomfort. ### **Durability and Long-Term Effectiveness** RefluxStop surgery has demonstrated durable results: 1. **Stable Acid Exposure:** - Acid exposure time remained low and stable between the 6-month (0.82%) and 5-year (1.57%) evaluations, confirming the mechanical and functional longevity of the anti-reflux barrier reconstruction. 2. **Quality of Life:** - Patients experienced sustained symptom relief and improved quality of life, with minimal dependence on medication. ### **Procedure-Specific Safety** RefluxStop avoids the invasive wrapping technique used in fundoplication, reducing the risk of complications like dysphagia, gas-bloating, and esophageal pressure damage. Early procedural refinements—such as ensuring proper fundic pouch tension and LES positioning—eliminated minor complications, demonstrating the reliability of the surgical technique. ### **Real-World Data Support** Independent European centers replicated the study’s findings, confirming consistent efficacy and safety across varied populations, including patients with large hiatal hernias and impaired esophageal motility. ### **Regulatory Validation** The study data were rigorously audited and independently verified by FDA consultants and third-party CROs, supporting the reliability of the safety and efficacy results. The procedure has received CE mark approval and is undergoing FDA PMA (Premarket Approval) submission. ### **Clinical Implications** RefluxStop surgery represents a paradigm shift in GERD management, offering: 1. Sustained symptom relief (>90% improvement). 2. Near-complete medication independence (97.9% off PPIs). 3. Minimal adverse effects (low dysphagia rates and no device-related complications). 4. Preservation of natural swallowing mechanics and belching ability. 5. Durable acid reflux control over the long term. This procedure has the potential to redefine the standard of care for long-term surgical correction of GERD, providing a safer and more effective alternative to traditional techniques like fundoplication.

H. Pylori Screening After Acute MI: HELP-MI SWEDEHEART Trial

The **HELP-MI SWEDEHEART trial** was a large, nationwide, cluster-randomized crossover study conducted across 35 hospitals in Sweden to evaluate whether routine screening for *Helicobacter pylori* (H. pylori) in patients hospitalized for acute myocardial infarction (MI) could reduce the risk of upper gastrointestinal (GI) bleeding, which is a common and serious complication after an MI. ### Key Details of the Trial: #### 1. **Purpose and Study Design:** - The primary aim was to determine if routine H. pylori screening and treatment in post-MI patients could lower the incidence of upper GI bleeding. - The trial utilized a **cluster-randomized crossover design** where hospitals alternated between two approaches: - **Routine screening periods**: Patients received urea breath testing for H. pylori in addition to standard care. - **Usual care periods**: Patients received only standard care without screening. - This design allowed real-world comparison of outcomes during the two periods. - The study was open-label and conducted nationwide across 18 clusters (35 hospitals). #### 2. **Study Population and Intervention:** - The trial included **18,466 patients** hospitalized with acute MI, with a median age of 71 years (71% male). - During the screening periods: - Patients underwent **urea breath testing** to detect H. pylori infection. - Of those tested, **23.6% tested positive for H. pylori**. - During the nonscreening (usual care) periods, patients were treated as per standard protocols without H. pylori testing. #### 3. **Primary Outcome: Upper GI Bleeding:** - Over a median follow-up of **1.9 years**, the incidence of upper GI bleeding was compared between the two groups: - **Screening group**: 299 patients experienced upper GI bleeding, corresponding to an incidence rate of **16.8 events per 1,000 person-years**. - **Usual care group**: 336 patients experienced upper GI bleeding, corresponding to an incidence rate of **19.2 events per 1,000 person-years**. - The **rate ratio (RR)** for upper GI bleeding was **0.90** (95% CI, 0.77–1.05; P = 0.18). - This indicates that routine H. pylori screening did not result in a **statistically significant reduction** in the risk of upper GI bleeding. #### 4. **Subgroup Findings and Heterogeneity:** - Subgroup analysis revealed that the effectiveness of H. pylori screening might vary based on the presence of anemia: - Among patients with **mild anemia**, the risk of upper GI bleeding was reduced (RR 0.64). - Among patients with **moderate-to-severe anemia**, the reduction was even greater (RR 0.44). - However, in patients **without anemia**, there was no benefit observed (RR 0.98). - The **P for interaction** was 0.03, suggesting that anemia status significantly influenced the benefit of H. pylori screening. #### 5. **Clinical Implications and Conclusion:** - **Overall Findings**: - Routine H. pylori screening after acute MI **did not significantly reduce the risk of upper GI bleeding** for the general post-MI population. - **Targeted Screening Approach**: - The subgroup analysis suggests that patients with **anemia** (especially moderate-to-severe anemia) may benefit more from H. pylori screening. - This finding highlights the potential for a **targeted screening strategy** focusing on high-risk groups, such as anemic patients, rather than universal screening for all post-MI patients. - **Conclusion**: - Routine H. pylori screening is **not recommended universally** for all post-MI patients. - A more **resource-efficient approach** could involve screening only patients at higher risk of upper GI bleeding, such as those with anemia. The trial underscores the importance of personalized medicine, where interventions are tailored to specific patient subgroups to maximize clinical benefits and minimize unnecessary resource use.

Autoimmune Gastritis related NET and Gut Microbitoa- Osaka Study

The Osaka Metropolitan University study explored the relationship between autoimmune gastritis (AIG) and the development of gastric neuroendocrine tumors (NETs), focusing on the role of gut microbiota and metabolic changes. AIG is a chronic autoimmune disorder where the immune system attacks the stomach lining, leading to tissue damage and prolonged inflammation. This inflammation is a known risk factor for NETs, tumors originating from hormone-producing cells. The study compared stomach tissue and gut microbiota profiles of AIG patients with and without NETs. AIG patients showed reduced α-diversity in gut bacteria, an indicator of poor gastric health. Distinct microbial profiles were observed between NET-positive and NET-negative groups. Harmful bacteria, such as *Haemophilus parainfluenzae* and Fusobacterium species (*F. periodonticum* and *F. nucleatum*), were elevated in NET-positive patients, while protective microbes like lactic acid bacteria and *Streptococcus salivarius* were diminished. This imbalance created a pro-inflammatory environment conducive to tumor formation. Metabolomic analysis revealed metabolic reprogramming in AIG patients, with a shift away from normal glycolysis and TCA cycles to alternative energy pathways. This disruption affected energy balance, inflammation control, and tissue repair mechanisms. The sequence of events suggested metabolic dysfunction occurred first, fostering conditions for harmful bacterial overgrowth and subsequent tumor development. The study identified microbial and metabolic biomarkers that could predict NET risk, offering potential for early diagnosis and preventive strategies. These findings underscore the combined impact of immune damage, altered metabolism, and microbiome imbalance in AIG-related cancer progression, paving the way for innovative diagnostic and therapeutic approaches.

Nonpharmacologic interventions for GERD

Nonpharmacologic interventions for gastroesophageal reflux disease (GERD) refer to therapeutic approaches that do not rely on medications but aim to improve symptoms, enhance lower esophageal sphincter (LES) function, and reduce esophageal acid exposure. These interventions can either be standalone options or used in combination with conventional therapies. Below is a detailed summary of the nonpharmacologic interventions studied, based on the provided context: --- ### **1. Acupoint Stimulation** - **Description**: Acupoint stimulation, often rooted in traditional Chinese medicine (TCM), involves stimulating specific points on the body to influence physiological functions. - **Effectiveness**: - Significantly increased LES pressure when combined with conventional or traditional Chinese medicine (Standardized Mean Difference [SMD] 3.88–7.77). - Reduced esophageal acid exposure time (SMD –2.33 to –5.01). - Improved GERD-related quality of life when used alone or in combination with other therapies. - **Safety**: - Associated with fewer adverse events compared to conventional Western therapies. - **Clinical Implication**: - Safe and effective, particularly for patients seeking culturally rooted or noninvasive options. - Offers measurable benefits as either a standalone or adjunctive therapy. --- ### **2. Breathing Training** - **Description**: Focused breathing exercises aim to strengthen the diaphragm and improve LES function. - **Effectiveness**: - Increased LES pressure when combined with conventional medicine. - Reduced esophageal acid exposure time. - **Advantages**: - Low-cost and noninvasive. - Can be easily integrated into conventional medical management. - **Clinical Implication**: - A practical and affordable adjunctive therapy for GERD patients. --- ### **3. Nissen Fundoplication** - **Description**: A surgical procedure in which the upper part of the stomach is wrapped around the LES to strengthen it and prevent acid reflux. - **Effectiveness**: - Significantly increased LES pressure (SMD 3.88–7.77). - Reduced esophageal acid exposure time (SMD –2.33 to –5.01). - **Risks**: - Higher rates of adverse events due to the invasiveness of surgery. - **Clinical Implication**: - Effective for severe or refractory GERD but may not be suitable for all patients due to surgical risks. --- ### **4. Transoral Incisionless Fundoplication (TIF)** - **Description**: A minimally invasive endoscopic procedure that creates a valve at the LES to prevent reflux. - **Effectiveness**: - Improved GERD-related quality of life. - **Advantages**: - Less invasive than traditional surgical fundoplication. - **Risks**: - Safety concerns remain, though risks are lower than with surgical fundoplication. - **Clinical Implication**: - A viable option for patients seeking minimally invasive solutions with quality-of-life benefits. --- ### **5. Integrative Approaches** - **Description**: Combining nonpharmacologic interventions with conventional medicine. - **Examples**: - **Acupoint stimulation + Traditional Chinese Medicine**: Enhanced LES pressure and reduced acid exposure time. - **Breathing training + Conventional medicine**: Additive benefits in improving LES function and acid exposure. - **Clinical Implication**: - Supports multimodal therapy tailored to individual patient needs and preferences. --- ### **6. Other Nonpharmacologic Interventions** - The analysis included a total of 11 distinct nonpharmacologic interventions across 34 randomized controlled trials (RCTs). However, specific details on all interventions were not provided in the context. --- ### **Key Findings** - **Primary Endpoint**: LES pressure was significantly improved by acupoint stimulation, breathing training, and Nissen fundoplication. - **Secondary Endpoints**: - Esophageal acid exposure time was reduced by acupoint stimulation, breathing training, and Nissen fundoplication. - GERD-related quality of life improved significantly with acupoint stimulation and transoral incisionless fundoplication. - Safety outcomes favored acupoint stimulation over more invasive interventions like fundoplication. --- ### **Safety vs. Efficacy Trade-Off** - **Acupoint Stimulation**: Emerged as both effective and safer than surgical interventions. - **Surgical Approaches**: Effective but associated with higher risks, making them suitable for severe or refractory GERD cases. - **Minimally Invasive Options**: TIF provided quality-of-life improvements with reduced invasiveness but requires careful consideration of safety. --- ### **Clinical Guidance** - **For Patients Intolerant to Medications**: Nonpharmacologic interventions provide an alternative pathway, particularly for those dissatisfied with or intolerant to long-term pharmacologic therapy. - **Personalized Care**: Clinicians should tailor therapy based on patient preferences, comorbidities, and risk tolerance. - **Adjunctive Potential**: Nonpharmacologic approaches, particularly acupoint stimulation and breathing training, can enhance outcomes when combined with conventional medicine. --- ### **Future Directions** - More high-quality, multicenter RCTs are needed to: - Validate the long-term efficacy of nonpharmacologic interventions. - Establish standardized protocols for their use in GERD treatment. --- ### **Conclusion** Nonpharmacologic interventions, particularly **acupoint stimulation** and **breathing training**, show promise as safe and effective adjunctive therapies for GERD. They offer physiological benefits (improved LES pressure, reduced acid exposure) and enhance patient-reported outcomes (quality of life). These interventions can serve as valuable alternatives or complements to conventional Western medicine, especially for patients seeking noninvasive or culturally integrated treatment options.

Bleeding risk , Blood thinners and Esophageal dilation

Esophageal dilation is a procedure used to widen a narrowed esophagus, often performed using tools such as balloon dilators or Savary dilators. While the procedure itself is generally considered low risk, the bleeding risk can increase significantly in patients using blood thinners (anticoagulants or antiplatelet agents). Below is a detailed discussion of the bleeding risk associated with blood thinners during esophageal dilation, based on the provided context: --- ### **Key Findings on Bleeding Risk** 1. **Anticoagulant Use:** - Patients on anticoagulants (e.g., warfarin, direct oral anticoagulants [DOACs] like rivaroxaban, dabigatran, apixaban, and edoxaban) had a **1.43-fold higher relative risk (RR)** of gastrointestinal (GI) bleeding within 30 days of esophageal dilation compared to nonusers. - Among anticoagulants, **warfarin** posed the highest bleeding risk, with a **1.92-fold increase in bleeding risk**. This is likely due to warfarin's narrow therapeutic index and the challenges of maintaining its optimal therapeutic range. 2. **Dual Antiplatelet Therapy (DAPT):** - Patients on DAPT (e.g., aspirin combined with ticagrelor, clopidogrel, or prasugrel) had numerically higher bleeding rates compared to nonusers or aspirin-only users. However, these differences did not reach statistical significance. - This suggests that while DAPT increases bleeding risk, the absolute risk may not be as pronounced as with anticoagulants. 3. **Aspirin Alone:** - Aspirin-only therapy was associated with a lower bleeding risk compared to DAPT, highlighting the additive bleeding risk when combining two antiplatelet agents. 4. **Timing of Antithrombotic Therapy Resumption:** - Whether anticoagulant or antiplatelet therapy was resumed early or delayed after the procedure did not significantly alter the bleeding risk. --- ### **Clinical Implications** 1. **Guideline Recommendations:** - Current guidelines recommend discontinuing anticoagulants before esophageal dilation to minimize bleeding risk, provided it is safe to do so. This is particularly important for patients on warfarin due to its higher risk profile. 2. **Thromboembolic vs. Bleeding Risk:** - For patients on blood thinners, clinicians must balance the risk of thromboembolic events (e.g., stroke or clot formation) against the risk of bleeding. This decision requires a personalized approach, often involving collaboration with cardiology or hematology specialists. 3. **Warfarin-Specific Considerations:** - Warfarin users represent a particularly high-risk group for postprocedural bleeding. These patients may require more cautious periprocedural planning, including temporary bridging with shorter-acting anticoagulants or careful INR (International Normalized Ratio) monitoring. 4. **Clinical Consequences of Bleeding:** - Postprocedural bleeding in anticoagulated patients was associated with significant clinical consequences, including higher rates of blood transfusions, ICU admissions, and even mortality. This underscores the importance of optimizing antithrombotic management before esophageal dilation. --- ### **Summary of Practice Implications** - **Anticoagulants:** - Discontinuation before esophageal dilation is generally recommended to reduce bleeding risk. - Warfarin users require extra caution due to their higher bleeding risk. - DOAC users may have a slightly lower bleeding risk compared to warfarin, but individual risk factors must still be considered. - **DAPT and Aspirin:** - DAPT increases the bleeding risk compared to aspirin alone, but the absolute risk may not always be statistically significant. - Aspirin-only therapy carries a relatively lower bleeding risk, making it a safer option in certain cases. - **Multidisciplinary Collaboration:** - Endoscopists should work closely with cardiologists and hematologists to individualize management strategies, especially for high-risk patients. - **Postprocedural Monitoring:** - Patients on anticoagulants or antiplatelets undergoing esophageal dilation should be closely monitored for signs of bleeding, given the potential for serious complications such as transfusion requirements, ICU admission, and mortality. --- ### **Conclusion** Anticoagulant use, particularly warfarin, significantly increases the risk of post-esophageal dilation bleeding. Dual antiplatelet therapy also poses a higher bleeding risk compared to aspirin alone, though the differences may not always be statistically significant. Clinicians must carefully weigh the bleeding risk against the thromboembolic risk when managing blood thinners in patients undergoing esophageal dilation, emphasizing guideline-based discontinuation of therapy whenever safely feasible. Close monitoring and individualized care are critical to optimizing outcomes.

VOYAGE trial

The **VOYAGE trial** was a **phase 2 clinical study** designed to evaluate the efficacy, safety, and tolerability of **etrasimod**, an investigational oral therapy, in adults with **eosinophilic esophagitis (EoE)**. Below is a detailed summary of the trial: --- ### **Background and Clinical Need** - **Eosinophilic Esophagitis (EoE)** is a chronic allergic inflammatory disease of the esophagus characterized by symptoms such as **dysphagia** (difficulty swallowing), **food impaction**, and **reduced quality of life**. - Current standard treatments (e.g., swallowed corticosteroids, proton pump inhibitors, and biologic therapies like dupilumab) have limitations, including **partial efficacy**, **long-term safety concerns**, and the lack of **approved oral small-molecule therapies**. - **Etrasimod** is a promising candidate for EoE treatment due to its mechanism of action as a **selective sphingosine 1-phosphate (S1P1,4,5) receptor modulator**, which reduces **lymphocyte trafficking** and inflammation. It has previously shown efficacy in other immune-mediated diseases, such as **ulcerative colitis**. --- ### **Trial Design** - **Type**: Randomized, double-blind, placebo-controlled phase 2 study. - **Duration**: Conducted between 2020–2022. - **Locations**: 64 sites across five countries. - **Participants**: 108 adults aged 18–65 years with **histologically active EoE** (≥15 eosinophils per high-power field [eos/hpf] and ≥2 dysphagia episodes per week). - **Groups**: - **41 patients** received etrasimod 2 mg. - **39 patients** received etrasimod 1 mg. - **28 patients** received placebo. --- ### **Baseline Characteristics** - Patients had a **mean disease duration** of 4–5 years. - Many had prior therapies: ~60% had used corticosteroids, ~40% used proton pump inhibitors (PPI). - High disease activity was noted: - **Mean Dysphagia Symptom Questionnaire (DSQ)** score: ~33. - **Peak eosinophil count (PEC)**: ~110 eos/hpf. - **Endoscopic Reference Score (EREFS)**: ~3.7. --- ### **Primary Endpoint** - **Week 16:** Reduction in **peak eosinophil count (PEC)**: - **Etrasimod 2 mg**: –58.4% reduction (**p=0.010 vs placebo**). - **Etrasimod 1 mg**: –39.4% reduction (**p=0.29 vs placebo**). - **Placebo**: –21.5% reduction. - The 2 mg dose demonstrated **significant efficacy** in reducing eosinophilia compared to placebo. --- ### **Key Efficacy Outcomes** 1. **Histologic Remission**: - **Week 16**: 22% of patients on **etrasimod 2 mg** achieved histologic remission (**PEC <15 eos/hpf**), compared to **0% on placebo**. - **Week 24**: Remission rates increased to **32%** for the 2 mg group. 2. **Deeper Remission**: - **Week 16**: 22% of patients on **etrasimod 2 mg** achieved deeper remission (**PEC ≤6 eos/hpf**), compared to **0% on placebo**. 3. **Symptom Improvement**: - **Dysphagia Symptom Questionnaire (DSQ)**: Significant improvement at **week 24** in non-dilated patients on **etrasimod 2 mg** (–21.6 vs –9.6 placebo, **p=0.031**). - **Patient Global Impression of Severity (PGI-S)**: Improved significantly with **2 mg** at week 24 (**p=0.012**). 4. **Endoscopic Improvement**: - **EREFS score**: Improved with **etrasimod 2 mg** at week 16 (–1.0, **p=0.014**) and sustained at week 24 (–0.9, **p=0.030**). 5. **Histology Scores**: - Both doses of etrasimod led to significant improvements in **Histologic Scoring System (HSS)** grade and stage at week 24 (**p<0.0001**) and sustained benefits through **week 52**. 6. **Durability**: - Improvements in eosinophilia, histology, and endoscopy were maintained during the **28-week extension phase**, demonstrating **long-term efficacy**. 7. **Rescue Therapy**: - Fewer patients required rescue therapy on **etrasimod** (10%) compared to placebo (18%), indicating better disease control. --- ### **Mechanism of Action** - **Peripheral lymphocyte counts** decreased dose-dependently: - **60% reduction** with etrasimod 2 mg. - **37% reduction** with etrasimod 1 mg (**p<0.0001**). - This is consistent with etrasimod's immune-modulating mechanism of reducing **lymphocyte trafficking**. --- ### **Safety Profile** 1. **Adverse Events (AEs)**: - Treatment-emergent adverse events (TEAEs) occurred in: - **71%** (etrasimod 2 mg). - **69%** (etrasimod 1 mg). - **75%** (placebo). - Most AEs were **mild-to-moderate**, with gastrointestinal events being the most frequent. 2. **Common AEs**: - Nausea, food impaction, and COVID-19 were reported. - No deaths, macular edema, or serious safety signals were observed. 3. **Cardiac Safety**: - Mild bradycardia occurred in two patients on **etrasimod 2 mg** and one on placebo, all resolving without intervention. - This supports a **manageable cardiac risk** profile. 4. **Comparative Tolerability**: - GI-related adverse events were more frequent in **placebo (50%)** than in etrasimod groups (27–33%), indicating **good tolerability** of the drug. --- ### **Clinical Implications** The **VOYAGE trial** demonstrated that **etrasimod 2 mg** provides significant **histologic, endoscopic, and symptomatic improvements** in adults with EoE. These findings establish proof of concept for **oral S1P receptor modulation** as a promising new therapeutic class for EoE. The drug also showed a **favorable safety profile** and long-term durability, making it a potential alternative to existing treatments for this challenging condition.

Retrograde Cricopharyngeal Dysfunction (R-CPD)

**Retrograde Cricopharyngeal Dysfunction (R-CPD)** is a medical condition that prevents individuals from burping due to the inability of the cricopharyngeal muscle (located in the upper esophageal sphincter) to relax and release trapped air. This condition was first formally recognized in 2019 and has since gained attention for its significant impact on patients' quality of life. ### **Key Features of R-CPD:** 1. **Symptoms:** - **Inability to burp:** Patients report never having been able to burp in their lives. - **Severe bloating:** Air trapped in the stomach and esophagus leads to discomfort. - **Chest pain and abdominal discomfort:** Often caused by the buildup of air. - **Excessive flatulence:** As air passes through the digestive system instead of being released through burping. - **Distinctive throat gurgling noises:** Caused by trapped air trying to escape, which is a hallmark symptom of R-CPD. 2. **Demographics:** - Most commonly affects individuals in their 20s to 30s. - Many patients describe the condition as debilitating, with significant physical and emotional distress. 3. **Impact on Quality of Life:** - R-CPD can interfere with daily activities, social interactions, and overall well-being. - Many patients suffer for years before receiving a diagnosis due to the condition's recent recognition. --- ### **Diagnosis:** Diagnosis of R-CPD is straightforward and primarily based on clinical symptoms: - **Key indicators:** The inability to burp combined with throat gurgling noises strongly suggests the condition. - No invasive tests are typically required for diagnosis. --- ### **Treatment Options:** The primary treatment for R-CPD is **botulinum toxin (Botox) injections** into the cricopharyngeal muscle. This procedure relaxes the muscle, allowing trapped air to escape and enabling patients to burp. 1. **Standard Operating Room Method:** - Performed under sedation using an esophagoscope. - Has a high success rate of **90–95%**. - Considered the most reliable and effective option. 2. **Alternative Techniques:** - **Electromyography-guided (EMG) injections:** - A more complex method involving electrical guidance. - Carries a risk of vocal cord paralysis. - **Transnasal fiberoptic injection:** - A newer, office-based procedure performed quickly without sedation. - Can treat multiple patients in a day but has a lower success rate of **around 60%**. --- ### **Prognosis:** - **Long-term outcomes:** Remarkably, most patients experience lasting relief after a single Botox injection. Even when the drug wears off, the body often "learns" to burp, providing sustained improvement. - **Side effects:** Generally mild and temporary, including: - Difficulty swallowing for a short period. - Rare cases of worsened reflux. --- ### **Significance of Recognition:** R-CPD was unrecognized for many years, leaving patients to suffer from unexplained symptoms without effective treatment. Since its formal identification, it is increasingly recognized as a treatable condition, offering hope and relief to those affected. The availability of effective treatments has transformed the outlook for individuals with this condition, significantly improving their quality of life.

Sucrose vs Sucralose – Appetite stimulation

The study highlights key differences between **sucrose (table sugar)** and **sucralose (a common artificial sweetener)** in terms of their effects on appetite and brain activity: ### **Sucrose (Sugar):** - **Appetite Suppression:** Sucrose consumption was associated with **lower hunger levels**. - **Brain Activity:** Sucrose reduced activity in the hypothalamus, the brain’s hunger regulation center. This suggests that sugar may signal satiety more effectively, potentially curbing appetite after consumption. ### **Sucralose (Artificial Sweetener):** - **Appetite Stimulation:** Sucralose **increased hypothalamic activity** compared to sucrose, which is linked to heightened hunger signals. In some individuals, sucralose made them feel hungrier. - **Brain Activity:** Sucralose raised brain activity in the hypothalamus and increased communication between the hypothalamus and brain regions involved in motivation and decision-making. This suggests that sucralose may influence cravings and eating behavior. - **Variable Effects:** The impact of sucralose varied among individuals: - People with **obesity** or **insulin resistance** showed stronger brain responses to sucralose. - **Women** also exhibited heightened sensitivity to sucralose compared to men. ### **Comparison:** - **Sucrose** appears to suppress appetite and reduce hunger-related brain activity, while **sucralose** may stimulate hunger-related brain activity and, in some cases, increase appetite. - Sucralose's effects on hunger and brain activity are more complex and may depend on individual factors such as metabolic health, gender, and body weight. ### **Implications:** The findings suggest that sucralose might not effectively mimic the appetite-regulating properties of sugar and could potentially lead to increased cravings or altered eating behavior in certain individuals. However, the study was short-term, and more research is needed to fully understand the long-term impacts of sucralose on appetite regulation and metabolic health. ### **Expert Recommendations:** Given the potential appetite-stimulating effects of sucralose and the health risks associated with excessive sugar consumption, experts currently recommend: - Limiting both sugar and artificial sweeteners. - Reducing overall sweetener use to support better metabolic health and avoid potential disruptions in hunger regulation.